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Part 1: Skintroduction
The skin is the largest organ of the body, and accounts for 15% of the total body 
weight of adults1. Besides giving the body strength, the skin has a dual protective 
function. From the outside it protects the body against extracellular stimuli like 
UV and other radiation, but also against pathogens. From the inside the skin 
protects against dehydration and regulates body-temperature. The skin consists 
of a stratified, cellular epidermis, separated by a basement membrane to the 
underlying dermis of connective tissue and the subcutaneous fat2. The different 
characteristic features of the skin are schematically represented in figure 1.1. The 
dermis gives the skin its tightness and is host for hair follicles, sweat glands and 
sebaceous glands, nerves and blood vessels. The epidermis consist of various 
cell types, but the majority, up to 90-95%, are keratinocytes. Other cells that 
are represented in the epidermis are melanocytes, Langerhans cells, Merkel 
cells and circulating lymphocytes. The epidermal keratinocytes are arranged in 
continuous layers with, from the inside to the outside, the basal layer or stratum 
basale (single layer), the prickle-cell layer or stratum spinosum (5-15 layers), the 
granular layer or stratum granulosum (1-3 layers) and the horny layer or stratum 
corneum (5-10 layers). Keratinocytes arise from mitotic division of stem cells in 
the basal layer. Daughter keratinocytes, also known as transit amplifying cells, 
migrate towards the skin surface while undergoing morphological and biochemical 
differentiation (a process called keratinisation). In the stratum corneum the cells 
lose their nucleus and fuse to squamous sheets, which are eventually shed 
from the surface (a process called desquamation). In normal skin, the complete 
journey from the basal layer to the shedding takes about 30 days and the rate of 
desquamation equals the rate of production3,4.
Figure 1.1 Structure of the 
human skin. The dermis con-
tains the hair follicles, sweat 
glands and sebaceous glands. 
The basal membrane  sepa-
rates the dermis from the epi-
dermis. In the epidermis four 
well-defined morphologically 
different layers (Stratum basa-
le, stratum spinosum, stratum 
granulosum and stratum cor-
neum) can be distinguished. 
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Keratinocytes that start dividing will soon accumulate cell-cell junctions on their 
surface, mainly desmosomes. Desmosomes anchor keratin intermediate filaments 
to the cell membrane, which is essential for withstanding trauma5. There are two 
types of keratins: type I (acidic) keratins and type II (basic to neutral) keratins. 
The process in which a type I keratin forms a heterodimer with a type II keratin 
is called pairing6. Through the epidermis different combinations of heterodimers 
can be distinguished, depending on the state of differentiation. The keratinocytes 
just above the basal layers are characterized by the presence of K5/K14 keratin 
pairs, while the uppermost layers of differentiated keratinocytes consist of K1/
K10 and K2/K10 keratin pairs7,8. The last layer of viable cells in the epidermis is 
the stratum granulosum, which name is derived from the presence of keratohyalin 
granules in the cytoplasm of cells in this layer9. Cells in the stratum granulosum 
will ultimately undergo programmed cell death and the rupture of cellular integrity 
results in the release of lysosomal proteases and other lytic enzymes. This leads 
to the loss of their nuclei and cytoplasmic organelles, resulting in the formation of 
corneocytes. Corneocytes form a stable and insoluble cornified envelope (CE), 
consisting of several specific proteins that are cross-linked together via Ca2+-
dependent transglutaminases in an orchestrated way10. The stratum corneum is 
the layer of the epidermis that contain most of the defensive functions that the 
skin harbours11.
Skin barrier function
The physical barrier of the skin is formed by lipid-depleted corneocytes 
embedded in a lipid-enriched, extracellular matrix, which is often compared with 
a wall composed of bricks and mortar12-14. The proteins and lipids involved in this 
process are secreted by lamellar granules, which are present in the cytoplasm 
of keratinocytes in the upper stratum spinosum layer and stratum granulosum11. 
The CE consists of at least 20 proteins of which loricrin accounts for more than 
70% of total cross-linked proteins15. Involucrin, the first identified CE protein, is 
expressed at the onset of terminal differentiation and is eventually incorporated 
into CEs in a cross-linking reaction catalyzed by transglutaminase-116,17. It has 
been shown that involucrin could be cross-linked to almost all CE-associated 
proteins18. Loricrin is expressed at the end of the differentiation process, but 
represents the majority of the CE proteins19. Another important protein of the 
CE is filaggrin, which is formed after dephosphorylation and proteolysis of 
profilaggrin during epidermal terminal differentiation. Filaggrin rapidly aggregates 
the cytoskeleton of granular keratinocytes, which contributes to the collapse of 
these cells resulting in the formation of corneocytes20. The importance of filaggrin 
for a correct epidermal barrier was shown by mutations in the filaggrin gene of 
ichthyosis vulgaris patients21, and also in patients with atopic dermatitis, which 
are both diseases characterized by a disturbed barrier function22. 
 Various classes of lipids are found in the stratum corneum, like ceramides, 
free fatty acids and cholesterol23. Keratinocytes in the stratum granulosum 
produce ceramides and deliver them to the stratum corneum via lamellar granules. 
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Insufficient production of ceramides, but also cholesterol, results in a delayed 
barrier repair after damage24,25. Free fatty acids and cholesterol sulphate are 
the only lipids in the stratum corneum with a charged/ionisable headgroup and 
therefore necessary for the formation of the stratum corneum lipid bilayer23. They 
also are expected to play a role in causing the acidic pH in the upper layers of the 
stratum corneum23. The importance of fatty acid for epidermal barrier function is 
illustrated by the defective barrier after fatty acid deficiency23. 
 Another protective function of the epidermis is the ability to absorb harmful 
UV light. Trans-urocanic acid is the major UV-absorbing pigment that is formed 
by the deimination of histidine. Histidine is released after hydrolysis of filaggrin11. 
Another mechanism to protect the skin against UV light is performed by 
melanocytes, who deposit melanin containing melanosomes via dendrites into 
adjacent keratinocytes. Melanosomes form complexes that are located close 
to the nucleus, preferentially at the apical site to form “caps” that protect the 
keratinocytes nuclei against UV light26.
 The epidermis has its own innate immune host defense system, as it is 
able to express peptides that posses antimicrobial activity. These antimicrobial 
peptides include human β-defensin (hBD)-1, 2, 3 and 4, secretory leukocyte 
proteinase inhibitor (SLPI), elafin, cathelicidin (LL-37), S100 proteins, RNAse 7, 
dermcidin and cystatin A. Some of them (elafin, psoriasin, LL-37 and β-defensins 
with the exception of hBD-1) are only expressed upon barrier disruption or chronic 
inflammation27, although psoriasin might also be expressed on normal skin, 
depending on the location of the body surface28. Each peptide is active against 
his own spectrum of antimicrobial targets. For example, hBD-3 is mainly directed 
against S. aureus29, while hBD-2 is mainly active against gram-negative bacteria 
like P. aeruginosa and E. coli28. Is has been shown that hBD-2 expression is 
induced by P. aeruginosa30,31 or by stimulation with interleukin (IL)-1α, IL-1β or 
IL-2230. SLPI and elafin are protease inhibitors that are produced early during 
inflammation as response to IL-1 and TNF-α. They are primary expressed to 
prevent injurious effects of excessive release of proteolytic enzymes from 
inflammatory cells. Aside, SLPI and elafin have been shown to have a broad 
antibacterial spectrum as well as anti-HIV and anti-fungal properties32-35. LL-37 
can be induced in human skin upon inflammatory conditions. It is secreted by 
keratinocytes and neutrophils and serves as a chemo-attractant for neutrophils, 
monocytes and T-cells36. LL-37 has also been shown to posses broad-
antimicrobial activity, including antiviral activity37. The S100 protein psoriasin 
(S100A7) is constitutively expressed in normal skin and can be upregulated 
by exposing keratinocytes to calcitriol (1,25 (OH)2D3)
38. Low concentration of 
psoriasin preferentially kills E. coli39, but at higher doses it could also posses 
antimicrobial activity against P. aeruginosa and S. aureus40. Calgranulins also 
belong to the S100 proteins and contain 3 proteins: calgranulin A (S100A8), B 
(S100A9) and C (S100A12). Calgranulin A and B can form a complex, which is 
called calprotectin41. Calgranulins exert proinflammatory functions, but they have 
also antimicrobial properties against bacteria (including E. coli, S. aureus and S. 
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epidermidis) and yeast (including C. Albicans)42. RNAse 7 is constitutively present 
at high levels in normal skin, although it can be induced in diseases like atopic 
dermatitis and psoriasis43. RNAse 7 exhibits a broad spectrum of antimicrobial 
activity against both gram-positive and gram-negative bacteria, but also against 
C. albicans28,44. Dermcidin is the principal sweat antimicrobial peptide that is 
constitutively expressed exclusively by eccrine gland cells28 and has antibacterial 
activity (S. aureus, E. faecalis and E. coli) and antifungal activity (C. Albicans)45. 
Cystatin A is a cysteine protease inhibitor present in keratohyalin granules and 
is, after phosphorylation, a minor cross-linked constituent of the CE. Cystatin A is 
proposed to posses both antibacterial and antiviral properties46. 
Skin diseases
Atopic dermatitis
Atopic dermatitis, or eczema, is a common inflammatory, chronically relapsing 
skin disorder. The skin of patients become red, flaky and is often very itchy (see 
figure 1.2). Affected regions are mainly found on the flexural surfaces of the 
joints. Disease onset might occur at any age, but in 85% it starts before the age 
of 547. The prevalence of atopic dermatitis in children is 5-20% worldwide, but 
is increased in industrialized countries48. In most of the cases (up to 70%), the 
disease disappears spontaneously before they reach adolescence47. 
 Patients with an extrinsic or allergic form atopic dermatitis are characterized 
with a cutaneous infiltration containing highly reactive cells of dendritic lineage, 
including Langerhans cells and epidermal dendritic cells both of which express 
the high-affinity receptor for the Fc region of IgE (FcεRI) on their membrane49. 
Although most patients with atopic dermatitis (70-85%) contain elevated levels of 
IgE50, a minority of patients is characterized with normal IgE levels51. This type of 
atopic dermatitis as referred to as intrinsic or nonallergic atopic dermatitis.
 Atopic dermatitis is a multifactorial disease in which both genetic and 
environmental factors are thought to be involved in its etiology. Several studies 
on twins have shown that the occurrence of atopic dermatitis among monozygotic 
twins is higher than among dizygotic twins52,53. Factors like stress and infections 
may influence the severity and amount of exacerbations in atopic dermatitis 
patients54,55. In general, two hypothesis have been proposed concerning the 
mechanism of atopic dermatitis47. In the first hypothesis the primary defect is 
ascribed to an immunologic disturbance that causes IgE-mediated sensitization, 
with epithelial-barrier dysfunction as a consequence of the local inflammation. 
This hypothesis is supported by the identification of several candidate genes 
on chromosome 5q31-33 that are associated with atopic dermatitis. All of them 
encode cytokines involved in the regulation of IgE synthesis: IL-4, IL-5, IL-12, IL-
13 and granulocyte-macrophage colony-stimulating factor (GM-CSF). The second 
hypothesis points to an inherent defect in epithelial cells, with subsequently 
could lead to immunological abnormalities. Single nucleotide polymorphisms 
(SNPs) associated with atopic dermatitis in genes located on chromosome 1q21, 
which harbours a family of epithelial-related genes known as the epidermal 
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differentiation complex (EDC), support the second hypothesis. Besides these two 
loci, also other atopic dermatitis-associated loci are found on chromosome 3q21, 
17q25, 20p and 3p2647. The most striking support for the second hypothesis was 
found when researchers identified mutations in filaggrin, a gene on chromosome 
1q21.3, in 30% of European patients56. These results were replicated in other 
cohorts57-59. Mutations in filaggrin result in reduced epidermal barrier function, 
fully supporting the second hypothesis.
Psoriasis
Psoriasis is a common, incurable chronic skin disease affecting 2-3% of the 
Western population60. This inflammatory disease is characterized by an increased 
epidermal growth and altered differentiation leading to the typical clinical features. 
There are several different types of psoriasis described, of which chronic plaque 
psoriasis (psoriasis vulgaris) is the most common one (approximately 90% of 
all cases). This form of psoriasis is characterized by sharply demarcated and 
erythematous papulosquamous plaques (see figure 1.3). Less common types 
of psoriasis include nail psoriasis, inverse psoriasis, guttate psoriasis, pustular 
psoriasis and scalp psoriasis. Although psoriasis can occur in children, its initial 
Figure 1.2 Atopic dermatitis. Typical atopic der-
matitis lesions on the back and in the face of a child 
and on the flexural sites of the knees with erythe-
ma, oozing and excoriations.
Figure 1.3 Psoriasis. Typical plaques of psoriatic 
skin. Thick, sharply demarcated plaques on the ex-
tensor site of elbows and legs with erythema and 
squamae.
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outbreak typically affects people in late adolescence or early adulthood61. Once 
initiated psoriasis usually persists for life, with a history of eruptions followed by 
temporary remissions62. In contrast to atopic dermatitis, there is a predilection 
for extensor sites of extremities. Also the scalp is often affected, as are hands, 
feet and presacrum. Based on linkage studies in twins and pedigrees, psoriasis 
has been characterized as a multifactorial disease in which both genomic63,64 
and environmental factors as stress65, trauma66 and infection67 might influence 
disease onset and activity. When patients develop lesions in response to physical 
trauma this is termed the Koebner effect66, which has been observed in up to 25% 
of patients68.
 Histological examination of a stable psoriatic plaque show elongated and 
tortuous capillaries in the dermis, expanding upward into elongated club-shaped 
dermal papillae. Only a small suprapapillary plate of epidermal cells covers the 
tip of these dermal papillae. A modest perivascular infiltrate consists primarily 
of lymphocytes and macrophages. There are elongated rete ridges, foci with 
parakeratosis and a diminished presence or absence of the granular layer. Other 
defining histological features of psoriasis include the presence of neutrophils 
within small foci in the horny layer and significant mononuclear infiltrate in the 
epidermis69.
 Initially, it was thought that the cause of psoriasis was the hyperproliferative 
state of keratinocytes. Keratinocytes in psoriatic epidermis are indeed 
hyperproliferative, their journey from basal layer to desquamation is accelerated 
to 6-8 days, which results in an altered differentiation as well70. Later the 
hypothesis was favoured that psoriasis is rather an immunological disease in 
which T lymphocytes are indirectly responsible for the phenotype of psoriasis71. 
According to the current point of view leukocytes and keratinocytes itself cause 
the characteristic changes in psoriasis72. Keratinocytes are no longer seen 
as bystander cells, but are actively involved in recruitment and activation of 
leukocytes in psoriatic lesions73. Clinical observations suggest an important role 
of the innate cytokine IFN-α that induces the production of IL-12 and IL-23 by 
myeloid dendritic cells. This leads to the differentiation of naïve T cells in Th1 
type (by IL-12) and Th17 type (by IL-23) cells. As a result, cytokines are produced 
that lead to the production of several antimicrobial peptides, proinflammatory 
cytokines, chemokines and S100 proteins involved in attracting activated dendritic 
cells and T cells. So, both the effector cells of the innate and adaptive immune 
system as well as the intrinsic character of keratinocytes are involved in inducing 
an inflammatory process leading to a psoriatic lesion74.
 As described above, psoriasis is a multifactorial disease in which genetic 
components could influence its onset. Classic genome wide linkage analysis 
have identified at least nine chromosomal loci with statistically significant linkage 
to psoriasis, referred as psoriasis susceptibility 1 till 9 (PSORS1 till PSORS9). 
PSORS1 accounts probably for 35-50% of the heritability of the disease75 and 
this loci is the strongest and invariably reproduced psoriasis susceptibility 
locus, which is located within the major histocompatibility complex (MHC) on 
Introduction
15
chromosome 6p. More detailed characterization of PSORS1 identified HLA-Cw6 
on 6p21.3 as very likely to be the disease allele at PSORS176. In addition to 
linkage studies genome wide association studies (GWAS) have subsequently 
resulted in numerous genetic variants linked to psoriasis. Most notably are the 
sequence variants in the genes coding for interleukin-23 receptor (IL23R) and 
its ligand (IL12B) that confer protection against psoriasis77. In contrast to these 
immunological oriented associations, also genomic associations that address an 
important role for keratinocytes in the onset of psoriasis are described. First, 
an increased risk for psoriasis was associated with an increased beta-defensin 
copy number on chromosome 8p23.178. One of the genes on this cluster, beta-
defensin 2 (hBD-2) is extremely upregulated is psoriatic skin79. Furthermore, a 
deletion of late cornified envelope genes LCE3B and LCE3C was associated with 
increased risk for psoriasis80,81.
Keratinocytes: key players in psoriasis and atopic dermatitis
Psoriasis and atopic dermatitis are the two most common chronic inflammatory 
skin diseases. In both disorders an important role in the pathogenesis is fulfilled 
by T cells, although the type of T cell lineage and the chemokine/cytokine profiles 
are different. Despite the role that the immune system plays in the pathogenesis of 
both diseases, there is growing evidence that also the keratinocytes themselves 
have an important role22,80,82. Several studies have compared lesional skin of 
patients with psoriasis and atopic dermatitis27,83,84. Initially, these studies were 
restricted to one or only a few genes or proteins43,85. The first large-scale study 
was performed by microarray analysis on RNA obtained from full-thickness 
skin biopsies from lesional psoriatic and atopic dermatitis skin83. In this study 
the differential expression of thousands of genes was compared resulting in 
a list of 80 genes that were significantly increased (>2-fold) in either psoriasis 
or atopic dermatitis. The maximal difference in gene expression level was 
found for the gene coding for Nel-like 2 (Nell2) protein, a neural tissue-specific 
epidermal growth factor (EGF)-like repeat domain-containing protein, which was 
upregulated in atopic dermatitis. Also several CC chemokines, known to attract 
Th2 cells, showed increased expression in atopic dermatitis when compared 
with psoriasis. The most highly upregulated gene in psoriasis as compared with 
atopic dermatitis was small proline-rich protein 2C (SPRR2C). Other genes with 
high expression levels in psoriasis code for several antimicrobial peptides and 
chemokines and cytokines that are known to attract Th1 cells and neutrophils. 
Although this microarray analysis showed differences in gene expression 
between psoriasis and atopic dermatitis, it is not clear which cells are responsible 
for the expression, because full-thickness biopsies were used. Keratinocytes are 
the main population of the epidermis, but resident dermal cells and immune cells 
were not removed in this study.
 To gain more insight on keratinocytes expression profiles in lesional psoriasis 
and atopic dermatitis skin, our group performed microarray studies on epidermal 
sheets27. Overall, we found more genes to be overexpressed in psoriasis, with 
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vanin-3 (VNN3) as the highest differentially expressed one (19-fold). Vanin 
family members had not been demonstrated in the epidermis before, and their 
possible role in psoriasis is unclear, but a role in inflammatory bowel disease has 
been suggested86. In line with previous studies, genes encoding antimicrobial 
peptides (hBD-1, hBD-2, elafin, calgranulin C and iNOS) were confirmed to be 
higher expressed in psoriasis compared with atopic dermatitis. In addition, also 
other antimicrobial peptides such as psoriasin, calgranulin A and B, chitinase and 
cystatin A, showed higher expression in psoriasis skin27. From these antimicrobial 
peptides, hBD-2, calgranulin A and C showed up in the top twenty of proteins 
being overexpressed in psoriasis compared with atopic dermatitis. Furthermore, 
several genes encoding cytokines known to be overexpressed in psoriasis are 
present in Table 1.1. One of the genes with the highest differential expression in 
atopic dermatitis compared with psoriasis is carbonic anhydrase II (CAII), which 
Classification Symbol PS/ADa RnRelb
Vanin 3 VNN3 18.90 17.56
Absent in melanoma 2 (PYHIN4) AIM2 17.88 3.60
Hyaluronoglucosaminidase HYAL4 9.71 4.68
Kynureninase (L-kynurenine hydrolase) KYNU 8.40 3.63
Human β-defensin-2 (hBD-2) DEFB4 7.94 7.79
Polycystic kidney disease 2-like2 PKD2L2 7.52 5.03
Calgranulin A (MRP8) S100A8 7.36 4.65
Calgranulin C (MRP6) S100A12 6.92 7.92
Solute carrier family 6, member 14 SLC6A14 6.87 7.70
Viperin (cig5) RSAD2 6.50 4.29
Interleukin receptor 2 gamma (CD132) IL2RG 5.66 4.49
Interleukin 1 family, member 8 IL1F8 5.66 6.51
Interferon inducible protein 44 IFI44 5.31 5.77
Nasopharyngeal epithelium specific protein 1 CCDC19 5.24 7.33
Interferon stimulated ubiquitin-like modifier ISG15 4.69 4.38
Inducible T-cell co-stimulator ligand (B7H2) ICOSLG 4.66 6.71
Guanine deaminase GDA 4.63 4.39
Nitric oxide synthase 2 (iNOS) NOS2 4.56 9.76
C-type lectin domain 7A (Dectin-1) CLEC7A 4.35 5.85
Interleukin 1 family, member 9 IL1F9 4.20 6.28
aFold difference of gene expression level in psoriasis compared with atopic dermatitis
bt-statistics; significant as RnRel>3.5
Table 1.1 Top 20 proteins upregulated in psoriasis detected by microarray analysis
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was also confirmed at the protein level87. CAII participates in several processes 
that involve pH regulation and water- and electrolyte homeostasis88. Other genes 
that are more abundant in atopic dermatitis skin compared with psoriasis are 
listed in Table 1.2 and include genes that code for chemokines and cytokines 
known to be involved in atopic dermatitis.
 The challenge for researchers is to estimate whether these up- or 
downregulated genes are involved in the pathogenesis of psoriasis or atopic 
dermatitis and whether there are druggable genes among them that might be 
suitable for specific therapy. Besides involved in pathogenesis or being druggable 
genes, highly expressed genes might also be good candidates for biomarkers. 
Classification Symbol PS/ADa RnRelb
Neurogenin 1 NEUROG1 7.89 5.03
Carbonic anhydrase II CA2 7.68 21.19
Claudin 8 CLDN8 5.15 6.20
ADAM metallopeptidase domain 8 ADAM8 4.88 6.47
Chemokine (C-C motif) ligand 17 CCL17 4.57 3.71
Calpain 2, (m/II) large subunit CAPN2 4.28 9.62
Amphiregulin AREG 3.97 6.25
Janus kinase 1 JAK1 3.81 5.42
TNF receptor superfamily, member 6 FAS 3.61 5.63
Inhibin, beta A INHBA 3.44 5.84
Pleckstrin homology-like domain A2 PHLDA2 3.37 7.50
Kruppel-like factor 4 KLF4 3.37 4.58
SLIT-ROBO Rho GTPase activating protein 1 SRGAP1 3.33 5.96
Integrin, alpha 6 ITGA6 3.32 3.99
Solute carrier family 43, member 1 SLC43A1 3.20 5.53
Platelet derived growth factor C PDGFC 3.13 7.60
Adrenergic, beta-2-, receptor, surface ADRB2 3.09 4.01
TSC22 domain family, member 1 TSC22D1 3.05 8.82
Actin, gamma 1 ACTG1 3.05 12.22
Peripheral myelin protein 22 PMP22 3.03 13.74
aFold difference of gene expression level in psoriasis compared with atopic dermatitis
bt-statistics; significant as RnRel>3.5
Table 1.2 Top 20 proteins downregulated in psoriasis detected by microarray analysis
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Part 2: Techniques
Reconstructed skin models: suitable for screening and in vitro skin research
Skin research has a history of different culture systems and models. In 1975, 
Rheinwald and Green89 were the first describing a method for cultivation of 
keratinocytes in in vitro systems. They showed that keratinocytes need fibroblasts 
to initiate colony formation. To overcome that fibroblasts could overgrow 
keratinocytes, they irradiated the fibroblasts prior to keratinocyte seeding. Once 
these colonies are formed they are able to maintain themselves in subsequent 
subcultures, although primary keratinocytes have a limited lifespan and proliferation 
rate decreases in time. Morphologically, these colonies contain features of 
differentiation with dividing keratinocytes and differentiated keratinocytes on top. 
Studies based on this system have gained much information about these cells 
in both a biological and pharmacological point of view. Although the utilization 
of culturing keratinocytes in monolayers on the bottom of a culture plates was 
historically important as this was an initial step in maintaining keratinocytes in 
in vitro models, scientifically these keratinocytes fail to reproduce the complex 
and dynamic processes of in vivo skin. Furthermore, 2D culture systems do not 
completely resemble the in vivo situation, as cultured keratinocytes are forced to 
adapt to an artificial, flat surface, which might results in altered gene expression 
profiles90. In order to study cell-cell interactions and effects on the regulation 
of melanogenesis, proliferation and differentiation of keratinocytes, but also 
the re-epithelialisation process after (burn)wounding, a model is required that 
resembles the basic architecture of the human skin. Therefore, a fully stratified 
epidermis containing all different layers beginning with basal cells on the bottom 
and a stratum corneum on top, is required. Over the past decades several 
systems have been published, describing 3D reconstructed skin equivalents. 
Basically all of these systems are based on the method describes by Pruniéras91 
in which keratinocytes are grown submerged on a dermal substitute to form a 
basal layer followed by an air-lifted phase in which the keratinocytes are forced 
to differentiate upwards, resulting in a stratified reconstructed skin. The dermal 
substitute can be composed of cell-free dermal matrices like de-epidermized 
dermis (DED), but also inert filters, fibroblast-populated collagen matrices and 
lyophilized collagen-GAG membranes might act as dermal substitute. Initially, 
the cellular components of the epidermis consist of solely primary keratinocytes 
which represents about 90% of the epidermal cells in human skin in vivo. More 
recently, also small proportions of melanocytes are introduced in reconstructed 
skin models, resulting in even more lifelike constructs92. Main drawback of 
these increasing sophisticated reconstructed skin models is that they became 
more labour intensive, thus more expensive. As a consequence, the number of 
commercially available skin models has increased over the past years. These 
skin equivalents are mostly derived from foreskin keratinocytes and used in a 
wide variety of biological studies, skin corrosion testing and irradiation studies93. 
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Although reconstructed skin models were primarily developed for treatment of 
skin defects like burn wounds and ulcers, they have had great impact on both 
basic and applied research94. Reconstructed skin models might also be a suitable 
alternative for animal testing. This would lead to a significant reduction of animal 
use and discomfort, and furthermore, testing for skin irritation in animals is not 
always predictive for human responses. 
Reconstructed diseased skin models: psoriasis and atopic dermatitis
A specific and challenging use of reconstructed skin models is to mimic a disease-
specific pheno- and genotype. These models may be useful to investigate the 
epidermal aspects of pathology and to study therapeutics that act at the level 
of keratinocytes biology. The first in vitro reconstructed model for diseased skin 
was described by Barker et al.95. They used keratinocytes and fibroblasts from 
psoriatic patients and compared the reconstruct skin with constructs obtained 
with keratinocytes and fibroblasts from healthy controls. Besides an increase in 
proliferation, as measured with Ki67-positive cell counting, in their patient derived 
constructs, they were also able to detect increased psoriasis associated gene 
expression of CXCR2 and induced expression of pro-inflammatory genes TNF-α, 
IFN-γ and IL-8. Another approach to achieve a psoriasis-like reconstructed skin 
construct was described by Harrison et al.96. They used keratinocytes derived 
from healthy individuals in combination with transglutaminase inhibitors. The 
inhibitors resulted in hyperproliferation and parakeratosis in their constructs, 
both hallmarks of a psoriatic phenotype. To obtain a psoriasis-like phenotype in 
a more controllable way using normal human keratinocytes, psoriasis-associated 
cytokines (TNF-α, IL-1α, IL-6, IL-22) can be added during to the last 4 days of 
the air-exposed phase. These cytokines are able to induce psoriasis-associated 
protein expression of hBD-2, elafin and K1697. Furthermore, it was shown that 
the anti-psoriatic drug retinoic acid was able to inhibit the cytokine-induced 
keratinocyte gene expression at both the mRNA and protein level97.
 In an attempt to obtain a reconstructed skin model with properties 
resembling atopic dermatitis, lymphocytes were integrated98. Infiltration of 
activated CD45RO+ T cells into the construct induces apoptosis in keratinocytes, 
which leads to reduced expression of the adhesion molecule E-cadherin and 
disruption of the epidermal barrier. Pro-inflammatory cytokines (IL-1α and IL-6 
and chemokines (i.e. IL-8 and RANTES) are induced and production could 
be inhibited with therapeutics (dexamethasone and FK506). Also other atopic 
dermatitis associated properties like upregulation of neurotrophin-4 (NT-4), 
involved in mediating pruritus in lesions, and intercellular adhesion molecule-1 
(ICAM-1), responsible for the attachment of leukocytes to epidermal cells, are 
found in these constructs98. Another atopic dermatitis model is principally similar to 
the psoriasis model described by Tjabringa et al.97. Normal human keratinocytes 
in a reconstructed skin model are stimulated with Th2 cytokines IL-4 and IL-
13. Morphologically, these Th2 cytokines induced intercellular oedema similar 
to spongiotic changes found in lesional atopic dermatitis. Furthermore, induced 
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apoptosis  and atopic dermatitis associated gene expression of CAII and Nell2 
was observed99. 
Transgenic expression systems: transfection and infection
In order to study specific gene function in vitro, two different approaches can 
be distinguished: overexpression and knockdown experiments. Both approaches 
could gain useful information about protein function. This section will give an 
overview on overexpression systems and their suitability for primary keratinocytes. 
The next section will focus on gene functionality studies after knockdown 
experiments.
 Overexpression is achieved after introducing foreign DNA into host cells that 
ultimately lead to transcription and translation of the introduced gene. Main problem 
is that cells, including mammalian cells, are impenetrable to large molecules that, 
like DNA, are electrically charged. Therefore, systems were created to overcome 
this problem (see figure 1.4). In general, two types of gene delivery systems 
can be distinguished, non-viral and viral systems. The non-viral system dates 
from the early 70s when researchers used carrier molecules that form, together 
with DNA, a non-charged molecule. DNA was coated with DEAE-dextran that 
help DNA to pass the membrane, a process they termed ‘transfection’100. Another 
carrier molecule, calcium phosphate appeared less toxic then DEAE-dextran101. 
To date, these systems are still used, although many labs prefer the subsequently 
described lipid-based transfection reagents. These reagents are, though more 
expensive then the previously described carrier molecules, easier to use and 
obtain higher efficiencies with lower toxicity. The first lipid-based reagents contain 
cationic and other lipids that envelope DNA, forming artificial liposomes that can 
fuse with the cellular membrane leading to the release of the DNA into cells102. 
The next generation of lipid-based reagents consists of lipids combined with 
polymers and are thought to form a complex with DNA in a non-liposomal way 
that will interact with the cell membrane. After endocytosis, the DNA is released 
in the cytoplasm. In contrast to liposomes, non-liposomal reagents form micelles 
of a uniform size resulting in more reproducible results103. Commercially available 
reagents like Lipofectamine 2000 and FuGENE 6 are based on this system, 
although their exact composition remain commercial secrecy104. Lipid- or polymer-
based gene delivery systems are sometimes referred to as chemical transfection 
reagents, which is rather a strange name as no chemical reactions are involved.
 Another non-viral method to introduce DNA into cells is by using physical 
power. A common method to physically transfect cells is by using high-voltage 
pulses of electricity, called electroporation105. The electric pulse produces holes 
in the cell membrane, through which DNA can enter. This method can be used 
for many cell types, including primary cells. Cells must be in solution and high 
amount of cells are needed as many cells die after the electric shock. Another 
physical system available for transfection is the gene gun. Using the gene gun 
particles of gold coated with DNA are shot via an adjustable low pressure helium 
pulse into cells or tissue. Although gene guns are mostly applied in plant biology, 
they also have been successfully used in animal and human research, including 
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skin research106.
 Although non-viral gene delivery systems are suitable for a wide variety 
of cell types, their transfection efficiencies might be disappointing, especially 
when working with primary cells. To achieve high efficiencies in hard-to-transfect 
cell-types, one could consider using a viral gene delivery system107. Although 
working with viruses is more time-consuming and often requires special biosafety 
facilities, viruses became a very popular alternative to the traditional gene delivery 
methods. Viruses are able to infect near 100% of almost any cell-type, a process 
referred as transduction: introducing nucleic acid into cells via virus particles. The 
mechanism by which viruses are able to enter the host cell are virus-specific108. 
In general viruses attach to specific receptors on the host cell surface via viral 
capsid proteins followed by endocytosis or membrane fusion, a process called 
penetration. Depending on the nature of the virus, mRNA transcription or the 
genomic integration mechanism will start. There are several viral vectors suitable 
for transduction of mammalian cells109, of which lentiviruses are the most promising. 
The modification of viruses in order to induce exogenous gene expression was 
Figure 1.4 Transfection methods. Schematic representation of four general transfection methods. 
DNA can be transferred into cells using a carrier to neutralize the DNA molecule like calcium phosp-
hate. Lipid-based transfection reagents were developed that envelope the DNA. After endocytosis, 
the DNA is released in the cell. The third method uses physical power, e.g. high-voltage pulses of 
electricity, to create holes in the cell membrane through which DNA can enter the cell. Also viruses 
can be used for transfecting cells. Viruses attach to the membrane via specific receptors on the cell 
membrane. Via penetration the DNA enters the host cell.
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first described in tobacco plants that were successfully infected with modified 
tobacco mosaic virus110. For transgenic expression in mammalian cells several 
virus-derived systems have been developed. The most common used viruses are 
derived from retrovirus, lentivirus, adenovirus and adeno-associated virus109. But 
also vectors derived from herpes simplex virus, poxvirus and Epstein-Barr virus 
have been successfully used to transducer mammalian cells111-113. Focusing on 
the most used viral vector systems, retroviruses are highly infectious viruses, but 
only dividing cells are susceptible for infection114. Once a cell is transduced with 
retrovirus, its DNA will be stable integrated into the host cells genome, resulting in 
sustained transgenic expression. In contrast, adenovirus and adeno-associated 
viruses are able to induce both dividing and non-dividing cells, but do not 
integrate into the genome of their host115. Thereby the transgenic effect will fade 
away upon cell division. The last common-used viral gene delivery system, the 
lentiviruses, are able to infect both dividing and non-dividing cells and are able 
to integrate into the genome of infected cells115. For safety issues it took a while 
before lentiviruses were suitable for routine laboratory use. After the introduction 
of so-called self-inactivating (SIN) lentiviral vectors, the use of lentiviral particles 
for transgenic expression grew extensively116. 
 For a long time it has been a challenge to induce stable transgenic protein 
expression in primary human keratinocytes. Non-viral gene delivery systems like 
calcium phosphate precipitation or commercially available reagents result in low 
transfection efficiencies of maximal 30% positive cells117. Another problem using 
primary cells versus cell-lines, is that primary cells have a limited lifespan, which 
makes it almost impossible to obtain clones using antibiotic selection. Therefore, 
viral gene delivery systems are ideal for human keratinocytes, as they are able 
to achieve high transduction efficiencies107. For in vitro studies retroviral systems 
are not favoured for primary human keratinocytes as they are unable to transduce 
non-dividing cells, however in vivo retrovirus based gene therapy has been 
successfully implemented118. Adenovirus and adeno-associated viruses are able 
to transduce both dividing and non-dividing cells, but these viruses are unable 
to integrate into the host cells genome, thereby causing a transient transgenic 
expression. These viruses are suitable for research on keratinocytes, but because 
of the transient expression properties lentiviral particles are preferred, as these 
result in a sustained transgenic expression119,120. It has been shown that primary 
human keratinocytes transduced with lentivirus containing a green fluorescent 
protein, result in nearly 100% fluorescent positive cells107. Furthermore, it was 
shown that these keratinocytes continue expressing the fluorescent protein in 
time107. 
RNA interference 
In the previous section systems were described to study gene function after 
overexpression. Another method to study gene function is by decreasing its 
expression, termed RNA interference (RNAi). RNAi is a mechanism that induces 
posttranscriptional gene silencing via sequence specific mRNA degradation121,122. 
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It was first described in 1984 when scientists observed transcriptional inhibition 
by antisense RNA123,124. In the early 90s it became clear that it was a conserved 
process functioning as an antiviral system via the silencing of viral genes125,126. 
RNAi occurs naturally in fungi, plants and animals, where long double stranded 
RNA (dsRNA) triggers RNAi127. RNAi involves a multistep process. First double-
stranded RNA (dsRNA) is recognized by Dicer, an RNAse III family member, and 
cleaved into small interfering RNA (siRNA) molecules of about 20-25 nucleotides 
long127,128. Dicer also initiates the formation of the RNA-induce silencing complex 
(RISC), which contains argonaute as catalytic component with endonuclease 
activity capable of degrading messenger RNA (mRNA) whose sequence is 
complementary to that of the siRNA guiding strand129. Subsequently, the guiding 
strand binds to the target mRNA, which is also cleaved by argonaute resulting in 
translational repression127 (see figure 1.5).
 RNAi has become an important research tool as an alternative for knock-
out animals to investigate gene function by repressing its expression. Since the 
discovery of RNAi several approaches were designed and described to perform 
RNAi in an easy and safe environment. In general there are three main types of 
RNAi that can be used to study gene function: synthetic RNAi delivery systems, 
plasmid transfection systems and viral infection systems. 
Figure 1.5 RNAi mechanism. Double-stranded RNA (dsRNA) is recognized by Dicer and cleaved 
into small interfering RNA (siRNA). Subsequently, Dicer initiates the formation of the RNA-induce si-
lencing complex (RISC). RISC unwinds the siRNA molecule and degrade the complementary strand, 
resulting in a single stranded RNA molecule. The guiding strand is guided to the target mRNA mole-
cule, which will be degraded by RISC, resulting is sequence specific gene silencing.   
Chapter 1
24
 The less labour-intensive way to achieve RNAi is by using synthetic RNA 
oligos130. Two complementary primers are designed that target a specific part 
of the gene of interest. Prior to transfection the primers are annealed, resulting 
is a double-stranded siRNA molecule. After transfection these molecules are 
recognized and processed by Dicer and enter the RNAi pathway130. Because this 
is an easy and quick method, it is feasible for testing different target sequences 
for testing which part of the mRNA is most sensitive for RNAi. A disadvantage 
is the relative short effect of these oligos. Each siRNA molecule is only active 
for one time and after cell division the oligo duplexes left are divided over two 
daughter cells. This can be overcome by transfecting cells multiple times, which 
increases the costs extensively.
 The second method uses plasmids containing a small hairpin under control of 
a polymerase III promoter (e.g. U6 or H1)131. After transformation into mammalian 
cells these plasmids starts to produce small hairpin RNAs (shRNA) which are 
recognized by Dicer and are subsequently transformed into siRNA molecules 
resulting in sequence specific gene silencing. The disadvantage of this method 
is that it is a cloning-based approach which requires more intensive laboratory 
work. First, plasmids containing your specific hairpins should be cloned. The 
advantage above synthetic oligos is that there is, once transformed into a cell, a 
continuous production of siRNAs, resulting in an almost infinite stock.
 The last method to achieve RNAi is by using viral constructs to infect cells. 
This method has a lot of similarities with the second one, but instead of using 
plasmids as shRNA delivery system a virus is used. The hairpin is cloned into 
a viral transfer plasmid, which is used to produce recombinant virus. These 
viruses can infect cells and the shRNAs are expressed under control of a H9 of 
U1 polymerase III promoter. As described in the previous section various viral 
vectors are available to date. For knock-down experiments mainly the same 
advantages and disadvantages account as for overexpression experiments 
using viral vectors. For primary human keratinocytes the lentiviral system is most 
suitable, as they will integrate into the target cells genome resulting sustained 
shRNA expression.
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Part 3: background on specific moleculed 
studied in this thesis
β-defensins
Defensins are secreted cationic peptides with a small molecular mass of 3-5 
kDa and are divided on alpha and beta subfamilies based on the intramolecular 
disulfide bonds132. Defensins are microbicidal peptides active against both 
gram-negative and gram-positive bacteria, fungi en enveloped viruses133. Alpha-
defensins are almost exclusively expressed in neutrophils, while beta-defensins 
expression is more found on epithelial cells134. 
 The genes coding for human β-defensins (DEFB genes) are grouped in three 
main gene clusters. Two clusters are located on chromosome 20 (20p13 and 
20q11.21) and one cluster is located on chromosome 8 (8p23.1)134. β-defensins 
are characterized by three pairs of intramolecular disulphide bonds and possess 
broad antimicrobial activity133. The spectrum of antimicrobial activity varies for 
each of the β-defensins. DEFB1 (hBD-1) and DEFB4 (hBD-2) have been shown 
to be particularly active against gram-negative bacteria and some fungi, but are 
relatively less potent against gram-positive bacteria135. In contrast, DEFB103 
(hBD-3) has a broad range of antimicrobial activity against yeast, gram-negative 
and gram-positive bacteria29. Besides antimicrobial activity β-defensins are also 
described to exhibit proinflammatory properties as chemoattractants for memory 
T-cells, immature dendritic cells, mast cells and neutrophils136.
 The cluster on chromosome 8 contains eight beta-defensin genes. All but 
DEFB1 are on a large repeat that is variable in copy number137. It was found 
that the human genome could contain up to 12 copies of this repeat per diploid 
genome, with a mode of four. Because expression of DEB103 and DEFB4, both 
positioned on the repeat, is induced in psoriatic skin, it was tempting to search 
for a correlation between beta-defensin copy number and psoriasis. Indeed, 
an association was found between a higher genomic copy number and risk for 
psoriasis78. Subsequently beta-defensin copy number is associated with other, 
mainly epithelial, diseases: Crohn’s disease (initially a lower copy number was 
associated138, but Benthley et al.139 found an association with higher copy numbers 
of the beta-defensin cluster), celiac disease (lower copy numbers are associated 
with patient140), severe acute pancreatitis (association between lower copy 
number and disease141), chronic obstructive pulmonary disease (copy number 
greater or equal to 5 was associated with increased risk142) and sporadic prostate 
cancer (high copy numbers above 9 are underrepresented in patients143).  
The vanin gene family
The first reference to vanins was in 1996. Mouse vanin-1 was found as a molecule 
involved in the regulation of thymus homing in hematopoietic precursor cells144. Its 
exact function remains unclear; no homology with other adhesion molecules was 
found, but sequence analysis showed some homology with human biotinidase145. 
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The name vanin was derived from vascular non-inflammatory molecule, pointing 
to the state and cell-type the protein was found144. Independently, Suzuki et al.146 
found a GPI-anchored protein (referred as GPI-80) on human leukocytes that 
was involved in the regulation of neutrophil adherence and migration. They found 
that GPI-80 was highly homologous with vanin-1 and subsequently GPI-80 was 
identified as VNN2. Finally the human vanin gene family appeared to consist 
of three genes (VNN1, VNN2 and VNN3), which are located on the long arm of 
chromosome 6 (6q23.2). Mice lack an orthologue of VNN2, so they only contain 
vanin-1 and vanin-3, which are located on mouse chromosome 10A2B1147. Via 
a glycosylphosphatidylinositol (GPI) anchor VNN1 and VNN2 are membrane-
bound ectoenzymes, while VNN3 is expected to be secreted as it lacks a GPI 
anchor. Free VNN2 has also been described148, possibly as a results of alternative 
splicing149.  
 Already in 1968, an enzymatic conversion of pantetheine to pantothenic 
acid (vitamin B5, a coenzyme A precursor) and the antioxidant cysteamine 
via hydrolysis of the carboamide linkage between them was found in horse 
kidneys150,151. The protein responsible for this conversion was called pantetheinase 
and its enzymatic conversion was termed pantetheinase activity (see figure 1.6a). 
The human enzyme had never been isolated, but pantetheinase activity has been 
observed in various human cells (fibroblasts, leukocytes and intestinal cells) and 
plasma152-154. In 1999, vanins were identified to be responsible for this activity 
after sequencing and aligning tryptic and chemotryptic peptides of this protein 
isolated from pig kidney155. This was confirmed for membrane-bound vanin-1 
in vanin-1 deficient mice, since these mice lack free cysteamine in tissues that 
express vanin-1 in wild-type mice156.
 As described above, vanins are enzymes that posses pantetheinase activity 
by hydrolyzing pantetheine into pantothenic acid and cysteamine and thus are 
likely to be involved in coenzyme A synthesis151,157. Wilson et al.158 described a 
theory in which vanin-1 has a central role in the recycling of coenzyme A after 
degradation, which releases free pantetheine (see figure 1.6b). They found 
transcription factor sites in the proximal promoter region that are involved in 
vanin-1 transcription. Steroidogenic factor-1 (SF-1) initiates the expression, 
which is further augmented by SOX8/9. Vanin-1 is suggested to be required to 
provide an appropriate environment for male cell development and thereby being 
a regulator during mouse testis development158,159.
 The development of a vanin-1 knockout mouse resulted in many new 
insights in the function of vanins. Vanins have been proposed to exert a role in 
inflammatory bowel disease, as mice lacking vanin-1 showed a decreased non-
steroidal anti-inflammatory drug (NSAID)- and Schistosoma-induced intestinal 
inflammation, which can be completely reversed by oral administration of 
cystamine, the oxidized form of cysteamine86. Vanin-1 licenses the production of 
inflammatory mediators by intestinal epithelial cells by antagonizing peroxisome 
proliferator-activated receptor (PPAR)γ160. In a colitis-associated colon cancer 
model vanin-1 knockout mice display a drastically reduced incidence of colorectal 
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cancer161. Furthermore, infecting vanin-1 deficient mice with Coxiella burnetti, 
a bacterium that causes Q fever, the formation of granuloma is reduced as 
compared with wild-type mice while mortality and morbidity of the mice were 
not affected162. These findings were correlated to a decreased expression of 
inducible nitric oxide synthase (iNOS) and MCP-1, while IL-10 and arginase 
expression were increased. On the other hand, the absence of vanin-1 in mice 
aggravates the development of type 1 diabetes. Apparently, cysteamine has a 
major cytoprotective role for islet cells, which cell death is a key initiating and 
perpetuating event in type 1 diabetes development163. 
 Studies on VNN2 showed expression mainly on neutrophils in various organs. 
VNN2 expression is sublocated in secretory vesicles and linked to play a role in 
Figure 1.6 Biological processes of vanins. (A) Vanins are enzymes that posses pantetheinase ac-
tivity by the hydrolysis of pantetheine into pantothenic acid (vitamin B5) and cysteamine. (B) Vanins 
are thought to play a role in CoA metabolism by recycling pantothenic acid. 
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neutrophil extravasation as a regulator of β2 integrin in neutrophils
164,165. In resting 
neutrophils VNN2 expression is associated with β2 integrin, but during neutrophil 
migration VNN2 is located on the pseudopodia while β2 integrin remains located 
on the cell body166. Using another antibody against VNN2, contradictionary 
results were found where VNN2 expression appears associated with β2 integrin 
during migration167, suggesting two different populations of VNN2. Indeed Nitto 
et al.149 found four splice variants of VNN2 expressed in neutrophils, resulting in 
different proteins. These findings suggest multiple functions for VNN2. TNF-α 
induces the release of VNN2 from human neutrophils, but did not affect surface 
VNN2 levels168. Besides on neutrophils VNN2 expression was also found on the 
subpopulation of monocytes that is more involved in phagocytosis and reactive 
oxygen production than antigen presentation (CD14-positive monocytes)169. 
Exogenous expression of VNN2 in Chinese hamster ovary (CHO) cells influences 
cell spreading via extracellular matrix molecules170.
 Occasionally, members of the vanin gene family are described in genomic 
studies in which the expression is altered, or an association with disease is found. 
In most cases the link between vanin expression and disease activity remains 
unclear. The absence of vanin-1 and vanin-3 mRNA in A/J mice is associated 
with susceptibility to malaria171. In this study the relation between malaria 
susceptibility and vanin activity appears clear as administration of cystamine 
to A/J mice partially restores their susceptibility as measured by reduced blood 
parasitemia and decreased mortality. Subsequently this group showed that 
cystamine acts specifically against plasmodium parasites, as cystamine does not 
protect against the parasite Trypanosoma cruzi or the fungal pathogen Candida 
albicans172, suggesting that cystamine does act directly on Plasmodium and does 
not modulate a host inflammatory response. Finally, they describe that cystamine 
potentiates the antimalarial agent artemisinin173. In an approach to discover cis-
regulated transcripts that influence complex traits in human, sequence variations 
in the VNN1 gene appear to influence high-density lipoprotein cholesterol 
concentration174. The VNN1 promoter contains methylation-sensitive SNPs, 
which makes the gene sensitive for allele-specific DNA methylation175. Another 
association was found in synovial fluids of rheumatoid arthritis patients, where high 
levels of soluble VNN2 were detected as compared with their serum concentration 
suggesting an active role of VNN2 in inflammation148. More recently, VNN1 has 
been ascribed as a blood biomarker in a 7-gene panel for colorectal cancer176. 
These results were independently confirmed in another group of patients177. The 
expression van VNN1 combined with expression of metalloproteinase 9 (MMP9) 
could be used to discriminate pancreatic cancer-associated diabetes from type 
2 diabetes178. A study for differentially expressed genes between invasive and 
noninvasive human thymoma revealed VNN2 to be highly upregulated179. As 
described in the previous section, VNN3 appears highly upregulated in lesional 
psoriatic epidermis as compared with affected epidermis derived from atopic 
dermatitis patients27. At this point, nothing was known of the expression of vanins 
in skin.
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1.10. Aims of this thesis
Over the last 6 years, the role of keratinocytes in the most common skin diseases 
has been extensively investigated. A microarray study by our group formed the 
basis of a PhD project granted by the Radboud University Nijmegen Medical 
Centre to our department. The broad aim was to investigate disease-specific 
epidermal gene expression, and to examine the relevance of genes (DEFB4 and 
VNN3) in the aetiology, diagnostics and therapy of psoriasis and eczematous 
diseases (chapters 2, 3 and 4) . We improved and designed skin models to 
investigate gene function with new sophisticated methods  (chapters 5 and 6). 
Finally, we designed small molecules that target the vanins (chapter 7), which 
might be useful in applications (antibiotics) that fall beyond the dermatological 
scope (chapter 8).  
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Abstract
The vanin gene family encodes secreted and membrane-bound ectoenzymes 
that convert pantetheine to pantothenic acid and cysteamine. Recent studies in 
a mouse colitis model indicated that vanin-1 has proinflammatory activity and 
suggest that pantetheinases are potential therapeutic targets in inflammatory 
diseases. In a microarray analysis of epidermal gene expression of psoriasis and 
atopic dermatitis lesions we identified vanin-3 as the gene showing the highest 
differential expression of all annotated genes that we studied (19-fold upregulation 
in psoriasis). Quantitative real-time PCR analysis confirmed the microarray data 
on vanin-3 and showed similar induction of vanin-1, but not of vanin-2, in psoriatic 
epidermis. Immunohistochemistry showed that vanin-3 is expressed in the 
differentiated epidermal layers. Using submerged and organotypic keratinocyte 
cultures we found that vanin-1 and vanin-3 are induced at the mRNA and protein 
level by psoriasis-associated proinflammatory cytokines (Th17/Th1) but not by 
Th2 cytokines. We hypothesize that increased levels of pantetheinase activity are 
part of the inflammatory-regenerative epidermal differentiation program, and may 
contribute to the phenotype observed in psoriasis.
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Introduction
The human vanin gene family consists of thee genes, vanin-1 (VNN1), vanin-2 
(VNN2) and vanin-3 (VNN3) that are located on chromosome 6q22-241,2. These 
genes show a similar structure consisting of seven exons, and encode proteins 
with a high degree of homology (~65% sequence identity)3. Human vanin-1 
and vanin-2 being membrane-associated ectoenzymes and vanin-3 a secreted 
enzyme. Vanins are conserved among species and two mice orthologues 
(vanin-1 and vanin-3, but not vanin-2) have been identified3. Vanin-1 was first 
described as a regulator of the late adhesion steps in thymus homing in mice4. 
Human vanin-2 was characterized as a molecule involved in the regulation of 
adherence and migration of neutrophils5. Subsequent studies identified vanins 
as enzymes that are involved in Coenzyme A (CoA) synthesis. Their enzymatic 
activity catalyzes the conversion of pantetheine to pantothenic acid (vitamin 
B5, a CoA precursor) and the anti-oxidant cysteamine2,6. In mice deficient for 
vanin-1 no free cysteamine was found in tissues, suggesting that at least in mice 
vanin-1 is a major pantetheinase7. These mice show decreased NSAID- and 
Schistosoma-induced intestinal inflammation, which can be completely reversed 
by oral administration of cystamine, the oxidized form of cysteamine8. Vanin-1 
deficiency is also able to control colitis in the 2,4,6-trinitrobenzene sulfonic acid 
(TNBS)-colitis model9. Another biological activity of cysteamine is its presumed 
antagonism of the peroxisome proliferator-activated receptor gamma (PPAR-γ). 
Based on these findings it was proposed that vanin-1 is an epithelial sensor of 
stress that exerts a dominant control over innate immune responses in mouse 
tissue9. Therefore, the pantetheinase activity of vanin family members could be a 
novel therapeutic target in inflammatory diseases.
 Psoriasis vulgaris and atopic dermatitis are two common chronic inflammatory 
skin diseases, characterized by various different clinical and histological features 
depending on the stage of the disease. Both diseases are generally regarded 
as immune-mediated conditions involving activated T-cells and cytokines of 
the Th1/Th17 type (psoriasis) or the Th2 type (atopic dermatitis)10-12. In lesional 
psoriatic skin, increased levels of pro-inflammatory cytokines like IL-1, TNFα, 
IFNγ, IL-6, IL-8, IL-17 and IL-22 are found. These cytokines, which are produced 
by T-cells, dendritic cells and/or keratinocytes, can act both on immunocytes and 
keratinocytes. Activation of keratinocytes by these cytokines induces specific 
gene expression profiles, that include secretion of antimicrobial proteins and 
chemokines13. In addition to the role of the adaptive immune system, recent 
genetic studies have indicated the importance of abnormalities in epithelium-
expressed genes as a primary cause. Loss of function alleles of the skin 
barrier protein filaggrin were found to be a major predisposing factor for atopic 
dermatitis14, and we have recently demonstrated that copy number variation of a 
beta defensin gene cluster was associated with increased risk for psoriasis15. The 
differences in gene expression between lesional psoriatic epidermis and lesional 
atopic dermatitis epidermis have been investigated by various methods13,16,17. 
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Using a microarray approach on purified epidermis we identified 183 genes to 
be differentially expressed between psoriasis and atopic dermatitis16. These data 
are accessible through GEO Series accession number GSE6601, http://www.
ncbi.nlm.nih.gov/geo. Remarkably, we identified vanin-3 as the gene showing the 
highest differential expression of all annotated genes that we studied (unpublished 
data). As there was no information on expression of vanin family members in 
human epidermis, and vanin-1 has recently been described as a potential drug 
target in inflammatory bowel disease, we decided to investigate the expression 
and induction of vanin-3 and other vanin family members in human epidermal 
keratinocytes in vivo and in vitro. Our results suggest that vanin-1 and vanin-3 
could be relevant mediators in Th17/Th1-drived inflammatory skin conditions.
Results
High expression levels of vanin-1 and vanin-3 in lesional psoriatic skin
The transcriptome of epidermal sheets of lesional epidermis from psoriasis 
and atopic dermatitis was analyzed using high-density oligonucleotide arrays 
as previously described (GEO Series accession number GSE6601). All known 
human vanin genes were present on the microarray. Vanin-1 and vanin-3 were 
detectable in all 12 samples, whereas vanin-2 was detected in none of them. 
Vanin-3 showed the highest upregulation (19-fold) of the annotated genes on 
the array in psoriasis compared to atopic dermatitis. Also vanin-1 was found 
to be relatively overexpressed in psoriasis (2.3-fold). Microarray data were 
confirmed by qPCR analysis on mRNA from lesional skin of psoriatic patients 
and atopic dermatitis patients, and normal skin of healthy volunteers. Figure 2.1 
shows that vanin-3 expression is high in psoriatic epidermis, but low in normal 
Figure 2.1 Analysis of vanin mRNA in healthy, psoriasis and atopic dermatitis skin. Quantita-
tive real-time PCR for vanin-1, vanin-2 and vanin-3 was performed on RNA of epidermal sheets from 
skin biopsies of healthy controls (n=7), psoriatic patients (n=9) and atopic dermatitis patients (n=6). 
Expression of target genes was normalized to that of RPLP0. For graphical representation all values 
were expressed relative to vanin-1 in normal skin, which was set at unity18. Primer sequences and 
efficiency of amplification are given in table 2.1. Vanin-1, vanin-2 and vanin-3 expression is induced 
in both psoriasis and atopic dermatitis as compared to normal skin. Values are presented as mean 
and SD. One-way ANOVA; *P < 0.001.
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skin and atopic dermatitis. Vanin-1 expression was strongly induced in psoriasis 
patients and moderately in atopic dermatitis patients as compared to normal 
skin. Although Vanin-2 expression was significantly induced in both psoriasis and 
atopic dermatitis, its expression is very low compared with vanin-1 and vanin-3
 As there is little quantitative information on relative expression levels of 
human vanin family members in most organs, we performed qPCR on a large 
panel of tissues including many epithelia, to allow comparison with epidermis. 
Figure 2.2 shows the expression of the vanin genes in different tissues. The 
highest expression levels of vanin-3 were found in liver and blood, being of 
similar magnitude as found in psoriatic epidermis. Other tissues where vanin-3 
expression was found are the urethra, the lymph nodes, parts of the respiratory 
tract and most parts of the gastrointestinal tract. Vanin-2 expression was found 
in almost all tissues, but by far the highest expression was found in spleen and 
blood. In lesional psoriatic epidermis vanin-2 expression was near the average 
expression. Vanin-1 was mainly expressed in the same tissues as vanin-3, but 
relatively high expression was found in spleen, kidney and blood. In lesional 
psoriatic epidermis vanin-1 expression was of the same magnitude as kidney 
and liver. 
Vanin-3 protein is expressed by differentiated keratinocytes
To investigate which cellular compartment of the epidermis express vanins, we 
performed immunohistochemical staining on normal skin, atopic dermatitis skin 
and psoriatic skin. As there were no commercial antisera available that were 
suitable for immunohistochemistry, we expressed recombinant vanin-3 as a 
Figure 2.2 mRNA expression of vanin family members in normal human tissues. Quantitative 
real-time PCR was performed on RNA of normal human tissues. Expression of target genes was nor-
malized to that of RPLP0. For graphical representation all values were expressed relative to vanin-1 
in tongue, which was set at unity, to allow comparison of the expression levels between tissues and 
genes18. Normal human tissues are from one individual. Values from epidermis (at least 6 biopsies) 
are given for comparison.
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TrXA-fusion protein which was used to raise a polyclonal antiserum in rabbits. 
Figure 2.3 shows that epidermal vanin-3 protein expression is largely confined 
to differentiated keratinocytes, both in normal and psoriatic epidermis. Vanin-3 
expression in normal and atopic dermatitis epidermis is restricted to the stratum 
granulosum, while in psoriatic epidermis strong vanin-3 expression is also found 
in the stratum spinosum. Dermal vanin-3 expression was limited to endothelial 
cells and a small proportion of the cellular infiltrate.
Induction of vanin expression by cytokines
The psoriasis-specific induction of vanin-1 and vanin-3 suggested to us that 
psoriasis-associated cytokines could be involved in vanin gene regulation. We 
have previously shown that in vitro stimulation of cultured normal keratinocytes 
by mixtures of psoriasis-associated cytokines (IFN-γ, TNF-α and IL-1 herein 
further referred to as Th1 cytokines) or atopic dermatitis associated cytokines 
(IL-4 and IL-13, herein further referred to as Th2 cytokines) results in disease-
specific gene expression in these cells. Figure 2.4 shows expression of vanin-1 
and vanin-3 by submerged cultures of human keratinocytes stimulated with 
Figure 2.3 Immunolocalization of vanin-3 in normal, atopic dermatitis and psoriasis skin. Im-
munohistochemical staining of normal skin (a) and lesional skin of an atopic dermatitis patient (b) and 
a psoriasis patient (c) with a polyclonal rabbit antiserum against recombinant vanin-3. Expression of 
vanin-3 in normal skin and atopic dermatitis skin was limited to the stratum granulosum, whereas in 
psoriasis skin strong vanin-3 expression is found in multiple layers of the stratum spinosum. Bar = 
100 µm. Control sections stained with pre-immune serum were virtually negative (see inserts).
Figure 2.4 Induction of vanin expression in submerged cul-
ture by proinflammatory cytokines. Quantitative real-time PCR 
of vanin-1 and vanin-3 was performed on RNA obtained from 
submerged cultured keratinocytes after stimulation with various 
combinations of proinflammatory cytokines and compared with 
non-stimulated keratinocytes (n=6). Concentrations of cytokines 
were previously optimized for induction of psoriasis-like phenoty-
pes in vitro. Vanin-1 and vanin-3 expression was strongly induced 
by the Th1-cytokine mixture (IFN-γ, TNF-α and IL-1α; n=6) and IL-
17 (n=5). IL-22 (n=5) induces vanin-1 expression, but not vanin-3 
expression. A Th2-cytokine mixture (IL-4 and IL-13; n=5) has no 
effects on vanin expression. A mixture of all cytokines showed a 
strong, synergistic induction of vanin expression (n=5). Repeated 
measures ANOVA; *P < 0.05, **P < 0.005.
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cytokines. The cytokine mixtures and concentrations were chosen based on 
previous experiments to establish optimal concentrations for induction of a 
psoriatic phenotype (expression of beta-defensin-2 (hBD-2) and elafin) or atopic 
dermatitis phenotype (expression of carbonic anhydrase II)13,19. We found that 
both vanin-1 and vanin-3 expression is induced after Th1-cytokine stimulation. 
Vanin-2 is not upregulated following cytokine stimulation (data not shown). Th2-
cytokines did not have a significant effect on expression of any of the vanin genes. 
In addition, we also tested the Th17 cytokines IL-17 and IL-22. Both vanin-1 and 
vanin-3 expression was increased upon stimulation with IL-17, but not after IL-22 
stimulation which only has a small stimulatory effect on vanin-1 expression. A 
combination of Th1 cytokines and Th17 cytokines resulted in a strong synergistic 
induction of both vanin-1 and vanin-3 expression, of similar magnitude as found 
in vivo in psoriatic epidermis (not shown).
Induction of vanin-1 and vanin-3 in reconstructed human epidermis by cytokines
We have recently described a reconstructed skin model in which we could induce 
a psoriatic phenotype (as witnessed by expression of the surrogate markers hBD-
2 and elafin) by the addition of psoriasis-associated cytokines. We found that in 
these reconstructed skin models the addition of interferon-γ was dispensable, 
whereas IL-6 strongly potentiated the effect of IL-1α and TNF-α20. For this 
reason we used cytokine mixtures of TNF-α, IL-1α and IL-6 or individual Th17 
cytokines such as IL-17 and IL-22 to examine the effect on vanin gene induction. 
Here these constructs were stimulated with various cytokines to investigate the 
induction of vanins. Using qPCR analysis we found similar effects of psoriasis 
and atopic dermatitis associated cytokines on vanin expression as found in 
submerged cultures (figure 2.5). Both IL-17 and the mix of TNF-α, IL-1α and 
IL-6 induced strong vanin-1 and vanin-3 expression. IL-22 induced a weak, non-
significant expression of vanin-1 and vanin-3. Th2 cytokine mix did not induce 
vanin-1 but showed a small but non-significant increase in vanin-3 expression. 
Immunohistochemical staining of these skin constructs confirmed the qPCR 
results, showing a strong induction of vanin-3 staining in the upper epidermal 
layers of cultures stimulated with IL-17 or with the mix of TNF-α, IL-1α and IL-6 
(figure 2.6).
Figure 2.5 Induction of vanin expression in reconstructed 
skin by proinflammatory cytokines. Quantitative real-time PCR 
of vanin-1 and vanin-3 was performed on RNA obtained from re-
constructed skin after stimulation with various combinations of pro-
inflammatory cytokines and compared with non-stimulated recon-
structed skin (n=5). Here we used a cytokine mixture containing 
TNF-α, IL-1α and IL-6 based on previous experiments for optimal 
induction of a psoriatic phenotype in vitro in reconstructed skin. 
Both this cytokine mixture (n=2) and IL-17 alone (n=3) strongly in-
duced vanin-1 and vanin-3 expression. The Th2-cytokine mixture 
(n=2) and the Th17 cytokine IL-22 (n=3) had no effects on vanin 
expression. One-way ANOVA; *P < 0.05, **P < 0.005.
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Discussion
Using microarray analysis, qPCR and immunohistochemistry we have analyzed 
expression of the vanin gene family, which has not been previously reported in 
skin. Expression of vanin-1 and vanin-3 was shown to be part of the inflammatory-
regenerative differentiation program that is characteristic for psoriasis. High 
expression levels of vanin-1 and vanin-3 could be induced by psoriasis-associated 
pro-inflammatory cytokines in submerged and air-exposed keratinocyte cultures. 
In vitro reconstructed skin can be used as a model for further study of the role of 
vanins in epidermal biology. 
 Apart from studies on gene structure, very little is known on human vanin 
gene expression at the mRNA and protein level. A putative function of vanin-2 
in cell adherence has been reported for human neutrophils, and recently the 
expression of vanin splice forms has been reported in these cells21. The existence 
of splice variants in the pantetheinase gene family suggested the possibility of 
alternative roles in addition to their enzymatic activity. Most functional data on 
vanin family members (predominantly vanin-1) come from studies in knockout 
mice (see introduction section). From these mouse studies vanins emerge as 
a class of enzymes that can have both proinflammatory effects and protective 
effects. Although there is no information at this moment whether increased vanin-1 
and vanin-3 expression leads to increased levels of metabolites (cysteamine, 
pantothenic acid) in psoriatic epidermis, we would argue that this could possibly 
Figure 2.6 Immunohistochemical staining of vanin-3 in reconstructed skin. Reconstructed skin, 
with or without cytokine stimulation, was stained for vanin-3 using a polyclonal rabbit antiserum 
against recombinant vanin-3. Control cultures (a) or Th2-cytokine stimulated cultures (c) showed 
a weak expression of vanin-3, predominantly in the upper differentiated layers. Stimulation with a 
cytokine mixture of TNF-α, IL-1α and IL-6 (b) or with IL-17 (c) results in strong expression of vanin-3 
in the upper differentiated layers. Bar = 100 µm. Control sections stained with pre-immune serum 
were virtually negative (see inserts).
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contribute to the skin abnormalities observed in psoriasis, as will be discussed in 
the next paragraphs. 
 In this study we have found that vanin-3 is expressed in differentiated 
keratinocytes. Although the exact function of vanins in skin remains to be 
elucidated it is attractive to speculate about a role of vanins in terminal 
differentiation. The products of the vanin-mediated enzymatic conversion of 
pantetheine are pantothenic acid and cysteamine. Pantothenic acid, a precursor 
of CoA, is involved in epidermal lipid synthesis. In normal human epidermis, 
high levels of lipid synthesis are found in both the basal layer and the stratum 
granulosum22. Lipids are important for skin barrier function as they are part of the 
lamellar bodies formed by keratinocytes in the stratum spinosum23. The contents 
of lamellar bodies are secreted into the extracellular spaces and transformed 
into lamellar bilayers to form an impermeable, lipid-containing sheet that serves 
as a water barrier. The increased expression of vanins in psoriatic epidermis 
could reflect the increased requirement of precursors to keep up with the lipid 
synthesis that is necessary to compensate the increased keratinocyte turnover 
(i.e. shortened half-life) in psoriasis. Notwithstanding this potentially increased 
supply of lipid precursors, the skin barrier function in psoriasis is abnormal 
with respect to water loss24. This could be due to the biochemical activity of 
cysteamine, the other metabolite of the vanin-mediated enzymatic conversion 
of pantetheine. Cysteamine is a strong transglutaminase (TGase) inhibitor by 
its binding to an important cysteine residue in the active site of the enzyme25,26. 
In skin TGase-1, TGase-3 and TGase-5 are the major TGases that catalyze the 
formation of ε-(γ-glutamyl)lysine bonds between cornified envelope precursor 
proteins27-29. TGases play an important role in normal skin development and they 
are expressed at different stages of epidermal differentiation and at different levels 
within the epidermis. In psoriatic skin TGase-5 expression is unaffected, while it 
has been demonstrated that TGase-3 expression is slightly downregulated27. The 
expression of TGase-1 is shifted from the granular layer in normal skin to the 
suprabasal spinous layer in psoriatic skin30. As most studies only determine the 
presence of TGase enzymes and not their activity within the tissue this does not 
provide information on a possible effect of epidermal cysteamine. Some authors 
argue that TGase activity in psoriasis is increased31,32, but these findings are 
mainly based on ex vivo experiments where endogenous epidermal cysteamine 
could easily be washed away resulting in active TGase proteins in their assays. A 
recent study by Harrisson et al. has investigated the effect of TGase inhibitors in 
a reconstructed skin model. Interestingly, they found that TGase inhibition caused 
a psoriatic phenotype in vitro, including hyperproliferation, parakeratosis and 
cytokeratin 16 expression which are hallmarks of the disease33. These findings 
support a role for vanin-dependent cysteamine production in the pathogenesis of 
the disease. 
 Another enzyme whose activity is inhibited by cysteamine is caspase-334. 
This enzyme is activated during terminal differentiation of keratinocytes. In normal 
skin caspase-3 is involved in both nuclear loss and correct filaggrin processing35. 
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Addition of caspase-3 inhibitors to reconstructed skin models prevents nuclei to 
be degraded which may lead to parakeratosis35. Also the alteration of filaggrin 
processing as a result of caspase-3 inhibition could contribute to a disturbed 
skin barrier as found in psoriasis and atopic dermatitis. Speculatively, increased 
cysteamine levels caused by vanin-1 and vanin-3 overexpression could inhibit 
caspase-3 activity thereby contributing to the phenotypic changes such as 
parakeratosis and compromised skin barrier seen in psoriasis.
 Finally, cysteamine is reported to be an antagonist for PPARγ9. In human 
epidermis PPARs (PPARα, PPARβ/δ and PPARγ) are important ligand-activated 
transcription factors that are involved in the maintenance of skin homeostasis 
by inhibiting epidermal cell growth, promoting epidermal terminal differentiation 
and regulating skin inflammatory responses36. These properties make PPARs 
interesting molecules with respect to psoriasis and other inflammatory skin 
disorders. In psoriasis the epidermal expression of PPARα and PPARγ is decreased, 
suggesting a role for these proteins37. In the last few years PPARγ activators 
have been used as an antipsoriatic drug; PPAR agonists thiazolidinedione (TZD) 
and its derivates rosiglitazone and pioglitazone have shown to be beneficial for 
psoriasis patients38-40. In a murine model, also the TZD derivates ciglitazone and 
troglitazone improve skin homeostasis41. The exact role of PPARγ in psoriasis is 
still not completely clear, but increased levels of an endogenous antagonist like 
cysteamine could explain the positive effects of these PPARγ activators.
 Since cysteamine is a potent antioxidant and skin is exposed to oxidative 
stress, vaninscould very well have a role in these processes. Surprisingly, vanin-1 
knockout mice, which lack cysteamine in tissues where vanin-1 is predominantly 
expressed, display resistance to systemic oxidative stress caused by paraquat 
administration or a lethal dose of γ-irradiation. This effect was ascribed to 
increased levels of glutathione, an even more potent antioxidant, in liver of 
these knockout mice and was reversible after administration of cysteamine. 
Some papers argue that oxidative stress plays a role in the pathogenesis of 
psoriasis42,43 and it has also been reported that there is insufficient antioxidant 
activity in psoriatic lesions44. In plasma of psoriatic patients the total plasma 
antioxidant capacity was increased compared with healthy individuals45, which 
could be the result of increased vanin expression in lesional skin leading to 
increased levels of cysteamine. One of the functions of the stratum corneum 
implies antioxidant defense, but most oxidative stress was found in the dermis 
and basal layers of psoriatic skin46. Vanin expression was predominantly found 
in the stratum granulosum and stratum spinosum indicating a possible role in 
the antioxidant defense against reactive oxygen species (ROS) generated by 
exogenous mechanisms (e.g. UV-light) rather than endogenous ROS. 
 In conclusion, this is the first report describing the strongly increased 
expression of vanin-1 and vanin-3 in psoriatic skin. However, many questions 
remain to be answered regarding the function of vanins in normal and psoriatic 
skin. Induction of vanin expression as part of the inflammatory-regenerative 
differentiation program of human epidermis could be a beneficial response to 
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supply the skin with anti-oxidant activity and sufficient pantothenic acid to restore 
skin barrier function. Alternatively, cysteamine could, via its inhibitory activity 
towards TGases and caspase-3, and its agonistic activity towards PPARγ, 
contribute to the pathology observed in lesional skin, which is clearly an area for 
future research.
Material and methods
Human tissues
Biopsies of normal human skin, psoriatic lesions and atopic dermatitis lesions 
were taken under local anesthesia with 4 mm punches. Psoriasis biopsies were 
taken from the centre of a chronique plaque. All samples were collected with 
written informed consent using protocols that comply with the Declaration of 
Helsinki Principles. Permission for these studies was obtained from the medical 
ethics committee (Commissie Mensgebonden Onderzoek Arnhem-Nijmegen). 
Archival autopsy material was obtained from the Department of Pathology, 
University of Nijmegen, The Netherlands. 
Submerged keratinocyte cultures
Primary human keratinocytes obtained from biopsies of healthy volunteers, 
psoriasis patients and atopic dermatitis patients were cultured following the 
Rheinwald-Green system47 and stored in liquid nitrogen until use. First-passage 
cells were cultured to confluency in keratinocyte growth medium (KGM), and 
induced to differentiate by growth factor depletion as described before48,49. 
Differentiating cell cultures were stimulated with a mix of 10 U/ml interferon-γ, 30 
ng/ml TNF-a and 30 ng/ml IL-1a (referred to as Th1 cytokine mix), a mix of 50 
ng/ml IL-4 and 50 ng/ml IL-13 (referred to as Th2 mix), 30 ng/ml IL-17, 30 ng/ml 
IL-22, a combination of IL-17, IL-22 and the Th1 mix, or left untreated (control)13. 
IL-1a, TNF-a, IL-4, IL-13, IL-17 and IL-22 were obtained from Peprotech (London, 
UK) and interferon-γ from HyCult Biotechnology (HBT, Uden, The Netherlands). 
The cells were harvested after 48 hours for mRNA isolation.
Three-dimensional reconstructed skin
Reconstructed skin was generated as described before20. Briefly, de-epidermized 
human dermis (DED) of 0.8 mm thickness and 8 mm diameter was used as 
a scaffold for keratinocytes in tissue culture inserts in a 24-well plate. These 
were cultured submerged for three days, and subsequently the medium level 
was lowered to allow air-exposure to induce terminal differentiation. After seven 
days of air exposure a fully stratified epidermis has developed that expresses all 
normal differentiation markers, but is negative for psoriasis-associated genes like 
cytokeratin 16 (CK16), elafin and hBD-2. At this point a mixture of proinflammatory 
cytokines (10 ng/ml IL-1α, 5 ng/ml TNF-α and 5 ng/ml IL6 ), Th2-cytokines (50 ng/
ml IL-4 and 50 ng/ml IL-13) or Th17-cytokines (100 ng/ml IL-17 or 100 ng/ml IL-
22) is added for 72 hours, which induces cytokine-specific gene expression. IL-6 
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was obtained from Gentaur (Brussels, Belgium). Two different donors of human 
keratinocytes were used. 
Real-time quantitative polymerase chain reaction
Epidermal sheets from skin biopsies or skin constructs were separated from the 
underlying dermis according to previously described protocols20,50. RNA extracted 
from twenty-six different normal human tissues, punch biopsies and cultured 
human keratinocytes was used for first strand cDNA synthesis with the iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according the manufacturer’s 
recommendation with an input of 1 µg of RNA. The reverse transcriptase product 
was used as a template for real-time quantitative PCR amplification of genes of 
interest with the MyiQ Single-Color Real-Time Detection System for quantification 
with Sybr Green and melting curve analysis (Bio-Rad, Richmond, CA, USA). 
Expression of target genes vanin1, vanin-2 and vanin-3 was normalized to that 
of the housekeeping gene human ribosomal phosphoprotein P0 (RPLP0). Primer 
sequences (Biolegio, Nijmegen, the Netherlands) and efficiency of amplification 
are given in table 2.1.
Vanin-3 antibody production
A vanin-3 PCR product from cDNA derived from cultured keratinocytes was cloned 
into pET-32a vector (Novagen, Madison, WI, USA), expressed as a TrxA-Vanin-3 
fusion protein in Escherichia coli. The fusion protein was emulsified with complete 
Freund’s adjuvant to immunize rabbits to generate polyclonal serum. Animals 
were boostered with TrxA-Vanin-3, and blood was obtained for serum preparation. 
Pre-immune serum was drawn for control staining in immunohistochemistry.
Immunohistochemistry
Human skin biopsies and human reconstructed skin were fixed in buffered 
4% formalin for 4 hours and processed for routine histology. Subsequently, 
the reconstructed skin was embedded in paraffin and 6 µm sections were cut. 
Sections were processed for staining using an indirect immunoperoxidase 
technique with avidin-biotin complex enhancement. All procedures have been 
described previously in detail51. Vanin-3 staining was performed using our vanin-3 
antibody raised in rabbit as primary antibody and a goat-anti-rabbit antibody as 
Gene Forward primer (5' → 3') Reverse primer (5' → 3') E*
Vanin-1 gaacccagtatgtctttcct catacaacctcccaaacaga 2.06
Vanin-2 gtgctacttaccgaaattcatc tttaccaaacgcccatctt 2.00
Vanin-3 gatcattctaagtgggagtca cgtccatctcttgaaatctca 2.20
RPLP0 caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag 2.00
*E is efficiency as fold increase in fluorescence per PCR cycle
Table 2.1 Primers for qPCR
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secondary antibody (Vector Laboratories, Burlingame, CA, USA). As a control, 
also the pre-immune serum was used in the same dilution (1:500) as the vanin-3 
antibody.
Statistics
Data are expressed as mean ± standard deviation. Statistical analysis of qPCR 
data was done on deltaCt values using the SPSS software (release 16.0 Chicago, 
IL, USA). One-way analysis of variance (ANOVA) and repeated measures 
ANOVA were performed followed by post-hoc testing corrected for multiple testing 
(Bonferroni). P-values of <0.05 were considered statistically significant.
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Abstract
Background
Previous studies have extensively documented antimicrobial and chemotactic 
activities of beta-defensins. Human beta-defensin-2 (hBD-2) is strongly expressed 
in lesional psoriatic epidermis, and recently we have shown that high beta-
defensin genomic copy number is associated with psoriasis susceptibility. It is not 
known, however, if biologically and pathophysiologically relevant concentrations 
of hBD-2 protein are present in vivo, which could support an antimicrobial and 
proinflammatory role of beta-defensins in lesional psoriatic epidermis. 
Methodology/Principal Findings
We found that systemic levels of hBD-2 showed a weak but significant correlation 
with beta defensin copy number in healthy controls but not in psoriasis patients 
with active disease. In psoriasis patients but not in atopic dermatitis patients, we 
found high systemic hBD-2 levels that strongly correlated with disease activity 
as assessed by the PASI score. Our findings suggest that systemic levels in 
psoriasis are largely determined by secretion from involved skin and not by 
genomic copy number. Modelling of the in vivo epidermal hBD-2 concentration 
based on the secretion rate in a reconstructed skin model for psoriatic epidermis 
provides evidence that epidermal hBD-2 levels in vivo are probably well above 
the concentrations required for in vitro antimicrobial and chemokine-like effects. 
Conclusions/Significance
Serum hBD-2 appears to be a useful surrogate marker for disease activity in 
psoriasis. The discrepancy between hBD-2 levels in psoriasis and atopic 
dermatitis could explain the well known differences in infection rate between 
these two diseases. 
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Introduction
Psoriasis is a highly prevalent inflammatory skin disease that has both 
environmental and genetic components to its etiology1,2. Genetic evidence for 
an (auto)immune basis of psoriasis is provided by the well-known association of 
the disease with the HLA-Cw6 gene3 and the recently discovered associations 
with IL12B and IL23R4,5. Lesional psoriatic skin is characterized by various 
morphological abnormalities of the epidermis, and a cellular infiltrate of activated 
T-cells. There are several arguments to invoke an important role of activated 
T-cells such as the oligoclonal T-cell expansion in psoriatic skin6 and the 
therapeutic efficacy of T-cell directed drugs such as cyclosporin A and some of 
the biologics that are currently available. Recent evidence also points to a role 
of other cell types such as plasmacytoid dendritic cells7, and cytokine networks 
associated with cells from the adaptive and innate immune system1,8. Based on 
clinical studies in humans and experimental studies in mice, several of these 
cytokines have been identified including IL-1, TNFα, interferon-γ and IL-6. In 
the epidermis a regenerative epidermal differentiation program is induced that 
includes hyperproliferation and expression of genes such as cytokeratin 16 
(CK16), SKALP/elafin, psoriasin and hBD-29,10. Expression of these genes is to 
some extent specific for psoriasis, as they are expressed at low levels, if at all, in 
lesional atopic dermatitis skin11-13. 
 Recent findings from various labs including our own have indicated that 
polymorphisms of genes that are expressed in the epithelium, but not necessarily 
in immunocytes, could also be risk factors for inflammatory skin diseases such 
as atopic dermatitis and psoriasis14-17. This finding was further supported at the 
cellular level when we found cell-autonomous differences between keratinocytes 
from psoriasis and atopic dermatitis patients18. From these studies we concluded 
that psoriatic keratinocytes are programmed to secrete large amounts of host 
defense proteins such as beta-defensins, in response to Th1 or Th17 cytokines. 
 Beta-defensins are secreted peptides of low molecular weight ranging from 
3 to 5 kDa. These peptides, which are expressed by epithelia, possess a broad 
spectrum of antimicrobial activity against both gram-positive and gram-negative 
bacteria, fungi and viruses19. Besides antimicrobial activity, they also exhibit 
pro-inflammatory properties as chemoattractants for memory T-cells, immature 
dendritic cells, mast cells and neutrophils20-22. These peptides, encoded by the 
DEFB genes, are present in three main gene clusters, two on chromosome 20 
and one on 8p23.1. The cluster on 8p23.1 contains eight beta-defensin genes 
of which seven (all but DEFB1) are on a large repeat that is variable in copy 
number. In humans up to 12 copies of this repeat have been found, with a mode 
of four copies per diploid genome23. Of the eight beta-defensin genes located on 
8p23.1, human beta-defensin-1 (hBD-1) protein, (encoded by DEFB1) and hBD-3 
(encoded by DEFB103) are constitutively expressed at low levels in skin24. hBD-
2 (encoded by DEFB4) is not expressed in normal skin but is highly expressed 
in psoriatic skin. hBD-4 (encoded by DEFB104) is less well characterized at 
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the protein level but is found in skin by RT-PCR. hBD-2, hBD-3 and hBD-4 can 
be induced by cytokines and bacterial lipopolysaccharides in various epithelial 
cell types25. It has also been shown that antimicrobial peptides in general, and 
above all hBD-2, are induced in lesional epidermal cells of patients with psoriasis, 
compared with lesional epidermal cells of patients with atopic dermatitis and 
normal skin10,11. These findings have been interpreted to explain the observed 
high infection rate in atopic dermatitis and the relatively low prevalence of bacterial 
and viral infections among psoriasis patients26.
 In addition to their direct antimicrobial activity, the chemotactic properties 
of antimicrobial proteins like LL-37 and beta-defensins are thought to amplify 
leukocyte recruitment27, thereby contributing to an effective antimicrobial 
response. In non-infectious inflammatory diseases like psoriasis, beta-defensins 
could augment the influx of T-cells and dendritic cells, and thereby contribute 
to chronicity and sustained disease. Although the antimicrobial and chemotactic 
activities in vitro have been well documented, there are no quantitative data on 
in vivo concentrations of beta-defensins to substantiate a role of these molecules 
in host defense or inflammation. In this study we have made a detailed analysis 
of systemic and epidermal defensin concentrations. We show that both genetic 
factors and disease activity determine defensin protein expression. Evidence 
is provided that the in vivo concentration of hBD-2 is well above the minimal 
concentrations that are required for biological activity in vitro.
Results
Expression of beta-defensin mRNA and protein in normal tissues and inflamed 
skin
Although expression of beta-defensins in some human tissues has been 
documented before, we wanted to obtain a comprehensive picture of beta-
defensin tissue distribution in order to estimate which specific tissues would 
contribute to systemic protein levels. We performed a qPCR analysis of two 
beta-defensin genes that are contained in the repeat on chromosome 8 (DEFB4 
and DEFB103) and one beta-defensin outside the repeat (DEFB1). Figure 3.1 
shows that hBD-1 mRNA is widely expressed whereas significant levels of hBD-
2 are predominantly found in oral epithelia. hBD-3 is expressed more broadly 
than hBD-2 as it is also found at low levels in normal epidermis and a few other 
tissues. As indicated in figure 3.1 (log scale) hBD-2 expression levels in lesional 
psoriatic epidermis are extremely high compared to any other tissue. hBD-2 
mRNA expression in atopic dermatitis is also increased, compared to normal skin 
where it is undetectable. We analyzed the expression of hBD-2 at the protein level 
by immunohistochemistry. Figure 3.2 confirm the moderate expression levels in 
tongue and plantar epidermis, and the absence of expression in normal skin. 
The extremely high mRNA expression level in psoriatic epidermis was indeed 
reflected by high levels of protein as we have described before10. 
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Figure 3.1 Analysis of beta-defensin mRNA expression in normal and inflamed human 
tissues. Quantitative real-time PCR was performed on RNA of normal human tissues (mostly 
obtained from one individual), purified epidermis from skin biopsies of healthy controls, psoriasis 
patients and atopic dermatitis patients, and inflamed synovium from rheumatoid arthritis patients. 
Expression of target genes was normalized to that of RPLP0. For graphical representation all values 
were expressed relative to hBD-2 in tongue, which was set at unity [34]. Primer sequences and 
efficiency of amplification are given in table 3.2. For details on normal human tissues see materials 
and methods. Bars represent mean and SD. 
Figure 3.2 Immunolocalization of hBD-2 in human epithelia. Immunohistochemical staining 
of normal human tissues (tongue, plantar skin and trunk skin, A-C) and psoriatic skin (D) with a 
polyclonal rabbit antiserum against recombinant hBD-2. Note that protein data largely follow the 
mRNA data demonstrating the absence in normal skin, low expression in tongue and plantar skin. 
Bar = 100 µm. Control sections stained with pre-immune serum were negative (not shown).
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Serum hBD-2 levels in healthy volunteers correlate with genomic copy number
As a next step we wanted to make a quantitative determination of systemic 
defensin protein levels. Defensins are secreted proteins that will easily pass 
basal membranes, and we expected that epithelium-expressed defensins would 
reach the circulation and could be measured in serum by ELISA. On the basis 
of the limited expression of hBD-2 in normal human tissues, as demonstrated 
in figure 3.1, we expected low levels of protein in normal human serum. We 
developed and validated an ELISA that was sensitive and specific for hBD-2 to 
allow measurement of low serum hBD-2 levels. In addition, commercially available 
ELISA kits were used to measure hBD-2 and hBD-3 protein in serum. We have 
previously shown that most beta-defensin genes on 8p23.1 (including those that 
encode hBD-2 and hBD-3) are subject to copy number variation. So far no studies 
have been published that investigated the relation between copy number and 
protein expression. Here we selected 70 healthy individuals without inflammatory 
skin disease, that were typed for beta-defensin copy number using multiplex 
amplifiable probe hybridization (MAPH), restriction enzyme digest variant ratio 
(REDVR) and paralogue ratio test (PRT). In the normal population, copy number 
classes of 3 to 5 defensin repeats per diploid genome are the most prevalent. We 
selected individuals to include sufficient numbers of the more rare copy classes of 
Diagnosis Disease severity Disease score N
Serum hBD-2 
(ng/ml)
Controls n.a. n.a. 70 0.21 ± 0.17 
Psoriasis remission, PASI 0-1 0.4 + 0.4 3 0.64 ± 0.36 
low, PASI 1-10 6.0 + 2.7 18 4.5 ± 4.6
moderate, PASI 10-20 15.1+ 2.8 12 11.5 ± 9.1
high, PASI > 20 30.2 + 3.6 5 84.2 ± 80.0
Atopic dermatitis remission, SCORAD 0-5 0 + 0 2 0.10 ± 0.01
low, SCORAD 5-15 12.0 + 2.8 2 0.12 ± 0.03
moderate, SCORAD 15-40 27.9 + 9.4 6 1.05 ± 0.95
high, SCORAD > 40 47.6 + 5.0 2 1.39 ± 0.74
Rheumatoid arthritis remission, DAS28 0-2.6 2.1 + 0.5 10 0.33 ± 0.16
low DAS28, 2.6-3.2 2.9 + 0.1 5 0.34 ± 0.19
moderate, DAS28 3.2-5.1 4.2 + 0.6 16 0.51 ± 0.41
high, DAS28 > 5.1 6.0 + 0.4 9 0.83 ± 0.59
Table 3.1 Disease severity and serum hBD-2 of patients and controls
Serum hBD-2 levels were determined by ELISA. Analysis of variance on log transformed data sho-
wed that there was a significant correlation between disease severity and serum hBD-2 levels in 
psoriasis patients (p< 2x10-5). Disease scores and serum hBD-2 concentration are given as mean 
and SD. n.a. not applicable.
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2 and 6 to allow analysis of correlation between genomic copy number and serum 
hBD-2 protein. Figure 3.3 shows that there is a modest but highly significant 
correlation between copy number and hBD-2 protein concentration in serum. No 
correlation between serum hBD-2 and age or gender was found. Low hBD-2 
levels were found up to 0.80 ng/ml in these human sera (mean and SD: 0.21 + 
0.17 ng/ml, see table 3.1), but clearly the variance is only partially explained by 
copy number. A similarly weak correlation (Pearson’s R=0.4, p=0.001) between 
copy number and serum protein was found using a commercially available 
hBD-2 ELISA, although absolute levels of hBD-2 appeared to be higher for the 
commercial kit, which was probably due to the difference in standards used (not 
shown). hBD-3 serum levels of individuals without inflammatory skin disease 
were all below the detection limit (0.1 ng/ml). These data show that hBD-2 (but 
not hBD-3) can be measured in normal human serum, and that these uninduced 
levels are at least in part determined by genomic copy number.
hBD-2 serum levels of psoriasis patients correlate with clinical severity
Because of the modest expression of hBD-2 mRNA in most normal tissues we 
expected relatively low levels of hBD-2 protein in the circulation, as was indeed 
found by ELISA in control individuals (figure 3.3). In view of the huge increase 
of hBD-2 mRNA in lesional psoriatic epidermis, the inflamed skin of psoriasis 
patients was likely to cause increased systemic levels of hBD-2 protein. We 
measured hBD-2 in sera of 38 psoriasis patients in a range of clinical severity as 
determined by the Psoriasis Area and Severity Index (PASI) score (see table 3.1). 
We could indeed demonstrate high levels of serum hBD-2 in psoriasis patients, 
which were found to be about 400-fold increased in severely affected patients 
compared to healthy individuals (see table 3.1). A significant effect of disease 
severity on serum hBD-2 was found by analysis of variance (p< 2x10-6). Figure 
Figure 3.3 Correlation between serum hBD-2 protein levels and genomic copy number. Serum 
hBD-2 protein levels of 70 healthy controls (determined by ELISA) were plotted against the genomic 
copy number of the beta-defensin repeat on chromosome 8p23, as determined by MAPH, REDVR 
and PRT. A significant linear correlation was found. Pearson's R = 0.46 and p< 7x10-5.
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3.4 shows that there is a strong linear correlation between PASI score and the 
log-transformed serum hBD-2 concentration. Strongly increased levels were also 
found in the urine of psoriasis patients whereas hBD-2 could not be detected in 
urine of healthy controls. Urinary hBD-2 levels were showed strong interindividual 
variation (2.2 + 3.2 ng/ml). These findings suggest that increased systemic levels 
are derived from high cutaneous production. It is obvious from figure 3.4 that 
the clinical severity in psoriasis patients is a far stronger determinant of hBD-2 
serum concentration than copy number for uninduced levels in healthy controls 
(figure 3.3). There were insufficient numbers of informative psoriasis patients 
from whom defensin copy numbers and PASI scores were available, to make 
a reliable estimate of the effect of copy number and disease severity on hBD-2 
levels. Remarkably, only in a minority of psoriasis patients we could demonstrate 
hBD-3 levels that exceeded the detection limit of the assay (not shown). 
  
  
 To investigate if high systemic hBD-2 levels could be caused by inflammation 
per se, irrespective of the tissue localization, we compared serum hBD-2 levels 
in psoriasis patients with that of 40 patients with rheumatoid arthritis (RA). Low 
hBD-2 serum levels were found in RA patients with low to high disease activity 
and in RA patients that were in remission (see table 3.1). In the combined RA 
patients with moderate to high disease activity, a small but significant increase 
of serum hBD-2 was found compared to the control group (t-test, p< 10-5). qPCR 
analysis of synovial tissue from RA patients with active disease showed that the 
synovium is unlikely to be the source of this small increase in hBD-2 protein, as 
no mRNA for hBD-2 could be detected (see figure 3.1). No significant correlation 
was found between serum hBD-2 and clinical severity as determined by Disease 
Activity Score (DAS28).
 As previously reported10, hBD-2 protein is expressed at low to undetectable 
levels (immunohistochemistry) in lesional atopic dermatitis, despite strong 
Figure 3.4 Correlation between serum hBD-2 protein and PASI score. Serum hBD-2 protein 
levels of 38 psoriasis patients of varying disease severity were plotted against their PASI score. A
significant linear correlation was found. Pearson's R = 0.82, p< 4x10-10.
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induction at the mRNA level. In sera from 8 patients with moderate to severe 
atopic dermatitis we found that, although serum hBD-2 levels were significantly 
higher than in control sera (t-test, p < 10-5), they were far lower than in sera of 
psoriasis patients of similar disease severity (see table 3.1). A significant linear 
correlation between log-transformed serum hBD-2 and atopic dermatitis disease 
severity, as determined by SCORing Atopic Dermatitis (SCORAD), was found 
(Pearson r = 0.7, p< 0.01), suggesting that also in atopic dermatitis increased 
systemic levels are derived from increased cutaneous production. 
Serum hBD-2 is a disease marker in individual psoriasis patients 
As serum hBD-2 showed a correlation with disease activity over a group of 
psoriasis patients, we next investigated if hBD-2 levels correlate with clinical 
status of individual patients. Serum hBD-2 was measured in 15 patients that 
participated in clinical studies for which PASI scores and serum was available 
on two different occasions over a 6-18 week interval. Figure 3.5 shows that there 
is a strong correlation between the change in hBD-2 (ΔhBD-2) and change in 
PASI score (ΔPASI) in eleven patients that showed clinical improvement and four 
patients that showed exacerbation of disease.
Estimation of in vivo hBD-2 concentration in psoriatic epidermis using in vitro 
reconstructed skin
The high serum levels of hBD-2 in psoriasis patients (up to 190 ng/ml), which we 
interpret to be derived from local production by the keratinocytes, suggest that 
the concentrations to which keratinocytes and infiltrated cells in the epidermis 
and papillary dermis are exposed must be several orders of magnitude higher. 
Figure 3.5 Correlation between the change in serum hBD-2 concentration and change in clini-
cal score. Serum hBD-2 protein levels of 15 patients for which PASI scores and serum was available 
on two different occasions over a 6-18 week interval, were plotted against the change in PASI score 
(ΔPASI). A significant linear correlation was found. Pearson R = 0.74, p< 0.002. Note that there was 
a decrease in serum hBD-2 in most patients that showed clinical improvement (negative ΔPASI) and 
an increase in serum hBD-2 in a few patients that showed exacerbation (positive ΔPASI).
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Based on in vitro studies, the concentrations required to have a relevant biological 
effect would vary between 0.1 and 100 µg/ml. Because these local tissue 
concentrations are difficult to estimate directly from in vivo data, we measured 
the production of hBD-2 in reconstructed skin as a model for human epidermis. 
Human reconstructed skin equivalents were obtained as described previously29, 
and stimulated with IL-1α, TNF-α and IL-6. This cytokine mixture was recently 
found to be optimal for induction of a psoriatic phenotype in vitro, as witnessed 
by high expression levels of CK16, SKALP/elafin and hBD-230. qPCR analysis 
of isolated epidermal sheets indicated that hBD-2 mRNA levels (determined as 
deltaCt values) in these cultures were much higher than in keratinocytes from 
submerged cultures (not shown), and reached similar high values as found in 
epidermal sheets from lesional psoriatic skin (see figure 3.1). Figure 3.6 shows 
hBD-2 protein expression by differentiated keratinocytes in the reconstructed skin 
model stimulated with pro-inflammatory cytokines. We collected culture medium 
from cytokine-stimulated reconstructed skin of two donors during 24 hours starting 
two days after addition of the cytokine mix. Using ELISA we found that these 
cultures, consisting of 8 mm diameter skin constructs, secreted approximately 66 
+ 19 ng hBD-2 per 24 hours into the tissue culture medium (mean and SD of four 
cultures). We derived the local epidermal concentration using an approximation 
based on the known diffusion coefficient of a small cationic protein in aqueous 
solution (see supplementary information for assumptions and dimensions 
of the system, used for modelling). Alternatively, a theoretical value for the 
diffusion coefficient was obtained based on Graham’s law (see supplementary 
information). The most conservative estimation of the hBD-2 local concentration 
in the compartment of the epidermis was 1.2 mg/ml (0.3 mM), which is far higher 
than concentrations required for in vitro antimicrobial activity, or those reported 
for chemotactic activity towards T-cells and dendritic cells.
Figure 3.6 Induction of hBD-2 protein expression in reconstructed skin by proinflammatory 
cytokines. Expression of hBD-2 in 3-D reconstructed skin following stimulation with psoriasis-as-
sociated cytokines (10 ng/ml IL-1α, 5 ng/ml TNFα and 5 ng/ml IL-6) for 72 hours. Note that without 
stimulation there is no hBD-2 expression (A), whereas the cytokine mixture induces high expression 
levels that are secreted into the underlying culture medium (147 ng/ml in 24 h). Part of the hBD-2 
protein remains adsorbed to the dermal matrix as witnessed by the staining of structures in the der-
mis (B). Bar = 100 µm.
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Discussion
Psoriasis is associated with increased beta-defensin genomic copy number 
but no quantitative information on defensin protein expression in vivo, as a 
function of copy number or disease status was available. We now present 
evidence that both genomic copy number and epidermal activation by psoriasis-
associated cytokines determine expression levels of hBD-2. We conclude that 
these increased circulating hBD-2 levels in patients are derived from cutaneous 
production, indicating that local hBD-2 concentrations in psoriatic epidermis are 
likely to be extremely high. Extrapolation from an in vitro model system suggests 
that the concentration in the epidermis or papillary dermis (0.3 mM) by far exceeds 
the concentrations required to be antimicrobial (2.5 to 25 µM) and chemotactic in 
vitro (250 nM) as described previously by others9,31.
 A number of studies have reported expression of human beta-defensins 
in various tissues, including normal skin, inflamed skin and non-cutaneous 
epithelia, using semi-quantitative RT-PCR or immunohistochemistry. Here 
we have quantified circulating levels of hBD-2 and hBD-3 by ELISA in healthy 
volunteers and patients with inflammatory diseases. To assess which of the 
normal human epithelia would contribute to steady state systemic protein levels, 
we first performed a comprehensive qPCR analysis of the three major epidermal 
defensins, hBD-1, -2 and -3 in a large panel of human tissues. As shown in 
figure 3.1, hBD-1 mRNA is widely expressed, and is not subject to regulation by 
inflammation, as it is not highly induced in psoriatic skin. Measurement of hBD-1 
protein in serum would have provided a reference value for a beta-defensin that 
is expected to be rather constant as it is not present on the psoriasis-associated 
repeat. We were however unsuccessful in measuring hBD-1 protein by ELISA (not 
shown). hBD-2 mRNA appears to be expressed constitutively by a few tissues 
(e.g. oral epithelia), and was indeed found at the protein level albeit weakly (figure 
3.2). hBD-2 is absent from normal trunk skin, but it is expressed at low levels in 
plantar skin. Consequently, serum hBD-2 levels in healthy individuals are very 
low (less than 1 ng per ml). In addition to our own ELISA (recombinant hBD-2 for 
calibration), we also used a commercial hBD-2 ELISA kit that uses synthetic hBD-
2 for calibration. Although there was a good correlation between the data of both 
assays (Pearson r =0.9), the commercial ELISA yielded apparent hBD-2 serum 
concentrations 10-fold higher than our ELISA. We found that this was caused by 
a difference in immunoreactivity of the calibration standards used. We used the 
values obtained with recombinant hBD-2 throughout this paper, as a conservative 
estimate of hBD-2 concentration.
 As shown in figure 3.3, genomic copy number only explains part of the 
variance in serum hBD-2 levels. This is unlikely to be caused by experimental 
error. We considered sampling error as a potential cause, but we did not find 
variation in serum hBD-2 level depending on the time of blood sample collection 
(early morning versus late afternoon). Longitudinal data showed only minor 
fluctuation of serum hBD-2 levels in blood taken with two-year intervals (not 
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shown). We speculate that the large variation of protein levels in each copy class 
could be caused by variation in expression regulation, or alternatively, by genetic 
variation in the defensin copies themselves. Although there is currently no 
information on the existence of non-functional gene copies within the repeat, this 
would obviously affect the gene-protein correlation, and it could also affect the 
observed association with psoriasis, which clearly requires further investigation.
 Although our findings indicate that uninduced hBD-2 production is subject 
to gene dosage effects, the high systemic serum levels in psoriasis patients are 
caused by disease activity itself. We think this indicates that hBD-2 can be used as 
an objective, quantitative marker for disease activity in psoriasis. There are very 
few reliable serum markers for disease activity in psoriasis. Candidate proteins 
that are overexpressed in lesional epidermis include SKALP/elafin and psoriasin/
S100A7, but only SKALP/elafin was found to correlate with disease activity32,33. 
Previous studies have suggested that conventional surrogate markers for 
disease activity in rheumatoid arthritis and psoriatic arthritis, such as erythrocyte 
sedimentation rate and levels of C-reactive protein (CRP) are not useful for 
chronic plaque psoriasis34. For this reason we looked at the correlation between 
PASI scores and CRP in a cohort of our own patients that were monitored over 
time. We did not find a significant correlation between CRP and PASI for 1305 
patient visits (data not shown), again suggesting that serum hBD-2 could be a 
convenient way to monitor disease activity or therapeutic effects. 
 At the tissue level, hBD-2 secretion will be determined both by copy number 
and by stimulation with proinflammatory cytokines. Our data also suggest that 
disease activity in atopic dermatitis is correlated with serum hBD-2. However, 
the epidermal expression in atopic dermatitis is far lower than in psoriasis10,11, 
presumably resulting from the distinct cytokine environments of these diseases8,35. 
We could indeed show that Th2 cytokines do not induce hBD-2 expression 
in cultured keratinocytes18 and that Th2 cytokines repress the Th1 induced 
expression (not shown here), as was previously shown for hBD-336. An additional 
level of regulation of hBD-2 expression is the responsiveness of cells to pro-
inflammatory cytokines. We have recently shown that cell-autonomous differences 
exist between keratinocytes of psoriasis patients, atopic dermatitis patients 
and controls with respect to innate immune responses following Th1 cytokine 
stimulation18 . We would speculate that there are apparently three mechanisms 
that contribute to high levels of hBD-2 in psoriatic epidermis: a dominant Th1 
or Th17 cytokine profile, increased cell-autonomous responsiveness to cytokine 
stimulation, and high defensin genomic copy number. Although defensins are 
endowed with cytokine-like properties themselves, there is no information on a 
possible autocrine effect of hBD-2 on keratinocytes whereby it would induce or 
sustain its own production. This is clearly an area worth investigating. 
 Several studies have demonstrated the biological activities of human and 
mouse beta-defensins, such as antimicrobial activity9, chemotaxis of T-cells 
and dendritic cells37, and activation of TLR438. In general, many antimicrobial 
proteins appear to be endowed with other immune-modulatory activities39-41. 
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These findings have raised the intriguing possibility that beta-defensins are part 
of the innate immune system that provides a link between the epithelium and the 
adaptive immune system. This would fit the emerging concept of inflammatory 
epithelial diseases14 that is supported by findings on the genetics of atopic 
dermatitis15, Crohn’s disease42 and celiac disease43. This would also explain the 
clinical observation that both T-cell directed drugs (cyclosporine A, UVB, some 
biologicals) and keratinocyte-directed drugs (retinoids, vitamin D3 derivatives) 
are effective in the treatment of psoriasis. 
 The defensin concentrations used in in vitro studies to demonstrate their 
biological activity and their relevance for the in vivo situation, should be interpreted 
with some caution. For example, the antimicrobial activity of hBD-2 can only be 
demonstrated at low salt conditions44, at least in low micromolar concentrations. 
Notwithstanding these considerations, we attempted to make an estimate of the 
actual hBD-2 concentration in an active psoriatic lesion. Although there are some 
caveats associated with modelling of the in vivo tissue concentrations based on 
an in vitro reconstructed skin model, it is clear that the hBD-2 levels in epidermis 
and papillary dermis are well above the minimal concentrations that would 
cause a biological effect in an experimental setting, even allowing for an error 
of one order of magnitude. Remarkably, we found very little hBD-3 protein in the 
circulation. Only in a few psoriasis patients we observed detectable levels up to 
0.5 ng/ml, which is 160-fold lower than the hBD-2 concentration in patients with 
severe psoriasis. Whether this also reflects low hBD-3 protein production in the 
epidermis requires further investigation.
 Our previous finding on the genetic association of psoriasis with the defensin 
cluster did not allow discrimination between the seven defensins or defensin-like 
genes contained in the repeated segment. On the basis of available expression 
data we predicted that hBD-2 and hBD-3 would be the best candidates. Here 
we provide further evidence that, based on copy number dependent and 
disease-specific gene expression, high cutaneous protein levels and its known 
proinflammatory properties, hBD-2 is one of the strongest psoriasis candidate 
genes contained in the beta defensin cluster on chromosome 8.
Materials and methods
Patients and healthy subjects
All psoriasis patients had plaque-type psoriasis diagnosed by a dermatologist. 
Atopic dermatitis was diagnosed by a dermatologist, according to the Hanifin 
criteria, and were of the extrinsic type35. Rheumatoid arthritis patients were 
diagnosed by a rheumatologist, according to the ACR criteria. Patients were 
recruited via the in-patient or out-patient departments of the Radboud University 
Nijmegen Medical Centre. Control sera and DNA samples were from the 
Nijmegen Biomedical Study (NBS)45. All controls and patients were of native 
European Dutch origin. Demographic data were as follows (age: mean and SD, 
and % female); Controls: 50 + 16, 59% female; Psoriasis patients: 47 + 13 year, 
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42% female; Rheumatoid arthritis patients: 59 + 8 years, 66% female. Available 
information of medication used during sample collection: 59% of the psoriasis 
patients were on biologicals (all TNF-blockers) and 36% were on other types 
of systemic medication (retinoids, MTX). Nearly all rheumatoid arthritis patients 
used NSAIDs, 45% was on MTX and 25% was on biologicals (various kinds, 
mostly TNF blockers). Blood was stored at -80oC and genomic DNA was isolated 
by standard procedures. Permission for these studies was obtained from the 
local medical ethics committee (Commissie Mensgebonden Onderzoek Arnhem-
Nijmegen), and volunteers gave written informed consent. The study was 
conducted according to the Declaration of Helsinki principles.
Clinical scores
As a measure of disease severity the clinical score was determined by medical 
specialists. For psoriatic patients the PASI (0 to 72 scale)46, for atopic dermatitis 
patients the SCORAD (0 to 103 scale)47 and for rheumatic arthritic patients the 
DAS28 (0 to 10 scale)48 was used to measure disease severity. Patients were 
classified as being in remission, or having low disease activity, moderate disease 
activity or high disease activity (see table 3.1).
Immunohistochemistry
Autopsy material and skin biopsies were fixed in 4% phosphate-buffered formalin 
and embedded in paraffin as described before49. Sections of seven micrometer 
were stained according to the avidin biotinylated-enzyme-complex method 
(Vector Laboratories, Burlingame, CA) using a goat anti-hBD-2 serum (Abcam, 
Cambridge, UK).
RNA extraction and real-time quantitative polymerase chain reaction
RNA from a variety of organs that included many epithelial tissues, was available 
from autopsy material of one individual. For this reason the qPCR data in figure 
3.1 have only n=1 for most organs. Additional RNA samples from lung (8), kidney 
(2), heart (1), testis (1), spleen (1) and liver (1), normal (5) and inflamed epidermis 
(7) and inflamed synovium (5) were obtained from different individuals and 
analyzed for beta defensin expression. Variability between the different samples 
from one type of organ was low, and similar profiles of differential expression of 
beta defensins 1, 2 and 3 were found. When multiple samples per organ were 
available, expression values are given as mean and SD in figure 3.1. 
 RNA was extracted from twenty-four different normal human tissues, 
punch biopsies and cultured human keratinocytes, and first strand cDNA was 
synthesized using an input of 1 µg of RNA with the iScript cDNA synthesis kit 
(Bio-Rad, Hercules, CA) according to the manufacturer’s recommendation. 
The reverse transcriptase product was used as a template for quantitative real-
time PCR amplification of genes of interest hBD-1, hBD-2 and hBD-3 and the 
housekeeping gene human ribosomal phosphoprotein P0 (RPLP0) with the MyiQ 
Single-Color Real-Time Detection System for quantification with Sybr Green and 
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melting curve analysis (Biorad, Richmond, CA). Expression of target genes was 
normalized to that of RPLP0. This housekeeping gene was not found to be subject 
to regulation in keratinocyte cultures, irrespective of stimulation or diagnosis, and 
is more reliable than other reference genes such as ACTB (actin) or GAPDH (data 
not shown). RPLP0 levels of the various tissues did not show large differences 
(mean and SD of Ct values of normal human tissues was 21.7 + 1.6). The deltaCt 
values were used for statistical analysis. For graphical representation (figure 
3.1) all values were expressed relative to hBD-2 in tongue, which was set at 
unity28. This allows comparison of all genes and all tissues for relative expression 
levels. Primer sequences (Biolegio, Nijmegen, The Netherlands) and efficiency of 
amplification are given in table 3.2. 
Production of recombinant hBD-2 and rabbit antiserum
A hBD-2 PCR product from cDNA derived from cultured keratinocytes was 
cloned into pGEX-2T vector (Amersham Pharmacia Biotech, Uppsala, Sweden), 
expressed as a GST-hBD-2 fusion protein in Escherichia coli and affinity-purified. 
Commercial recombinant hBD-2 (Peprotech, Rocky Hill, NJ) was cross-linked to 
ovalbumin, using glutaraldehyde, to increase immunogenicity. This preparation 
was dialysed against phosphate-buffered saline and emulsified with complete 
Freund’s adjuvant to immunize rabbits to generate polyclonal serum. Animals 
were boostered with GST-hBD-2, and blood was obtained for serum preparation.
ELISA
Affinity-purified goat anti-hBD-2 (Abcam) was used to coat 96-well microtiter 
plates. After blocking in 1% (v/v) bovine serum albumin, serum samples were 
applied in a serial 2-fold dilution range, followed by our rabbit anti-hBD-2 
as a second antibody, and detection by the ABC kit (Vector). All steps were 
followed by appropriate washing in phosphate-buffered saline with 0.05% (v/v) 
Tween-20. The serum hBD-2 concentrations were read from a calibration curve 
of recombinant hBD-2 (Peprotech). The detection limit of this ELISA was 0.03 ng/
ml, using recombinant hBD-2 (Peprotech) for calibration. Anti-hBD-2 antibodies 
were checked for specificity against hBD-2, and we found that recombinant 
hBD-1 (Abcam) and hBD-3 (Abcam) were not recognized. We found no 
evidence for circadian differences in serum hBD-2 in healthy individuals (data 
Gene Forward primer (5' → 3') Reverse primer (5' → 3') E*
hBD-1 atggcctcaggtggtaactttc cacttggccttccctctgtaac 2.00
hBD-2 gatgcctcttccaggtgttttt ggatgacatatggctccactctt 1.97
hBD-3 gtgaagcctagcagctatgaggat tgattcctccatgacctggaa 2.06
RPLP0 caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag 2.00
*E is efficiency as fold increase in fluorescence per PCR cycle
Table 3.2 Primers for qPCR
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not shown). Serum hBD-2 was found to be stable upon storage at -20oC. No 
large differences were found for individuals from whom we had serum samples 
taken with a two-year interval. Commercially available ELISA kits for hBD-2 and 
hBD-3 were purchased from Phoenix (Belmont, CA) and performed according 
to manufacturer’s recommendations. The detection limits for these assays were 
0.05 and 0.1 ng/ml respectively, using synthetic hBD-2 and hBD-3 for calibration.
Genotyping of defensin copy number
Genomic DNA from seventy control individuals without inflammatory skin disease 
was analyzed for genomic copy number. Most of these individuals were analyzed 
by three methods: MAPH, REDVR and PRT as described previously in great 
detail16,23,50. These analyses were used to obtain the best estimate of integral 
copy number. 
Three-dimensional reconstructed skin
Reconstructed skin was generated as described before30. Briefly, de-epidermized 
human dermis (DED) of 0.8 mm thickness and 8 mm diameter was used as 
a scaffold for keratinocytes in tissue culture inserts in a 24-well plate. These 
were cultured submerged for three days, and subsequently the medium level 
was lowered to allow air-exposure to induce terminal differentiation. After seven 
days of air exposure a fully stratified epidermis has developed that expresses all 
normal differentiation markers, but is negative for psoriasis-associated genes like 
CK16, SKALP/elafin and hBD-2. At this point a mixture of 10 ng/ml IL-1α, 5 ng/
ml TNFα and 5 ng/ml IL-6 is added for 72 hours, which induces high expression 
levels of psoriasis-associated genes. The culture medium, 450 µl per culture, was 
harvested and changed at 24, 48 and 72 hours and used for hBD-2 ELISA. Two 
different donors for human keratinocytes were used.
Statistics
All statistical analyses were performed using the Statistica software package 
version 7, Statsoft Inc. Analysis of variance was performed on log transformed 
data of serum hBD-2. Analysis of qPCR data was done on deltaCt values. 
Modelling of epidermal hBD-2 concentrations
Fick’s law for mass transport was applied. For the diffusion coefficient (D) of hBD-
2 we used 1.44 x 10-10 m2/sec as experimentally determined for bovine pancreatic 
trypsin inhibitor (BPTI)51, a protein of similar mass and isoelectric point as hBD-
2, or we used an approximation based on Graham’s law using the known value 
for BSA (10-10 m2/sec). The hBD-2 production) in a reconstructed skin model 
stimulated with proinflammatory cytokines was used estimate the concentration 
in the epidermal compartment in vitro, as an approximation of the concentration 
in psoriatic epidermis. See supplementary information for details.
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Supplementary information
Diffusion model of the air-liquid keratinocyte culture
           ........ = C = [hBD-2]
Compartment A:
Multiple layers of karatinocytes
Unstirred compartment, [hBD-2]=constant, 50 μm thick
Compartment B:
De-epidermised dermis
Unstirred compartment, gradient of  [hBD-2], 800 μm thick
Compartment C:
Unstirred compartment, [hBD-2] = low and homogenous, volume is large
All compartments have a cylindrical shape with a diameter of 4 mm
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Abstract
Background
Microarray studies on the epidermal transcriptome in psoriasis and atopic 
dermatitis have revealed genes with disease-specific expression in keratinocytes 
of lesional epidermis. These genes are possible candidates for disease-specific 
pathogenetic changes, but could also provide a tool for molecular diagnostics of 
inflammatory skin conditions in general.
Objectives
To analyze if gene expression signatures as found in purified epidermal cells from 
atopic dermatitis are also present in other eczematous conditions such as allergic 
and irritant contact dermatitis.
Methods 
We used real-time quantitative PCR, immunohistochemistry and bioinformatics 
to investigate gene expression in different forms of eczema. Normal epidermis 
and psoriatic epidermis were analysed for comparison.
Results
Carbonic anhydrase II was highly induced in epidermis from all forms of eczema 
but not in psoriasis. Remarkably, the presumed neuron-specific Nel-like protein 
2 showed a strong induction only in atopic dermatitis epidermis. Interleukin-1F9, 
elafin, beta-defensin-2 and vanin-3 were strongly induced in psoriasis, but not in 
any type of eczema. High levels of the chemokines CCL17 and CXCL10 were 
predominantly found in epidermis of allergic contact dermatitis. The chemokine 
CXCL8 was highly expressed in psoriasis, atopic dermatitis, and allergic contact 
dermatitis, but not in irritant contact dermatitis. Cluster analysis or multinomial 
logistic regression indicated that expression levels of a set of seven genes are a 
strong predictor of the type of inflammatory response.
Conclusions
These observations contribute to molecular diagnostic criteria for inflammatory 
skin conditions.
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Introduction
Atopic dermatitis and psoriasis are two major chronic inflammatory skin diseases 
that show distinct differences with respect to clinical appearance of the lesions, 
itch, trans-epidermal water loss, surface pH and bacterial colonization/infection1. 
Several non-overlapping genetic associations have recently been established for 
both diseases, including genes involved in adaptive immunity, innate immunity 
and skin barrier function2-5. Although there are some histopathological similarities 
such as epidermal hyperproliferation, acanthosis and a pronounced T cell 
infiltrate, a number of differences at the cellular and molecular level can be noted. 
The immune responses are markedly polarized towards Th1 and Th17 cytokine 
profiles in psoriasis6,7, and a Th2 profile in atopic dermatitis, particularly in the 
(sub)acute phase8. Using expression profiling by microarrays or large scale real-
time quantitative PCR (qPCR), several studies have found striking differences 
between expressed genes in the epidermis of lesional skin from patients with 
psoriasis and with atopic dermatitis, which appear to be determined both by the 
cytokine environment and cell-autonomous processes9-11. The transcriptome of 
lesional psoriasis skin is very similar to that of cultured keratinocytes stimulated 
with pro-inflammatory cytokines (interleukin (IL)-1 or IL-1/tumour necrosis 
factor (TNF)-α/Interferon (IFN)-γ) as demonstrated by several groups11,12. In 
contrast, it was shown that the transcriptome of atopic dermatitis skin is quite 
distinct and is similar to that of Th2 cytokine-stimulated cultured keratinocytes. 
Large differences between epidermal gene expression in psoriasis and atopic 
dermatitis were found for antimicrobial proteins such as human β-defensin (hBD)-
2 , hBD-3, S100 proteins and elafin, for chemokines such as CCL18, CCL27, 
CCL13, CXCL8, and for genes that do not have obvious functions in inflammation 
such as vanin-3 (VNN3), Nel-like 2 (NELL2) and carbonic anhydrase II (CAII)9-
11,13-16. It was demonstrated that induction of these genes is likely to be under 
control of the specific psoriasis and atopic dermatitis cytokine environments11,17;18. 
Antimicrobial proteins, many chemokines and VNN3 were found to be induced 
in cultured keratinocytes by psoriasis-associated cytokines (e.g. TNF-α, IL-
1, IL-6, IL-17 and IL-22), whereas the atopic dermatitis specific genes CAII 
and NELL2 were induced by Th2 cytokines (IL-4 and IL-13). Low expression 
levels of antimicrobial proteins in atopic dermatitis have been interpreted to 
contribute to the high prevalence of skin infections in atopic dermatitis compared 
with psoriasis10,11,13. It remains to be investigated to what extent other highly 
differential genes, notably the psoriasis-associated vanin genes (VNN1 and 
VNN3), and the atopic dermatitis-associated genes NELL2 and CAII, contribute 
to the pathogenesis of these skin conditions. Based on the disease-specific 
patterns and the biological properties, there is sufficient reason to suspect that 
differentially expressed genes detected in the aforementioned studies are not 
merely innocent bystanders, but could have a causal relationship with the disease 
process. For this reason we wanted to investigate if atopic dermatitis-associated 
epidermal gene expression was specific for atopic dermatitis or could also be 
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demonstrated in other eczematous conditions such as allergic and irritant contact 
dermatitis. Allergic contact dermatitis and irritant contact dermatitis represent 
two common skin conditions that are mechanistically different but share clinical 
and histopathological similarities with atopic dermatitis such as itch, spongiosis 
and increased transepidermal water loss due to skin barrier disruption19,20. Here 
we have compared gene expression patterns in lesional skin of patients with 
psoriasis and atopic dermatitis with experimentally induced eczematous lesions 
of allergic contact dermatitis and irritant contact dermatitis. Our results indicate 
that psoriasis is molecularly quite distinct from atopic dermatitis, allergic contact 
dermatitis and irritant contact dermatitis. The eczematous conditions, however, 
show similar expression patterns for some but not for all genes. Our results 
indicate that, using a set of only seven genes, a molecular distinction can be 
made between epidermis from normal skin, psoriasis, atopic dermatitis, allergic 
contact dermatitis and irritant contact dermatitis.
Results
mRNA expression profiles in psoriasis, atopic dermatitis, allergic contact 
dermatitis and irritant contact dermatitis
Previous studies have identified a number of genes that are associated with 
psoriasis and atopic dermatitis. Some of these studies used microarrays without 
confirmation by qPCR or protein expression. We therefore first tested a number 
of these proposed candidate genes by qPCR to confirm microarray data as 
published previously. We focused on genes that were reported to be differentially 
expressed in two different studies9-11, and gave robust signals in qPCR assays 
(see supplementary information and Table S4.1). The following inflammation-
associated genes were selected for further study by qPCR: the antimicrobial 
proteins elafin and hBD-2; the cytokines IL-1F9, IL-1β and IL-18; the chemokines 
CCL17, CXCL8 and CXCL10; the hyperproliferation-associated keratin KRT6. 
Based on two microarray studies and subsequent qPCR confirmation we selected 
four additional genes not known to have a function in inflammatory processes. 
These genes NELL2, CAII, VNN3 and VNN1 were among the most highly 
differential genes in studies that compared psoriasis and atopic dermatitis gene 
expression. The skin conditions studied here can be quite diverse in their clinical 
manifestations, but care was taken to include lesions of similar clinical severity 
with respect to erythema. Lesions of all skin conditions were from strongly inflamed 
skin. Irritant contact dermatitis and allergic contact dermatitis were by definition in 
an acute phase as they were induced for that purpose, the atopic dermatitis skin 
was from erythematous skin of individuals with chronic eczema during a relapse, 
and psoriasis biopsies were taken from chronic plaques that were nevertheless 
clearly inflamed. As the skin conditions studied here are likely to have varying 
amounts of cellular infiltrate in the epidermal compartment, we measured CD45 
mRNA expression as a semiquantitative marker for cells from hematopoietic 
origin. Figure 4.1 shows the results of these analyses for mRNA expression 
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of the most informative genes in epidermal sheets from normal skin and from 
individuals with psoriasis, atopic dermatitis, allergic contact dermatitis and irritant 
contact dermatitis. Our results confirmed findings from previous studies on atopic 
dermatitis and psoriasis, showing a strong increase of antimicrobial genes (hBD-
2, elafin), IL-1F9 and vanins in psoriasis, whereas CAII and NELL2 were strongly 
increased in atopic dermatitis. Remarkably, hBD-2, elafin, IL-1F9 and VNN3 were 
Figure 4.1 qPCR data on informative genes. qPCR data on 12 informative genes, i.e. genes that 
showed differential expression between the 5 diagnoses normal skin (NS), psoriasis (PS), atopic 
dermatitis (AD), allergic contact dermatitis (ACD) and irritant contact dermatitis (ICD). Fold induction 
was expressed relative to normal skin (set at 1). Statistical analysis was performed on ΔCt values. 
ANOVA showed that for each gene there was a significant effect of the factor diagnosis on the gene 
expression level. Post-hoc analysis (Bonferroni test) was used to analyze significant differences be-
tween diagnoses. * and ** indicate significant p-values of < 0.01 and < 0.05 respectively, compared 
with normal skin.
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quite specific for psoriasis. Although some induction was found in eczematous 
conditions compared with normal skin, the expression levels in psoriasis were 
significantly higher. The induction of CAII, first observed for atopic dermatitis 
and not for psoriasis, was also found for allergic and irritant contact dermatitis. 
High expression of NELL2 was only found for atopic dermatitis, and a small but 
significant increase compared with normal skin was found in allergic contact 
dermatitis. The functional significance of this highly specific atopic dermatitis-
associated molecule for the disease process remains to be investigated. Two 
chemokine genes, CCL17 and CXCL10, showed high expression levels only 
in allergic contact dermatitis epidermis. Although the number of infiltrating T 
lymphocytes is also higher in allergic contact dermatitis than in any other of the 
conditions studied (see qPCR data in Figure 4.1 and immunohistochemistry in 
Figure 4.2) we assume that high levels of CCL17 and CXCL10 are derived from 
keratinocytes as T lymphocytes are not known to be strong producers of these 
chemokines. None of the studied molecular markers was specifically upregulated 
in irritant contact dermatitis as shown in Figure 4.1. IL-1β and CXCL8 were found 
to discriminate between irritant contact dermatitis and the other inflammatory 
conditions, as irritant contact dermatitis was the only condition that did not show 
strong induction of these genes compared with normal skin. IL-18 and KRT6 
expression did not significantly discriminate between the four inflammatory 
conditions (not shown).
Protein expression of selected genes in normal skin, psoriasis, atopic dermatitis, 
allergic contact dermatitis and irritant contact dermatitis
Although qPCR is by far the most sensitive and accurate method for gene 
expression quantitation, these findings do not necessarily reflect protein 
expression levels. We used immunohistochemistry and flow cytometry to analyse 
a number of markers for which reliable staining protocols were available. Staining 
of hBD-2 and elafin confirmed the known high levels of expression in lesional 
skin of patients with psoriasis (Figure 4.2). Sixteen of seventeen allergic contact 
dermatitis patients showed no or hardly any hBD-2 staining. In all patients with 
atopic dermatitis and irritant contact dermatitis hBD-2 staining was minimal to 
absent. Elafin, however, was strongly expressed in the stratum granulosum of all 
patients with irritant contact dermatitis. Staining for elafin in patients with allergic 
contact dermatitis and atopic dermatitis was variable and less intense. Normal 
skin was, as expected, always negative for hBD-2 as well as for elafin. In general 
there was a good correlation between mRNA and protein expression levels of 
elafin and hBD-2.
 In earlier studies we showed that CAII mRNA and protein is upregulated in 
lesional skin of atopic dermatitis, whereas in psoriasis a downregulation of CAII 
mRNA is found14. In Figure 4.1 of this study we show that CAII induction is found 
in all three eczematous conditions as it is also elevated in allergic and irritant 
contact dermatitis. Immunohistochemistry, however, was not suitable to reliably 
detect quantitative differences in CAII staining between atopic dermatitis, allergic 
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contact dermatitis, irritant contact dermatitis and normal skin (not shown). To 
investigate whether upregulation of CAII protein could be demonstrated in allergic 
contact dermatitis, a flow cytometric analysis was performed on epidermal cells 
obtained from nonlesional and lesional allergic contact dermatitis skin. Staining 
of epidermal cell populations for CAII was found to be heterogeneous. All six 
patients showed an elevated CAII signal and/or a higher percentage of epidermal 
cells positive for CAII (Figure 4.3). These results indicate that similar to atopic 
dermatitis, CAII protein is also upregulated in allergic contact dermatitis, albeit 
less strongly than at the mRNA level. 
 Keratin 16 (KRT16) is generally regarded as a keratin that is induced in 
the context of epidermal hyperproliferation, as found in psoriasis. KRT16 
forms a heterodimer with KRT6, which was not found to be informative at the 
mRNA level to distinguish between the four inflammatory conditions. Recent 
studies in our laboratorium have shown that KRT16 expression and epidermal 
hyperproliferation are also present in atopic dermatitis. Here we also investigated 
Figure 4.3 Flow cytometric analysis of CAII protein expression in epidermal cell suspensions 
derived from six individuals with allergic contact dermatitis. Cell suspensions were labeled in-
directly using a polyclonal anti-CAII antibody and a Alexa fluor 488-conjugated secondary antibody. 
CAII expression of six patients (AC6, AC8, AC12, AC14, AC17 and AC19) is shown in frequency 
histograms. Lesional skin (solid line) and normal skin (dotted line) are overlayed after normalization. 
Expression of CAII in epidermal cells was heterogeneous and in all cases it was higher in cell sus-
pensions derived from lesional skin compared with normal skin. In three out of six patients (AC12, 
AC14 and AC19) part of the cells in the lesional skin showed a lower CAII expression compared to 
control skin, suggesting that these cells were newly formed in the basal layer and had lowest CAII 
protein content. Overall CAII expression in allergic contact dermatitis involved skin was on average 
two times higher than the uninvolved skin from the same patient.
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allergic and irritant contact dermatitis for KRT16 and Ki67 staining. Increased 
numbers of Ki67 positive nuclei correlated with suprabasal KRT16 expression, 
but both were found to be quite variable among all inflammatory conditions. 
KRT16 expression and increases of Ki67 positive nuclei were least prominent in 
allergic contact dermatitis. Collectively, Ki67 and KRT16 staining appeared to be 
poor discriminators for these inflammatory conditions as was already suggested 
by qPCR experiments (not shown).
 Although most of the aforementioned marker genes investigated here are 
predominantly expressed by keratinocytes, there could be a small contribution 
of infiltrating cells to the mRNA levels described in Figure 4.1. To investigate the 
presence of cells of hematopoietic origin in the epidermis, immunohistochemical 
staining for CD45 was performed, which showed a massive amount of immune 
cells in the dermis of patients with allergic contact dermatitis, and to a lesser 
extent in atopic dermatitis and psoriasis. In irritant contact dermatitis, only a 
mild perivascular infiltrate was observed compared with normal skin. Epidermal 
presence of immune cells, as determined by CD45 expression, was highest in 
allergic contact dermatitis, less so in psoriasis and atopic dermatitis, and nearly 
absent in irritant contact dermatitis skin. These immunohistochemical data 
confirm the observed qPCR data on CD45, which indicated that allergic contact 
dermatitis epidermis showed the highest number of infiltrating cells.
Classification of inflammatory skin conditions based on seven selected genes
In the previous paragraphs we showed that several genes were selectively 
expressed in one or more specific inflammatory conditions. It remains to be 
investigated whether these genes are involved in the pathogenesis, as will be 
discussed hereafter. We next wondered whether a limited set of informative genes 
could be used to distinguish the four inflammatory dermatoses that we studied 
based on their expression levels. We used a one-way clustering approach to 
analyze the similarity between the inflammatory conditions based on the ∆Ct-
values obtained from our qPCR data of CAII, NELL2, hBD-2, IL-1F9, CXCL8, 
CXCL10 and CCL17. Figure 4.4 shows that clustering of the 63 individuals 
based on expression of these 7 genes provides a good separation of sample 
groups. Normal skin samples are distinct from all biopsies of inflamed skin. 
Secondly, psoriasis could be discriminated from the different forms of eczema 
(atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis), 
which are all clustered together. Within the eczematous skin conditions, three 
distinct clusters emerge for atopic dermatitis, allergic contact dermatitis and 
irritant contact dermatitis. Only two samples (one atopic dermatitis and one 
allergic contact dermatitis) were classified in other clusters. The separation of 
psoriasis and atopic dermatitis is not surprising because the genes were selected 
on the basis of known differential expression in these conditions. It is, however, 
striking that allergic contact dermatitis and irritant contact dermatitis could also be 
discriminated on the basis of the same gene set.
 Polytomous logistic regression analysis, in combination with a forward 
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selection procedure, using the expression levels of the 7 selected genes as 
continuous predictors and the diagnosis group (five levels: normal skin, psoriasis, 
atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis) as the 
nominal outcome variable, resulted in ‘perfect’ prediction with error rate 0/63 = 
0%. Only the genes CCL17, hBD-2 and NELL2 were selected by the forward 
selection procedure, that is to say that the ‘perfect’ prediction rule used only these 
3 genes. To account for possible overfitting, leave-out-one cross-validation was 
performed, including the same forward selection procedure. This resulted in an 
internally validated error rate of 8/63 = 12.7%. In 55 of the 63 models (87.3%) 
of the leave-out-one analyses the same genes CCL17, hBD-2 and NELL2 were 
selected as predictors.
Figure 4.4 One-way clustering approach to assess the similarity between the inflammatory 
conditions. qPCR data from skin biopsy samples were analyzed using a one-way clustering ap-
proach to assess the similarity between the inflammatory conditions based on the ΔCt-values from 
CAII, NELL2, hBD-2, IL-1F9, CXCL8, CXCL10 and CCL17. A good separation of diagnosis groups 
is obtained. Normal skin (NS) samples are distinct from all biopsies of inflamed skin. Secondly, pso-
riasis (PS) could be discriminated from the different forms of eczema, atopic dermatitis (AD), allergic 
contact dermatitis (ACD) and irritant contact dermatitis (ICD) which are clustered under a separate 
node. Within the eczematous skin conditions, three distinct clusters emerge for atopic dermatitis, 
allergic contact dermatitis and irritant contact dermatitis. Only two samples (one AD and one ACD) 
were classified in other clusters.
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Discussion
Recent genetic and cell biological investigations from various labs including our 
own have indicated that epidermal keratinocytes are not passive bystanders in 
cutaneous inflammation, but play an active role in diseases such as psoriasis and 
various forms of eczema. For this reason we have studied gene expression in 
isolated epidermal sheets rather than full thickness skin biopsies. Our data specify 
the contribution of the epidermis and as such they convey a different message 
than other studies that use full thickness biopsies, with varying contributions of 
inflammatory cells and resident dermal cells. In this study we analysed if gene 
expression signatures as found in atopic dermatitis are also present in lesional 
epidermis of other eczematous skin conditions such as allergic and irritant 
contact dermatitis. Normal epidermis and psoriatic epidermis were analysed for 
comparison. While CAII was found in all investigated forms of eczema, NELL2 
showed a strong induction only in atopic dermatitis epidermis. CXCL10 and 
CCL17, in contrast, were highly upregulated predominantly in epidermis from 
patients with allergic contact dermatitis. IL-1F9, elafin and hBD-2 were strongly 
induced in psoriasis, but not in any type of eczema. The chemokine CXCL8 was 
highly expressed in psoriasis, atopic dermatitis and allergic contact dermatitis but 
not in irritant contact dermatitis. Cluster analysis on a limited set of genes allowed 
a molecular discrimination between these four inflammatory conditions.
 To date, no specific keratinocyte-derived biomarkers have been identified 
to distinguish atopic dermatitis from other forms of eczema at the molecular 
level. Several genes including CAII and NELL2 were, however, found to be 
overexpressed in atopic dermatitis lesions compared to psoriatic epidermis9,10,14. 
Although our data do not allow conclusions on the involvement of these genes in 
the disease-specific pathogenetic processes, we observed a remarkable, strong 
expression of CAII in all eczematous conditions (Figure 4.1). Previous in vitro 
studies showed that CAII is induced by atopic dermatitis-associated Th2 cytokines 
but not by Th1 cytokines that are predominantly associated with psoriasis, 
and to a lesser extent with chronic atopic dermatitis14. Although the cytokine 
environment of atopic dermatitis, allergic contact dermatitis and irritant contact 
dermatitis is generally thought to be different, there are several publications that 
report the involvement of overlapping cytokine/chemokine profiles, including 
both Th1 and Th2 cytokines, in these conditions21-25. We speculate that the 
presence of Th2 cytokines in all three eczematous conditions could drive the 
CAII expression. Another characteristic that is present in all forms of eczema 
is a decreased barrier function that results in increased trans-epidermal water 
loss. As carbonic anhydrases are involved in water transport26, CAII upregulation 
could be a response to restore fluid balance following impaired barrier function. 
Obviously this assumption requires further investigation. Analysis of CAII at the 
protein level showed a discrepancy between mRNA and protein data. Similar to 
earlier findings in atopic dermatitis, we now observed a strong increase in allergic 
contact dermatitis at the mRNA level but only a minor increase at the protein level, 
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as determined by flow cytometric analysis. From this analysis it can be concluded 
that CAII induction is only useful as a disease marker at the mRNA level, in 
view of the low and heterogeneous expression of the protein. In contrast, NELL2 
was predominantly upregulated in atopic dermatitis, to a much lesser extent in 
allergic contact dermatitis, and not at all in irritant contact dermatitis. NELL2 is 
a thrombospondin-like molecule that shows a significant homology with NEL, 
which is strongly expressed in neuronal tissues of chicken27. NELL2 contains 
six EGF-like repeats and is strongly expressed in adult and fetal brain, weakly 
in the kidney28. It promotes the survival of hippocampal and cortical neurons15 
and increases the differentiation of spinal cord progenitors, while at the same 
time exerting paracrine proliferative activity29. In a previous study we showed 
that cultured keratinocytes do express NELL211, and in the present study we 
show that NELL2 is expressed in keratinocytes of atopic dermatitis skin in vivo. 
Bearing in mind its function in brain, NELL2 expression could be associated with 
the increased amount of nerve fibers in the epidermis that are found in lesional 
skin of atopic dermatitis30. 
 Earlier studies have shown CXCL10 upregulation in several diseases 
that are associated with a Th1-response, like allergic contact dermatitis31 
and psoriasis32, while in atopic dermatitis only a week staining was shown by 
immunohistochemistry33. We, however, found a high expression of CXCL10 
mRNA in allergic contact dermatitis, but only a comparatively minor upregulation 
in psoriasis. Another chemokine we found highly upregulated in allergic contact 
dermatitis and only mildly in atopic dermatitis is CCL17. This chemokine can bind 
to the CC chemokine receptor (CCR)834 and CCR435, which is expressed by Th2-
type lymphocytes, and is a chemoattractant for these cells36. Injection of CCL17 
in the skin of mice results in a Th2-dominated inflammation37. CCL17 expression 
is found in lesional skin of patients with atopic dermatitis and high serum levels of 
CCL17 correspond to disease severity38,39. The high CCL17 expression we found 
in allergic contact dermatitis suggests that besides a Th1-type of inflammation also 
Th2-type lymphocytes are involved. This is in agreement with several studies that 
have reported an overlap of cytokine/chemokine profiles in eczematous diseases 
(see above).
 Irritant contact dermatitis is mainly caused by epidermal reactivity to 
skin penetrating agents, resulting in inflammation largely mediated by innate 
immunity20. The types of cytokines released after exposure to an irritant are not the 
same for all irritants. TNF-α, for example, is induced after exposure to tribulyltin40 
and sodium dodecyl sulphate (SDS)41 in mice, but not after benzalkonium chloride 
exposure42. Despite a vigorous inflammatory response, most of the cytokines and 
chemokines we investigated were only weakly upregulated in experimental irritant 
contact dermatitis compared to other eczematous conditions. Another difference 
we observed was the absence of a strong inflammatory infiltrate in irritant contact 
dermatitis, both in the dermis (Figure 4.2) and in the epidermis (Figures 4.1 and 
4.2). In previous studies IL-1β and CXCL10 were only upregulated after allergen 
painting and not after irritant exposure in BALB/c mice41 and also in human 
Molecular diagnostics
95
studies CXCL10 and CCL17 were upregulated in allergic contact dermatitis but 
not in irritant contact dermatitis43. This is in contrast with data on elevated levels 
of CXCL10 in (epi)dermal fluid samples after exposure of forearm skin to 10% 
SLS23. This could be due to the time point measured: samples were collected 
16 hours after exposure to SLS, while the biopsies in our study were taken after 
48 hours. Alternatively, the CXCL10 could be entirely derived from the dermal 
compartment and not from the keratinocytes. The acute irritant contact dermatitis 
reaction that we observed here has features of both psoriasis (elafin induction, 
hyperproliferation and KRT16 expression) and atopic dermatitis (absence of 
hBD-2, induction of CAII).
 Cluster analysis clearly shows that psoriasis is distinct from all forms of 
eczema, and the high expression levels of genes such as hBD-2, IL-1F9 
and VNN3 were unique to psoriasis. Recent studies have indicated that the 
transcriptome of psoriasis resembles that of keratinocytes stimulated by IL-112 
or a combination of IL-1, TNF-α and IFN-g11. Indeed, all psoriasis-associated 
genes reported here are strongly induced by these cytokines11,12,16. We would 
speculate that the similarities between the eczematous conditions are caused by 
their similar, albeit not identical, cytokine environments, which could include IL-4 
and/or IL-13 produced by Th2 lymphocytes. The question whether the induced 
genes also contribute to the disease process remains to be addressed.
 A number of caveats should be considered for our study. For practical 
reasons the number of samples is limited and internal validation of the predictive 
power indicated a 12.7% error rate. We have not considered the effect of disease 
severity on expression of genes and disease classification, as we included only 
strongly inflamed skin lesions. Another limitation is the fact that atopic dermatitis 
and psoriasis biopsies were taken from existing lesions in patients, whereas in 
allergic and irritant contact dermatitis induced lesions were biopsied at 48 hours 
after elicitation by allergen or irritant. Recent studies have shown that cytokine 
profiles of acute and chronic irritant reactions are largely similar, but some 
cytokines like CCL5 are different23.
 Finally, the question arises whether a classification based on molecular 
diagnostic criteria has any practical significance for a group of inflammatory 
conditions. Although these conditions can usually be discriminated quite well 
by clinical criteria, it is not uncommon to encounter diagnostic difficulties in 
discriminating irritant contact dermatitis from allergic contact dermatitis, e.g. in 
hand eczema44. Likewise, nonpustular palmoplantar psoriasis is often difficult 
to delineate from hyperkeratotic eczema of the palms or soles45. It would be 
interesting to analyse expressed genes in these conditions, and to see if clear-
cut molecular patterns emerge. Alternatively, molecular diagnostics could also 
result in mixed, inconclusive results thereby confirming the assertion that these 
conditions represent intermediate phenotypes both clinically and molecularly.
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Materials and methods
Patients and healthy volunteers
Patients and healthy volunteers were recruited by the Dermatology clinic of the 
Radboud University Nijmegen Medical Centre. All diagnoses were made by a 
dermatologist. The study was approved by the local medical ethical committee 
(Commissie Mensgebonden Onderzoek Arnhem-Nijmegen) and conducted 
according to the Declaration of Helsinki principles. Written informed consent 
was obtained from each volunteer. Patients who suffered from chronic atopic 
dermatitis, diagnosed according to the Hanifin criteria46, were in an active phase of 
disease for which they were hospitalized and biopsies were taken from subacute 
lesions. Care was taken to exclude vesicles or scratched skin. All patients with 
psoriasis had moderate to severe plaque type psoriasis. To induce allergic contact 
dermatitis, patients with a known allergy were exposed for 48 hours to nickel or 
perfume I (European standards series) on the lower back. 72 hours after exposure 
3-mm biopsies were taken from these allergic contact dermatitis patients, and 
healthy skin was used as a control. To induce irritant contact dermatitis, 400 
µl 5% SDS solution was applied on a 2x2 cm patch of absorbent non-woven 
fabric (Medicomp, Hartmann, Heidenheim, Germany), which was subsequently 
placed on the lower back of healthy volunteers and covered with Tegaderm (3M 
Health care, Neuss, Germany) and Soft Cloth Surgical Tape (3M Health care) 
as described previously. After 4 or 8 hours the patch with SDS was removed. 48 
hours after exposure, 3-mm biopsies were taken from these patients with irritant 
contact dermatitis, and healthy skin was used as a control. Skin reactions to SDS 
application were found to be variable. Biopsies were only taken from individuals 
that showed a clear response as witnessed by strong erythema. Some individuals 
showed severe epidermal damage and a subsequent wound-healing response 
as assessed by histological analysis. These samples were excluded from the 
analysis.
Isolation of epidermal sheets and preparation of cells for flow cytometry
Isolation of epidermal sheets for mRNA isolation was performed as previously 
described47. In short, a 3-mm punch biopsy was incubated for four hours at 4˚C 
in phosphate-buffered saline (PBS) with Ca2+/Mg2+, containing 12 mg/ml Dispase 
(Roche diagnostics, Basel, Switzerland) and 5 μg/ml Actinomycin-D (Sigma-
Aldrich, St. Louis, MO, USA). After incubation, the epidermis was removed 
with tweezers and stored in Trizol (Invitrogen, Groningen, the Netherlands) at 
-80˚C until use. Cell suspensions for flow cytometry were prepared as described 
before48. Biopsies were incubated overnight in PBS containing 2.5 mg/ml trypsin 
(trypsin 250, Difco Laboratories, Detroit, MI, USA) at 4°C. Ten percent fetal calf 
serum (Harlan Sera-Lab, Loughborough, UK) was added and the epidermis 
and dermis were separated with tweezers. The epidermal side of the dermis 
was gently scraped to ensure detachment of basal cells. Both the epidermis 
and dermis were mixed on a vortex to allow detachment of all keratinocytes. 
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Table 4.1 Primer sequences of all genes examined by qPCR
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Subsequently, the stratum corneum and dermis were removed and the remaining 
cells were pelleted and fixed by slowly adding 1 ml cold ethanol while vortexing at
low speed. Cell suspensions were stored at 4ºC for at least two hours.
RNA extraction and real-time quantitative PCR
Epidermal sheets were used for RNA extraction, and a DNase I treatment was 
performed following manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). 
Reverse transcriptase reactions were performed with 1 μg RNA as described 
previously10. The reverse transcriptase reaction products were used for qPCR, 
which was performed with the MyiQTM Single-Colour Real-Time Detection System 
for quantification with SYBR Green Supermix (Biorad, Richmond, CA, USA) 
and melting curve analysis, as described previously48. DNA was PCR-amplified 
under the following conditions: 4.5 minutes at 95ºC, followed by 40 cycles of 15 
seconds at 95ºC and 1 minute at 60ºC, with data collection in the last 30 seconds. 
All primer concentrations were 300 nM in a total reaction volume of 25 µl. The 
amount of mRNA for a given gene in each sample was normalized to the amount 
of mRNA of the human ribosomal phosphoprotein P0 (RPLP0) reference gene in 
the same sample. The RPLP0 gene is, at least for skin biopsies, more suitable 
than commonly used genes such as actin or GAPDH, as RPLP0 correlates far 
better with 28S ribosomal RNA. Primers for qPCR were only accepted if their 
efficiency was 100 ± 10 %, which means that the PCR product was doubled 
at each cycle and the threshold cycle (Ct) will be linear with the log of the initial 
concentration. Corrections were made for primer efficiency.
 For graphic representation of relative mRNA expression levels we used the 
delta-delta Ct method49. Primer sequences are shown in Table 4.1. All primers 
were obtained from Biolegio (Nijmegen, the Netherlands).
Immunohistochemistry
Skin biopsies were immediately fixed in a 10% formalin solution (Baker 
Mallinckrodt, Deventer, The Netherlands) for 4 hours and subsequently embedded 
in paraffin. Before staining with antibodies that recognize CD45 (Dako, Glostrup, 
Denmark), Ki67 (Immunotech, Fullerton, CA) and KRT16 (Monosan, Uden, The 
Netherlands), a citrate treatment was performed: sections were boiled for 10 
minutes in a microwave in a solution containing 1.8 mM citric acid and 8.2 mM 
sodium citrate. 6 μm sections were blocked for 15 minutes with PBS with 20% 
normal rabbit serum (for hBD-2), normal goat serum (for elafin) or normal horse 
serum (for CD45, Ki67 and KRT16) and subsequently incubated with anti-hBD-2 
(Abcam, Cambridge, UK) in a 1:100 dilution, anti-elafin in a 1:500 dilution, anti-
CD45 in a 1:100 dilution, anti-Ki67 in a 1:50 dilution, and anti-KRT16 in a 1:50 
dilution for 1 hour at room temperature. After washing in PBS, sections were 
incubated for 1 hour with a secondary antibody (biotinylated rabbit anti-goat, 
biotinylated goat anti-rabbit or biotinylated horse anti-mouse in PBS containing 
1% BSA, Vector laboratories, Burlingame, CA). After 30 minutes incubation with 
Avidin-Biotin complex (Vector Laboratories), sections were treated with 3-amino-
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9-ethyl carbazole (Calbiochem, San Diego, CA) for 10 minutes. Nuclei were 
stained with Mayer (Sigma-Aldrich), and subsequently sections were mounted in 
glycerol gelatin (Sigma-Aldrich).
Flow cytometry
Ethanol fixed cells were washed with PBS/1% fetal bovine serum and subsequently 
labeled with anti-CAII (Abcam) in a 1:500 dilution. After 30 minutes incubation 
at 4˚C, cells were washed and incubated with Alexa fluor 488 goat anti-rabbit 
secondary antibody (Invitrogen). After 30 minutes incubation cells were washed, 
resuspended in propidium iodide and 0.1% RNase (Sigma-Aldrich). The labeled 
cell suspensions were analyzed on an EPICS Elite flow cytometer (Coulter, 
Luton, UK). A bandpass filter of 515–535 nm (green, FITC) was used to measure 
emitted light, while a gate in the right angle scatter (a measure of regularity) 
versus the forward scatter (a measure of size) was used to exclude debris. To test 
for CAII specificity, the CAII antibody was pre-incubated with excess CAII protein 
and added to epidermal cells instead of the primary antibody alone. Only a very 
few CAII positive cells could now be detected by flow cytometry (not shown), 
indicating a high specificity of the CAII antibody.
Cluster analysis and statistics
All data were analyzed with the Statistica software package version 7.0 (StatSoft 
Inc) or SPSS v16.0 (SPSS Inc). For the qPCR experiments, statistical analysis 
by ANOVA was performed on ∆Ct values corrected for primer efficiency. ∆Ct is 
the difference between the Ct of the target gene and the reference gene. These 
values are normally distributed. A Bonferroni post-hoc test was used to test the 
significance of the difference between each of the groups. Note that for graphical 
representation of the data (Figure 4.1) we used the relative expression levels 
as described by Livak and Schmittgen24. Cluster analysis was performed on 
corrected ∆Ct-values of 7 selected genes (CAII, NELL2, hBD-2, IL-1F9, CXCL8, 
CXCL10 and CCL17). The values were subjected to a Z-transformation, where 
Z = (x-μ)/σx. This will yield a matrix with a row mean of 0 and a SD of 1. After 
this transformation, the Euclidean distance is used as the dissimilarity measure. 
Samples were clustered by Ward’s amalgamation rule. Polytomous logistic 
regression analysis, including forward selection procedure, was used to predict 
the diagnostic group based on the expression levels of the above mentioned 7 
selected genes. Leave-one-out cross-validation was applied to obtain an estimate 
of the error rate that is not biased by overfitting.
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Supplementary information
Gene selection
A number of microarray studies on gene expression in psoriasis, atopic dermatitis 
and normal skin have been performed9,10,50-52. These analyses have identified 
a large number of genes that were differentially expressed between lesional 
psoriatic epidermis and normal skin. Two of these studies9,10 have focused on 
a comparison of lesional psoriasis and atopic dermatitis skin in order to identify 
disease-specific expression patterns. These data have been deposited at  the 
NCBI (Gene Expression Omnibus). A limited number of these genes have been 
verified by qPCR or immunohistochemistry. Our own study10 focused on host 
defense proteins, and we could indeed confirm most of the array data by qPCR. 
In this study we identified 180 genes that were differentially expressed between 
atopic dermatitis and psoriasis. These genes showed a significant difference 
after correcting for false discovery. Table S4.1 provides a list of all these genes. 
From this list we tested a number of genes with qPCR to verify the differential 
expression, including CA2, IL1F9, PI3 and VNN3. As the observed expression 
could be confirmed, they were included in the analyses of the current manuscript. 
Other genes that we examined were selected on the basis of available literature 
such as NELL2, CCL17 and VNN19,10. The remaining genes were selected for 
reasons that they have been associated with psoriasis or atopic dermatitis in 
other studies (e.g. KRT6 and CXCL10). IL1B and IL18 were selected because 
of the reported gene expression signature of psoriasis resembling that of IL-1 
stimulated keratinocytes. Finally PTPRC (CD45) was not selected on the basis of 
known differential expression, but as a convenient marker to assess the presence 
of hematopoietic cells in our isolated epidermal sheets. We could indeed 
demonstrate, using qPCR and histology, that CD45+ cells are largely absent from 
normal skin, but clearly present in psoriasis, allergic contact dermatitis and atopic 
dermatitis.
Table S4.1
All genes that were found to be differentially expressed in a microarray analysis 
performed on isolated epidermal cells taken from lesional epidermis of 6 psoriasis 
and 6 atopic dermatitis patients. The experimental details of the microarray 
analysis has been published before10,11, and the data on gene expression levels 
have been deposited, compliant with MIAME criteria, at http://www.ncbi.nlm.nih.
gov/geo/ and are accessible through GEO Series accession number GSE6601. 
For convenience of the reader we here present all 180 genes that passed 
the criterion for false discovery rate. Several genes from this list were used in 
the current study to define a limited gene set that could differentiate between 
inflammatory skin diseases. 
 Gene ID: the reference sequence from which the oligonucleotide sequence 
on the chip was derived. Mean and Standard deviation: 2log of the normalized 
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expression ratio of psoriasis/atopic dermatitis. N: the number of chips that 
gave a reliable signal and were used for analysis. Unigene ID: the Unigene 
entry identification code for each gene (see http://www.ncbi.nlm.nih.gov/sites/
entrez?db=unigene). Description: the given gene name and HUGO gene name. 
Gene_Ontology: the putative function of the gene in a biological process.
 The list is sorted from the highest mean (4.2 for the VNN3 gene) to the 
lowest mean (-2.9 for CA2). As the mean is the 2log of the ratio psoriasis/atopic 
dermatitis, all genes with a mean >0 are overexpressed in psoriasis, whereas 
all genes with a mean <0 are overexpressed in atopic dermatitis. The selection 
criterion was set at a mean > 1 and < -1, combined with false discovery rate 
correction. This gave a list of 180 genes whose expression was significantly 
different between psoriasis and atopic dermatitis.
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Abstract 
The use of tissue engineered human skin equivalents (HSE) for fundamental 
research and industrial application requires expansion of keratinocytes from a 
limited number of skin biopsies donated by adult healthy volunteers or patients. 
A pharmacological inhibitor of Rho-associated protein kinases, Y-27632, was 
recently reported to immortalize neonatal human foreskin keratinocytes. Here, we 
investigated the potential use of Y-27632 to expand human adult keratinocytes 
and evaluated its effects on HSE development and in vitro gene delivery 
assays. Y-27632 was found to significantly increase the life span of human adult 
keratinocytes (up to 5-8 passages). Epidermal morphology of HSEs generated 
from high passage, Y-27632-treated keratinocytes resembled native epidermis 
and was improved by supplementing Y-27632 during the submerged phase of 
HSE development. In addition, Y-27632-treated keratinocytes responded normally 
to inflammatory stimuli, and could be used to generate HSEs with a psoriatic 
phenotype, upon stimulation with relevant cytokines. Furthermore, Y-27632 
significantly enhanced both lentiviral transduction efficiency of primary adult 
keratinocytes and epidermal morphology of HSEs generated thereof. Our study 
indicates that Y-27632 is a potentially powerful tool for a variety of applications of 
adult human keratinocytes. 
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Introduction 
There is a growing demand for tissue engineered in vitro skin models for industrial 
applications and in fundamental research. In vitro pharmacotoxicological testing 
and industrial screening of drugs are nowadays accepted as an alternative to 
experimental animal testing and in vitro skin models are increasingly used to study 
skin biology and pathophysiology of skin diseases. Although the development 
of organotypic cultures, furtherdesignated as human skin equivalents (HSEs), 
for reconstructive purposes has been disappointing over the last decades, 
there are several indications that they may find their way to the clinic. Their 
potential use ranges from application in chronic ulcers1, to treatment of patients 
with keratinization disorders or blistering diseases using epidermal grafts of 
keratinocytes derived from genetically corrected induced pluripotent stem cells2.
 Submerged keratinocyte cultures have been extensively used as in vitro 
skin models, however, over the last decade, or HSEs have emerged as a more 
biologically and physiologically relevant model as they more closely mimic native 
epidermis. To meet the increasing need for HSEs, large quantities of primary 
human keratinocytes are required. Recently, increased cloning efficiency of 
neonatal human foreskin keratinocytes3 and even efficient immortalization due to 
increased telomerase expression and stabilization of the telomere lengths4 has 
been described. Both studies used a selective inhibitor of the Rho-associated 
coiled-coil forming protein serine/threonine kinase (ROCK), Y-27632. 
 The Rho/ROCK pathway is essential in a variety of cellular functions in 
keratinocytes including, actin cytoskeletal organization5, keratinocyte adhesion6 
and motility7,8. Related to skin morphogenesis, it was recently described that RhoE, 
a member of the Rho GTPase family, is required for epidermal morphogenesis by 
regulating epidermal stratification9. RhoA, however, was found to be dispensable 
for skin development, as knockout mice lack a skin phenotype8. In contrast, 
downstream effectors of RhoA, ROCK I and II, have been reported to regulate 
keratinocyte differentiation10,11.
 Hitherto, studies describing ROCK inhibition by Y-27632 use HaCaT 
cell lines or neonatal foreskin keratinocytes. However, in HSE development, 
primary human adult keratinocytes are preferably used since they generate 
HSEs that more closely resemble native epidermis in structure and function12. 
For application of HSEs in reconstructive surgery or gene therapy, expansion 
of primary keratinocytes isolated from a few biopsies is required to generate 
sufficient amounts of cells. However, the life span of primary adult keratinocytes 
is relatively short and senescence is usually observed after a few passages. In 
the light of the emerging applications of HSEs, we anticipate a strong need for 
human adult keratinocytes and have therefore evaluated the potential of Y-27632 
to prolong the life span of these cells. In addition, we thoroughly investigated 
the effects of Y-27632 on HSE development. Finally, we studied the potential 
of Y-27632 to facilitate gene delivery studies using lentiviral-transduced adult 
keratinocytes to generate HSEs. 
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Results
Y-27632 increases the life span of primary adult keratinocytes 
As described previously for freshly isolated neonatal foreskin keratinocytes4, we 
cultured liquid nitrogen-stored primary adult keratinocytes obtained from 3mm 
skin biopsies and neonatal foreskin keratinocytes with or without Y-27632. The 
population doubling rate was calculated at each passage. Based on previous 
work and dose optimization studies, a 10 μM concentration of Y-26732 was 
used. As shown in Figure 5.1a, senescence was observed between days 30 
and 60 of culture in all five adult keratinocyte donors cultured without Y-27632, 
this in contrast to neonatal foreskin keratinocytes which remained proliferative 
throughout the culture period, which indicates the profound differences between 
foreskin and adult keratinocytes. All adult keratinocytes cultured in presence of 
Y-27632 showed a markedly increased life span and three out of five keratinocyte 
donors remained proliferative for 80 days or longer. Morphologically, high 
passage keratinocytes cultured with Y-27632 resembled primary keratinocytes 
as they were small and homogenous in size and formed a honeycomb pattern 
of cohesive polygonal cells. Adult keratinocytes cultured in absence of Y-27632 
became large and heterogeneous in size with bloated cytoplasm, which are signs 
of senescence (Figure 5.1b). Since immortalization of foreskin keratinocytes 
by Y-27632 due to induced telomerase expression was previously reported4, 
Figure 5.1 Effect of Y-27632 on life span and cloning efficiency of primary human adult ke-
ratinocytes. Growth rate of human keratinocytes from one neonatal foreskin (HFK) donor or five 
adult (HAK1-5) donors (abdominal wall skin) cultured in the presence or absence of 10 μM Y-27632. 
The arrows indicate cells lines that continued to divide after 100 days in culture. The growth rate is 
measured as population doubling per day (a). Images of primary adult keratinocytes (left), passage 
4 adult keratinocytes cultured without Y-27632 (middle) and passage 13 adult keratinocytes cultured 
with Y-27632 (right). Scale bar, 100 μm (b). Fold increase in cloning efficiency of freshly isolated 
keratinocytes and liquid nitrogen-stored primary keratinocytes cultured with Y-27632 as compared to 
culture without Y-27632 (c). Error bars represent SD (n=3).
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we analyzed telomerase mRNA expression in high passage, Y-27632-treated 
adult and foreskin keratinocytes, however, we were unable to detect telomerase 
expression in all samples (data not shown). We also studied the effect of Y-27632 
on the proliferation rate of freshly isolated adult keratinocytes as compared to 
liquid nitrogen-stored, primary adult keratinocytes and found no differences 
between both keratinocyte batches (Figure 5.1c and Supplemental figure 5.1), 
suggesting that keratinocyte culture of previously isolated and liquid nitrogen 
stored adult keratinocytes can benefit from Y-27632 treatment.
Normal human skin equivalent can be generated from Y-27632-treated 
keratinocytes 
To evaluate the effect of Y-27632 on HSE development, we used our 3D skin 
model consisting of de-epidermised dermis as a matrix, and supplemented the 
culture medium with 10 μM Y-27632. Y-27632-treated keratinocytes (passage 6) 
were used to generate skin equivalents and we compared them to liquid nitrogen-
stored, primary adult keratinocytes (passage 1), with Y-27632 supplemented 
during different phases of the skin equivalent development. Passage 6 adult 
keratinocytes generated high quality HSEs, with a multilayered epidermis, 
presence of stratum granulosum and a basket weave stratum corneum 
(Supplemental figure 5.2). Normal expression patterns of major epidermal 
differentiation proteins were observed and HSEs were negative for the stress/
psoriatic marker human beta defensin-2 (hBD-2) (Figure 5.2). (See Supplemental 
Figure 5.3a for epidermal differentiation analysis in control HSEs). Even at 
passage 12, Y-27632-treated adult keratinocytes still generated high quality 
HSEs comparable to native epidermis (Supplemental Figure 3b). Furthermore, 
epidermal morphology appeared more regular when Y-27632 was supplemented 
during the submerged phase of the culture period (Supplemental figure 5.2c and 
d), this in contrast to HSEs cultured with Y-27632 during the entire culture period 
in which epidermal morphology was negatively affected and deep epidermal 
ridges were observed (Supplemental figure 5.2e and f). Therefore, it was decided 
to use Y-27632 only during the submerged phase of the HSE development for 
further experiments.
 As we observed that timing of Y-27632 exposure clearly affected HSE 
morphology, we also addressed possible adverse effects of high concentrations 
of the ROCK inhibitor on epidermal morphology. At 30 and 100 μM of Y-27632, 
deep epidermal ridges were observed and at 100 μM epidermal protrusions were 
seen in the stratum corneum (Figure 5.3a). These morphological changes were, 
however, not associated with significant alterations in epidermal differentiation 
gene expression (Figure 5.3b) or protein expression (Supplemental Figure 
5.4), or caused by induction of a keratinocyte inflammatory response as all 
HSEs lacked hBD-2 expression (Supplemental Figure 5.4). Protein expression 
of involucrin, however, was slightly extended towards the stratum spinosum in 
HSEs cultured with 30 and 100 μM of Y-27632, which may be indicative of an 
activated epithelium.
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In vitro psoriasis skin models can be generated from Y-27632-treated keratinocytes
As human primary keratinocytes are extensively used in vitro to study their 
function in the innate immune system, we cultured adult keratinocytes (passage 
1) submerged with various concentrations of Y-27632 and used pro-inflammatory 
cytokines IL-1α, TNF-α and IFN-ү to mimic an inflammatory milieu in vitro. As 
Figure 5.3 Y-27632 concentration dependant changes in epidermal morphology. (a) Deep rete 
ridges are observed in human skin equivalents (HSEs) generated in the presence of 30 or 100 μM 
Y-27632 and epidermal protrusions are observed at 100 μM. Scale bar, 100 μm. (b) Relative mRNA 
expression levels of various epidermal differentiation genes in HSEs generated with 10, 30 or 100 
μM Y-27632. The relative amount of mRNA in Y-27632 stimulated HSEs is normalized to the mean 
of unstimulated HSEs. Error bars represent SD (n=2).
Figure 5.4 Normal keratinocyte response to inflammatory stimuli after exposure to Y-27632. 
Primary adult keratinocytes (a) and passage 6 Y-27632-treated keratinocytes (b) were cultured sub-
merged with 10 or 100 μM Y27632 and stimulated with pro-inflammatory (Th1) cytokines IL-1α (10 
ng/ml), TNF-α (50 ng/ml) and IFN-ү (500 U/ml). Relative mRNA expression levels of human beta 
defensin-2 (hBD-2), TNF-α, IL-8 and IL1-β were compared to unstimulated (control) keratinocytes. 
Significant induction (P<0.01) of all analyzed genes was observed after cytokine stimulation. The 
already low basal hBD-2 levels further decreased by 10 (P<0.05) and 100 μM (P<0.01) of Y-27632, 
while basal IL-1β levels significantly increased (P<0.05) at 10 and 100 μM of Y-27632. Error bars re-
present SD (n=3-5). (c) Immunohistochemical staining of psoriatic markers, hBD-2 and SKALP/elafin 
shows strong induction of both markers in HSEs generated from Y-27632-treated keratinocytes with 
10 μM Y27632 supplemented during the submerged phase of HSE development, upon stimulation 
with psoriasis-associated cytokines IL-6 (5 ng/ml), TNF-α (5 ng/ml) and IL-1α (10 ng/ml). Scale bar, 
100 μm.
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depicted in Figure 5.4a, unstimulated (control) keratinocytes showed lower 
expression levels of hBD-2, while IL-1β mRNA expression levels were slightly 
elevated at 10 and 100 μM Y-27632. More importantly, keratinocyte activation 
was unaffected by Y-27632 as hBD-2, TNF-α, IL-8 and IL-1β mRNA expression 
levels were still significantly induced after cytokine stimuli. High passage Y-27632-
treated keratinocytes also showed significant induction of hBD-2 when cultured 
with 10 μM Y-27632 (Figure 5.4b). To verify this in our 3D skin model, we generated 
HSEs from Y-27632-treated keratinocytes and added 10 μM Y-27632 during the 
submerged phase of HSE development. Thereafter, HSEs were stimulated with 
psoriasis-associated cytokines, IL-6, IL-1α and TNF-α during the last three days 
of air-exposed culture. Protein expression of the psoriatic markers hBD-2 and 
SKALP/elafin was strongly induced in cytokine-stimulated HSEs (Figure 5.4c), 
indicating that psoriatic skin equivalents can be generated from Y-27632 treated 
keratinocytes. 
 In the experiments described above we used keratinocytes from healthy 
donors to generate a psoriasis-like phenotype in vitro. We also successively used 
Y-27632 to prolong the life span of keratinocytes derived from patients with skin 
diseases such as psoriasis or atopic dermatitis (data not shown), which could be 
subsequently used for HSE development.
Y-27632 facilitates gene delivery studies in human adult keratinocytes
Application of gene knock-down or overexpression techniques in HSEs is 
an elegant way to functionally analyze individual genes in an organ-like 
environment. We have observed that the proliferative capacity of high passage 
adult keratinocytes after lentiviral transduction is insufficient to generate HSEs 
thereafter (data not shown). Therefore, we assessed whether adult keratinocyte 
culture and subsequent HSE development can benefit from Y-27632 treatment 
in gene delivery assays. We used eGFP lentivirus as a model system for gene 
transduction and generated HSEs of eGFP-transduced keratinocytes which were 
cultured in the presence or absence of Y-27632, and compared gene transduction 
efficiency and HSE morphology. eGFP-transduced HSEs generated in the 
absence of Y-27632, showed a poorly formed epidermis consisting of only few cell 
layers, no stratum granulosum and parakeratosis present in the stratum corneum. 
HSEs generated from Y-27632-treated keratinocytes with Y-27632 present during 
the submerged phase of the HSE development, generated significantly improved 
skin equivalents with a multilayered epidermis, presence of stratum granulosum 
and no parakeratosis in the stratum corneum (Figure 5.5a). Expression of 
epidermal differentiation markers in Y-27632 treated, eGFP-transduced HSEs 
appeared similar to native skin as shown by the normal expression pattern of 
major epidermal differentiation proteins: keratin 10, involucrin, loricrin and LCE2 
(Figure 5.5b). Importantly, Y-27632-treated keratinocytes showed a significantly 
higher percentage of eGFP-transduced cells after recovery (Figure 5.5c), and this 
was also prominent in the Y-27632-treated HSEs with the majority of keratinocytes 
expressing eGFP (Figure 5.5d).
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Discussion
HSE development has been extensively optimized over the last decade to 
generate HSEs highly comparable to native skin. HSEs can nowadays be 
generated using a variety of dermal matrices such as animal-derived collagen 
matrices populated or not with human fibroblasts13, human de-epidermised 
dermis12 or human fibroblast-derived dermal equivalents14. Large scale HSE 
development is therefore only restricted by the limited availably of human adult 
keratinocytes. Here, we demonstrate an adequate solution for this problem, as 
Y-27632 prolongs the life span of human adult keratinocytes and improves HSE 
Figure 5.5 Lentiviral transduc-
tion of human adult keratino-
cytes. (a) HSEs generated from 
transduced keratinocytes that 
express eGFP driven by a GSK 
promoter cultured in presence of 
Y-27632 show superior epider-
mal morphology to transduced 
HSEs generated in absence of 
Y-27632 (control). (b) Epidermal 
differentiation markers keratin 10, 
LCE2, involucrin, and loricrin are 
normally expressed in Y-27632 
treated, eGFP transduced HSEs. 
(c) Flow cytometric analysis 
shows a significantly higher per-
centage of eGFP-positive cells 
in Y-27632-treated keratinocytes. 
Error bars represent SD (n=3). * 
P<0.05. (d) HSEs generated from 
Y-27632-treated keratinocytes 
show eGFP expression in the ma-
jority keratinocytes while in untre-
ated lentiviral-transduced HSEs 
only few eGFP positive cells are 
detected (d). Scale bar, 100 μm.
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quality. 
 Increased cloning efficiency by Y-27632 has been described for 
several freshly isolated epithelial cells15, including, human neonatal foreskin 
keratinocytes3,4, human and murine prostate epithelial cells3,16, human vaginal 
and cervical epithelial cells4 and also for human embryonic stem cells17. Here, 
we describe increased cloning efficiency and a prolonged life span of human 
adult keratinocytes which have been stored in liquid nitrogen prior to Y-27632 
treatment. Our findings may therefore have wide spread applications for other 
institutes to expand their established cell banks. 
 Immortalization of human foreskin and cervical keratinocytes due to 
increased telomerase expression and stabilized telomere lengths was described 
by Chapman et al. We, however, were not able to detect such phenomena in our 
adult keratinocytes. This is probably due to the very high passage number (from 
passage 34 onwards) in which they reported these characteristics while we were 
only able to culture our human adult keratinocytes till passage 15. The differences 
in life span between the Y-27632-treated keratinocytes used in our study and 
those used by Chapman et al. may result from differences in cell source (neonatal 
foreskin vs. adult keratinocytes). Moreover, liquid nitrogen stored keratinocytes 
might have a shorter life span than freshly isolated keratinocytes, although during 
the first passages we observed no differences in proliferation rate between freshly 
isolated or liquid nitrogen stored keratinocytes. 
 It has been reported that high passage Y-27632-treated epithelial cells 
display normal cell cycle progression, karyotype and DNA damage response4,15. 
Also Y-27632-treated epithelial cells are not capable of inducing tumors after 
subcutaneous injection in mice15. These data suggest that Y-27632 treatment of 
epithelial cells does not result in permanent DNA damage or induction of tumor-
like characteristics. Our study shows that, at least for the biomarkers used here, 
the Y-27632-treated adult keratinocytes do not behave differently from control 
cells.
Chapman et al. generated organotypic cultures from Y-27632-treated foreskin 
keratinocytes without the addition of Y-27632 during the entire culture period. The 
morphology of these organotypic cultures, however, did not completely resemble 
native epidermis, as a recognizable stratum granulosum was absent and 
involucrin expression extended into the stratum spinosum. The latter is abnormal 
and only observed in activated epidermis (e.g. psoriasis or skin injury). Also, from 
our previous studies we know that foreskin-derived HSEs show an activated 
phenotype as witnessed by parakeratosis and expression of the psoriasis marker 
SKALP/elafin12. Here, we demonstrate that HSEs generated from high passage, 
Y-27632-treated, adult keratinocytes faithfully mimic native epidermis, both in 
epidermal morphology and protein expression. We performed elaborate protein 
expression analysis and all investigated major epidermal differentiation proteins 
showed similar expression patterns to that of native skin. We can, however, not 
exclude that other genes or biological processes may be affected by Y-237632 
treatment. The beneficial effect of Y-27632 on HSE morphology when used during 
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the first three days (submerged phase) of HSE culture might be due increased 
keratinocyte survival and/or proliferation by Y-27632, resulting in a well formed 
multilayered epidermis later on. Even when Y-27632 was added during the 
terminal differentiation phase, we were able to generate HSEs with multilayered 
epidermis and stratum granulosum which corresponds to the finding that RhoA 
is dispensable for epidermal morphogenesis8. The previously reported effects 
of ROCK I and II depletion on keratinocyte differentiation were obtained from 
submerged keratinocyte cultures6 and/or HaCaT cell lines10. Such models are, 
however, considered less biologically relevant than in vitro generated HSEs. Also, 
the normal terminal differentiation observed in our Y-27632-treated HSEs may be 
indicative of compensatory mechanisms only present in an organ-like environment 
to overcome ROCK depletion as a necessity in epidermal morphogenesis. The 
observed changes in HSE epidermal morphology when using Y-27632 throughout 
the HSE culture period or at high concentrations of Y-27632, might be due to 
the roles of the Rho/ROCK pathway in actin-cytoskeletal architecture5 or cell 
migration7,8. In addition, Y-27632 has also been described to inhibit other kinases 
such as citron kinase, protein kinase C and myosin light chain kinase18, Although 
the potency of Y-27632 for ROCK is >100 times higher than for these kinases, 
additional effects on other kinases when using Y-27632 at high concentrations 
cannot be completely excluded.
 Primary keratinocytes are widely used to model skin inflammation in vitro 
as they play pivotal roles in inflammatory skin diseases as psoriasis and atopic 
dermatitis (reviewed by Guttman-Yassky et al.19). We have previously described 
induction of a psoriatic12,20 and atopic dermatitis21 phenotype in submerged 
keratinocytes cultures and HSE models. For these models, large quantities of 
human adult keratinocytes are required and here we demonstrated that Y-27632-
treated keratinocytes can be used for such purposes as keratinocyte activation 
remains unaffected by Y-27632. 
 In vitro skin irritation and corrosion testing of new chemical compounds 
or drugs using HSEs is now recognized as a validated method to substitute 
experimental animal use22,23 For this purpose, also, large quantities of human 
primary keratinocytes are needed. Companies developing HSEs at a large scale 
for commercial use, may therefore benefit from the effects of Y-27632 on adult 
keratinocytes herein reported.
 Over the last decade, small interfering RNA (siRNA) and transgenic 
techniques have made it possible to investigate gene function and signaling 
pathways in vitro. Only few studies have described in vitro gene therapy in 
HSEs using various methods for gene delivery24-26. Low transduction efficiency 
and poor epidermal morphology of transduced HSEs appears to be a common 
hurdle for which Y-27632 might provide a solution. Here, we have demonstrated 
increased lentiviral transduction efficiency in Y-27632-treated keratinocytes and, 
importantly, epidermal morphology of transduced HSEs was markedly improved 
by Y-27632. As Y-27632 has been described to suppress dissociation-induced 
apoptosis in murine prostate cells16 and to increase thaw-survival rates of stem 
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cells after cryopreservation17, keratinocytes might overcome transduction-induced 
stress when cultured with Y-27632, and Y-27632 might prevent cell death after 
dissociation of transduced keratinocytes to generate HSEs. 
 We have demonstrated that Y-27632 is a powerful tool for large scale 
human adult keratinocyte culture and HSE development, as high passage adult 
keratinocytes generated HSEs comparable to native epidermis. Furthermore, 
Y-27632 enhances lentiviral transduction efficiency and improves epidermal 
morphology of transduced HSEs, thereby facilitating gene delivery studies in 
primary keratinocytes and providing biologically relevant applications. 
Methods
Cell culture
Cells from the mouse fibroblast cell line 3T3 were cultured in Dulbecco’s modified 
Eagle’s medium (Life Technologies, Inc., Grand Island, NY) supplemented 
with penicillin/streptomycin (50 IU/ml; ICN Biomedicals, Zoetermeer, The 
Netherlands) and 10% calf serum with iron (Hyclone, Logan, UT). Keratinocytes 
were isolated from human abdominal skin derived from donors who underwent 
surgery for abdominal wall correction as previously described12. The study was 
conducted according to the Declaration of Helsinki principles. Keratinocytes were 
stored in liquid nitrogen or were used directly. Keratinocytes were cultured in 
Greens medium (2:1 [v/v] DMEM:Ham’s F12 (both from Life Technologies, Inc.) 
supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, 
UT), l-glutamine (4 mmol/l; Life Technologies, Inc.), penicillin/streptomycin (50 
IU/ml; Life Technologies, Inc.), adenine (24.3 μg/ml; Calbiochem, San Diego, 
CA), insulin (5 μg/ml; Sigma, St. Louis, MO), hydrocortisone (0.4 μg/ml; Merck, 
Darmstadt, Germany), triiodothyronine (1.36 ng/ml, Sigma) and cholera toxin 
(10−10 mol/l, Sigma) in the presence of irradiated 3T3-J2 feeder cells. After three 
days, medium was replaced by Greens medium containing epidermal growth 
factor (EGF, 10 ng/ml; Sigma). Cells were grown in the presence or absence of 
10 μM Y-27632 (Sigma) as indicated and were refreshed every two to three days. 
Upon 90-100% confluency, cells were subcultured by removal of feeder cells by 
EDTA (Sigma) and subsequent trypsinization with trypsin-EDTA (0.05%; Sigma) 
after which they were passaged 1:10 on irradiated 3T3-J2 feeder cells. 
Estimation of population doubling rate
At each passage the number of cells harvested was determined and population 
doubling was calculated as: PD= 3.32(log[number of cells harvested/number of 
cells seeded])4.
Analysis of cloning efficiency
To assess the effect of Y-27632 on cloning efficiency of freshly isolated adult 
keratinocytes versus liquid nitrogen stored adult keratinocytes, cells were seeded 
at different seeding densities on 3T3-J2 feeders cells and cultured as described 
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above. Cells were grown in presence or absence of 10 μM Y-27632 and after three 
days, 3T3-J2 feeder cells were removed by EDTA treatment and keratinocyte 
colonies were fixed using 3.7% paraformaldehyde for 20 minutes at room 
temperature. Cells were washed two times with PBS (Braun) and stained with 
freshly prepared 1% Rhodanile Blue (Sigma) in PBS for 15 minutes. Afterwards 
the cells were washed extensively with tap water and photographs were taken. 
Quantification analysis was performed using Image J software.
Generation of Human Skin Equivalents
De-epidermized dermis was generated as reported previously12 and 8-mm tissue 
samples were obtained using a biopsy punch. De-epidermized dermis was 
placed in a 24-wells transwell system and seeded with 105 keratinocytes. Liquid 
nitrogen stored primary adult keratinocytes (passage 1) or Y-27632-treated 
keratinocytes (passage 6 or 13) were used for experiments as indicated. After 
culturing the HSEs submerged for three days in medium containing 5% serum, 
consisting of two parts Dulbecco’s modified Eagle’s medium and one part Ham’s 
F12 medium (both from Life Technologies, Inc.) supplemented with 5% calf 
serum (Hyclone), 4 mmol/l l-glutamine and 50 IU/ml penicillin or streptomycin 
(both from Life Technologies, Inc.), 24.3 μg/ml adenine (Calbiochem), 1 μmol/l 
hydrocortisone (Merck KGaA), and 50 μg/ml ascorbic acid, 0.2 μmol/l insulin, 1.36 
ng/ml triiodothyronine, and 10−10 mmol/l cholera toxin (all from Sigma), the HSEs 
were cultured at the air-liquid interface for ten days in medium without serum, 
consisting of two parts Dulbecco’s modified Eagle’s medium and one part Ham’s 
F12 medium (both from Life Technologies, Inc.) supplemented with 4 mmol/l 
l-glutamine and 50 IU/ml penicillin or streptomycin (both from Life Technologies, 
Inc.), 24.3 μg/ml adenine (Calbiochem), 1 mg/ml l-serine and 2 μg/ml l-carnitine 
(both from Sigma), bovine serum albumin lipid mix (25 μmol/l palmitic acid, 7 
μmol/l arachidonic acid, 15 μmol/l linoleic acid, and 0.4 μg/ml vitamin E; all from 
Sigma), 1 μmol/l hydrocortisone (Merck KGaA), and 50 μg/ml ascorbic acid, 0.1 
μmol/l insulin, 1.36 ng/ml triiodothyronine, 10−10 mmol/l cholera toxin, 5 ng/ml 
keratinocyte growth factor, and 2 ng/ml epidermal growth factor (all from Sigma). 
Y-27632 was supplemented in the culture medium at indicated culture periods 
and concentrations.
Cytokine stimulation 
Liquid nitrogen-stored primary adult keratinocytes or Y-27632-treated adult 
keratinocytes (passage 6) were cultured to confluency in keratinocyte growth 
medium (KGM), consisting of KBM (0.15 mM Ca2+ BioWhittaker, Verviers, Belgium) 
supplemented with ethanolamine (0.1 mM; Sigma), phosphoethanolamine (0.1 
mM, Sigma), bovine pituitary extract (0.4% vol/vol; BioWhittaker) epidermal 
growth factor (10 ng/ml; Sigma), insulin (5 μg/ml; Sigma), hydrocortisone 
(0.5 μg/ml; Collaborative Research, Lexington, MA), penicillin (100 U/ml; Life 
Technologies, Inc), and streptomycin (100 μg/ml; Life Technologies, Inc.), with 
different concentrations of Y-27632. Cells were switched to KGM depleted of 
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growth factors (bovine pituitary extract, epidermal growth factor, hydrocortisone, 
and insulin) for 48 hours. Differentiating cell cultures were stimulated with pro-
inflammatory cytokines IL-1α (30 ng/ml), TNF-α (30 ng/ml) and interferon-γ (500 
U/ml) (all from Preprotech, London, UK), or left untreated. After 48 hours the cells 
were harvested for mRNA isolation using Trizol reagent (Life Technologies, Inc.). 
 Psoriatic skin equivalents were generated by stimulating HSEs during the 
last three days of the air-liquid interface culture with a mixture of IL-1α (10 ng/
ml) and TNF-α (5 ng/ml) and IL-6 (5 ng/ml) (all from Preprotech), as described 
previously12.
Lentiviral vector production
For generation of recombinant lentiviral particles, we used the third-generation 
self-inactivating transfer vector pRLL-cPPT-PGK-GFP-PRE-SIN (kind gift from 
Dr F. van de Loo, Department of Rheumatology, Radboud University Medical 
Centre Nijmegen. See Geurts et al.27 for details on plasmids and cells used for 
virus production). Packaging of VSV-G pseudotyped viruses was performed by 
transient transfection of 293T cells. 293T cells were seeded in a T225 flask at 
1x105 cells/cm2 in DMEM (Life Technologies, Inc.) supplemented with 10% bovine 
cals serum (BCS, Hyclone), 100 µg/ml penicillin (Life Technologies, Inc.), 100 µg/
ml streptomycin (Life Technologies, Inc.), 1 mM sodium pyruvate (Sigma) and 
0.01 mM water-soluble cholesterol (Sigma). At least one hour prior transfection, 
the medium was replaced with 24 ml DMEM supplemented with 10% BCS, 1 
mM sodium pyruvate and 0.01 mM water-soluble cholesterol. For each flask the 
following DNA mixture was prepared containing 56.7 µg transfer vector, 42.3 µg 
packaging vector pMDL-g/p-RRE, 20.0 µg expression vector pHIT-G and 14.2 
µg expression vector pRSV-REV in a final volume of 100 µl water. Subsequently 
1.5 ml 0.5 M CaCl2 (Sigma) was added and 1.5 ml 2xHBSS (Hepes-buffered 
saline solution, Sigma) was added gently under constant mixing. The formed 
precipitates were immediately added to the cells. 16 hours after transfection 
the medium was refreshed with DMEM supplemented with 100 µg/ml penicillin, 
100 µg streptomycin and 1 mM sodium pyruvate. 48 hours post transfection the 
virus-containing supernatant was filtered through a 0.45 µm Stericup (Millipore) 
to remove cell debris. Recombinant lentiviral particles were concentrated to 1.5 
ml and dialyzed against sterile PBS using an Amicon filter (MWCO 100 kDa, 
Millipore). Viral stocks are aliquoted and stored at -80 oC. Viral titers were 
determined using an enzyme-linked immunosorbent assay (ELISA) kit (Abbott) 
targeting the viral envelope protein p24gag and expressed as ng p24/µl. 
Lentiviral transduction of adult keratinocytes
Primary adult keratinocytes from three different donors were grown to 40% 
confluency in a 6-wells plate using KGM medium (Lonza) supplemented or not 
with 10 μM Y-27632. Subsequently, each well was incubated with 2 μg of eGFP-
lentivirus for 4 hours after which the cells were washed twice with sterile PBS. 
After 24 hours of recovery in KGM supplemented or not with 10 μM Y-27632, cells 
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were harvested with trypsin-EDTA and washed twice using PBS. The percentage 
of eGFP positive keratinocyte was analyzed by flow cytometry (EPICS Elite flow 
cytometer, Coulter, Luton, UK).
 To generate eGFP-transduced HSEs, 1.5x105 harvested keratinocytes were 
seeded onto DED in 24-wells inserts and HSEs were generated as described 
above with 10 μM Y-27632 supplemented during the submerged phase of the 
HSE culture as indicated.
Quantitative real-time PCR
For the skin equivalents, epidermis was separated by dispase (Roche Diagnostics, 
Mannheim, Germany) treatment for 2 hours at 4°C, and total RNA was isolated 
from the epidermis using Trizol reagent (Life Technologies, Inc.) and subsequent 
RNeasy mini kit (Qiagen Benelux B.V.) according to manufacturers specifications. 
cDNA was generated and used for quantitative real-time PCR (qPCR), which 
was performed with the MyiQ Single-Colour Real-Time Detection System for 
quantification with Sybr Green and melting curve analysis (Bio-Rad Laboratories, 
Inc) as previously described28. Primers for KRT10, KRT14, INV, LOR, Ki-67, FLG, 
TGM1, LCE3E, hBD-2, TNF-α, IL-8, IL-1β, and the housekeeping gene human 
acidic ribosomal phosphoprotein P0 (RPLP0) were obtained from Biolegio 
(Malden, The Netherlands). Relative mRNA expression levels of all examined 
genes were measured using the method described by Livak et al.29. See Table 
5.1 for primer sequences.
Morphological and immunohistochemical analysis
HSEs were fixed in buffered 4% formalin for 4 hours, processed for routine histology 
and embedded in paraffin. 6-μm sections were stained with heamatoxylin and 
eosin (H&E) (Sigma) or processed for immunohistochemical staining using an 
indirect immunoperoxidase technique with avidin-biotin complex enhancement 
(Vectastain Laboratories, Burlingame, CA, USA). To study epidermal proliferation, 
an antibody directed against Ki-67 (1:50; MIB-1; Dako, Denmark) was used 
whereas epidermal differentiation was studied using antibodies directed against 
cytokeratin 10 (1:100; Sanbio, Uden, The Netherlands), cytokeratin 14 (1:50, 
Novocastra, UK), involucrin (1:50; Mon150; Sanbio), loricrin (1:500; BAbCO, 
Richmond, CA, USA), filaggrin (1:200; Novocastra), transglutaminase 1 (1:200, 
Santa Cruz) and late cornified envelope 2 (LCE2; 1:1000, See Bergboer et 
al.30). The stress or psoriatic marker, hBD-2, was stained using goat anti-hBD-2 
polyclonal serum (1:100; Abcam, Cambridge, UK) and SKALP/elafin was stained 
using polyclonal antibodies as described previously31. Detection by 3-amino-9-
ethylcarbazole (Calbiochem) was followed by nuclei counterstaining with Mayer’s 
hematoxylin solution (Sigma), and sections were mounted using glycerol gelatin 
(Sigma).
Statistics
Statistical significance was determined using paired two-tailed Student’s t test.
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Table 5.1 Primer sequences of all genes examined by qPCR
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Supplementary information
Supplemental figure 5.1 Effects of Y-27632 on cloning efficiency. Effects of Y-27632 on cloning 
efficiency of (a) liquid nitrogen-stored keratinocytes compared to (b) freshly isolated keratinocytes. 
Keratinocytes were cultured in the presence or absence of 10 μM Y-27632 and images were taken 
after Rhodanile blue staining.
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Supplemental figure 5.2 Epidermal morphology of human skin equivalents (HSEs) genera-
ted from Y-27632-treated keratinocytes. Primary adult keratinocytes (control) and passage 6, 
Y-27632-treated keratinocytes cultured on de-epidermised dermis without Y-27632 (a and b), with 10 
μM Y-27632 supplemented during the submerged phase (c and d) or during the entire culture period 
(e and f) of HSE development show a fully differentiated epidermis with a stratum granulosum and 
cornified layer with superior morphology in HSEs generated with Y-27632 supplemented during the 
submerged phase. Scale bar, 100 μm.
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Supplemental figure 5.3 Epidermal differentiation patterns in human skin equivalents (HSEs) 
Epidermal differentiation patterns in HSEs generated from (a) primary adult keratinocytes with 10 
μM Y-27632 supplemented during HSE development and (b) HSEs generated from high passage, 
Y-27632-treated adult keratinocytes with 10 μM Y-27632 supplement only during the submerged 
phase of HSE development. HSEs show normal expression patterns for all analyzed epidermal mar-
kers: Ki-67 (proliferative cells), keratin 14 (basal keratinocytes), keratin 10 (suprabasal keratino-
cytes) and involucrin and transglutaminase 1 (terminal differentiation). HSEs are negative for the 
stress/psoriatic marker, human beta defensin-2 (hBD-2). Scale bar, 100 μm.
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Supplemental figure 5.4 Epidermal differentiation patterns in human skin equivalents (HSEs) 
generated in the presence of 10, 30 or 100 μM Y-27632. HSEs show normal expression patterns 
for epidermal markers: Ki-67 (proliferative cells), keratin 14 (basal keratinocytes), keratin 10 (supra-
basal keratinocytes) and transglutaminase 1 (terminal differentiation). Involucrin expression (terminal 
differentiation) is slightly extended towards the stratum spinosum at 30 and 100 μM Y-27632. HSEs 
are negative for the stress/psoriatic marker, human beta defensin-2 (hBD-2). Scale bar, 100 μm.
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Abstract
The protease inhibitor cystatin M/E regulates a biochemical pathway involved in 
stratum corneum homeostasis, and its deficiency in mice causes ichthyosis and 
neonatal lethality. Cystatin M/E deficiency has not been described in humans so 
far, and we did not detect disease-causing mutations in the cystatin M/E (CST6) 
gene in a large number of patients with autosomal recessive congenital ichthyosis 
(ARCI), who were negative for mutations in known ichthyosis-associated genes. 
To investigate the phenotype of cystatin M/E deficiency in human epidermis, we 
used lentiviral delivery of short hairpin RNAs that target cystatin M/E in a 3D 
reconstructed skin model. Knockdown of cystatin M/E expression did not lead 
to the expected ichthyosis-like phenotype, but prevented the development of a 
multilayered epidermis. The phenotypic discrepancy between mouse and human 
may be explained by the differences in specificity of cystatin M/E towards one 
of the target proteases (legumain), differences between the mouse and human 
cathepsin L orthologues or the presence of cathepsin V, a paralogous gene of 
cathepsin L that is absent in mice.
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Introduction
Cystatin M/E (CST6) is a cysteine protease inhibitor that exerts regulatory and 
protective functions against uncontrolled proteolysis by the cysteine proteases 
cathepsins L and V (CTSL, CTSV) and the asparaginyl endopeptidase legumain 
(LGMN)1,2. Cystatin M/E deficient mice display a hyperplastic, hyperkeratotic 
epidermis3,4 and die shortly after birth of dehydration, due to a disturbed skin 
barrier function5. Based on this phenotype we considered CST6 as a candidate 
gene for human disorders of cornification with unknown etiology. We have 
performed mutation analysis for 106 autosomal recessive congenital ichthyosis 
(ARCI) patients, who were negative for mutations in known ichthyosis-associated 
genes. (Table 6.1), however no disease-causing mutations in the CST6 gene 
were found6.
 By generating several double knockout mouse models, we recently showed 
that a tightly regulated balance between cathepsin L and cystatin M/E is essential 
for tissue integrity of the epidermis, but also for maintenance of healthy hair follicles 
and corneal epithelium7. Considering this, we have screened three patients with 
ichthyosis follicularis with atrichia and photophobia (IFAP syndrome, MIM 308205) 
and one patient with keratosis pilaris (KP, MIM 604093) for mutations in the CST6 
gene (Table 6.1). However, no mutations were found in the CST6 exons or exon/
intron boundaries. Besides, the cystatin M/E protein expression in the skin of 
these patients were normal. We also performed mutation analysis in one patient 
with ichthyosis follicularis with photophobia (IFAP) syndrome, who presented with 
whorled follicular keratosis and focal scarring alopecia and in addition showed 
punctate corneal lesions of the eyes8, that resembled the phenotype of our Cst6-
/-Ctsl+/- mice7. Again, we found no mutations in the CST6 gene and also Multiplex 
Ligation-dependent Probe Amplification (MLPA) on the patient’s DNA and its 
parents revealed no genomic deletions or insertions.
 Even though no human patients with CST6 mutations were found so far, 
we hypothesized that cystatin M/E deficiency in humans, like our mouse models, 
would lead to an ichthyosis-like phenotype. In the current study, we attempted 
to uncover the human skin phenotype of cystatin M/E deficiency by knockdown 
of the CST6 gene in primary human keratinocytes by RNA interference using 
lentiviral vectors. These lentiviral-infected keratinocytes were subsequently 
Diagnosis Nijmegen Munster Cologne Total
Ichthyosis (ARCI) 5* 13* 88** 106
Keratosis Pilaris 1 - - 1
IFAP syndrome 2 1 - 3
IFAP syndrome with corneal lesions 1 - - 1
Table 6.1 Patients screened for CST6 mutations
* Negative for mutations in TGM1
** Negative for mutations in TGM1, ALOX12B, ALOXE3, NIPAL4 and CYP4F22
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used to generate human skin equivalents, to study the pathway of epidermal 
differentiation and stratum corneum formation in which cystatin M/E is thought to 
play a crucial role (Figure 6.1). Surprisingly, cystatin M/E deficiency did not cause 
an ichthyosis-like phenotype but interfered with epidermal morphogenesis.
Figure 6.1 Regulation of epidermal protease activity by cystatin M/E. Regulation of epidermal 
protease activity by cystatin M/E in processes that control epidermal cornification and desquamation 
based on in vivo (mouse) and in vitro (human) studies2,7. Inhibition of legumain (LGMN) regulates 
the processing of (pro)-cathepsins. Inhibition of cathepsin V (CTSV) regulates desquamation, as 
CTSV is able to degrade (corneo)-desmosomal proteins like desmoglein-1, desmocollin-1, and cor-
neodesmosin. Inhibition of human cathepsin L (CTSL) activity by cystatin M/E is important in the 
cornification process, as CTSL is the elusive processing and activating enzyme for transglutamina-
se-3 (TGM3). CTSL is also able to process cathepsin D (CTSD), which in turn can activate transglu-
taminase-1 (TGM1). As CTSV is only expressed in humans (shaded oval), murine CTSL probably 
controls the specific functional enzymatic activities of both human CTSL and CTSV. Solid lines repre-
sent biochemical functions that are known from literature (grey) or deduced from our studies (black). 
Dashed lines represent unknown functions. BM, basal membrane; SB, stratum basale; SS, stratum 
spinosum; SG, stratum granulosum; SC, stratum corneum.
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Results
Mutation analysis
An overview of all sequenced patients that were considered as candidates for 
CST6 mutations are listed in Table 6.1.
Validation of lentiviral shRNA constructs for cystatin M/E knockdown
Primary human keratinocytes were infected with lentiviruses that were engineered 
to produce shRNAs that suppress the expression cystatin M/E. shRNA-CST6 
(nos. 1-4) and controls (no virus and scrambled sequence) were first examined 
in submerged keratinocyte cultures. qPCR analysis revealed a strong reduction 
(80-90%) at the mRNA level for all designed shRNAs (2 µg of virus/well), when 
compared to the scrambled “mock” control (Figure 6.2a).
 Figure 6.2 Validation of lentiviral expressed shRNAs to knockdown cystatin M/E. (a) Lentiviral 
(2 µg/well) infection of monolayers with cultured primary human keratinocytes revealed that all four 
designed shRNAs significantly reduce the CST6 mRNA expression. (b) STAT1 and OAS2 both sho-
wed slightly increased mRNA levels (not significant), as the control (no virus) was compared to the 
lentiviral infected keratinocytes. The mock control and shRNA-CST6 nos. 1-3 showed comparable 
levels of these interferon response genes. (c) Genes that are normally expressed in the basal layer 
(ITGB1, KRT14), all epidermal layers (CTSL) or are known as proliferation specific (MKI67), were 
not drastically affected by knockdown of the CST6 gene. Only the expression of the IVL gene (supra-
basal layer) was slightly increased. (d) Cystatin M/E protein knockdown was confirmed by ELISA on 
cell extracts of lentiviral infected keratinocytes.
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Potential off-target effects including interferon activation due to gene knockdown by 
siRNA delivery must be checked9,10, especially since keratinocytes are sensitive to 
interferon stimulation11. Therefore, two genes that indicate an interferon response 
(STAT1 and OAS2) were analyzed by qPCR (Figure 6.2b). The scrambled control 
showed a small increase (2-fold) for STAT1 and OAS2 expression levels. Three 
shRNA-CST6 constructs (nos. 1-3) showed no differences in mRNA expression 
levels when compared to the mock control. shRNA-CST6-4, however, showed a 
2-fold increase in OAS2 mRNA expression when compared to the mock control, 
and a 4-fold increase when compared to the cultured cells that were not infected 
with virus.
 In addition, we checked if infection with lentiviral shRNA-CST6 constructs 
and subsequent knockdown of cystatin M/E showed off-target effects or exert 
influence on the expression level of other genes that are known to be expressed in 
human epidermis (Figure 6.2c). All shRNA-CST6 constructs showed comparable 
levels (~2-fold induction) of gene expression for cathepsin L (physiologic target 
protease for cystatin M/E), the antigen identified by monoclonal antibody Ki-67 
(proliferation marker), and b1-integrin and keratin 14 (both expressed in the basal 
layer of the epidermis). Only involucrin (expressed in the suprabasal layers) 
showed a slight increased expression (approximately 3-fold) for all used shRNA-
CST6 lentiviral constructs, and was hence not considered to be an off-target 
effect but a genuine result of CST6 knockdown. After we validated cystatin M/E 
knockdown at the protein level (Figure 6.2d), we used the shRNA-CST6-1 and 
shRNA-CST6-3 lentiviral constructs for knockdown studies of cystatin M/E in a 
3D reconstructed skin model.
Cystatin M/E knockdown impairs epidermis formation in a human skin equivalent
The effect of cystatin M/E knockdown on the development and morphology 
of human skin equivalents was evaluated by histological analysis. A fully 
differentiated epidermis with a stratum granulosum and cornified layer is formed 
in the control and mock constructs (Figure 6.3a and b), whereas cystatin M/E 
knockdown with shRNA-CST6-1 and shRNA-CST6-3 completely disturbed the 
development of a multilayered epidermis (Figure 6.3c and d). From these skin 
equivalents no mRNA and protein could be extracted for respectively qPCR 
analyses and protease activity assays. Using lower concentrations of both viral 
constructs led to insufficient knockdown of cystatin M/E protein levels resulting 
in a normal epidermal development (shRNA-CST6-1) or a moderately disturbed 
(shRNA-CST6-3) morphology of the human skin equivalents (Figure 6.3e and f).
Discussion
In vitro biochemical approaches as well as the use of in vivo mouse models have 
revealed that cystatin M/E is a key molecule in a biochemical pathway that controls 
skin barrier formation by regulation of both crosslinking and desquamation of 
the stratum corneum (Figure 6.1). As cystatin M/E deficiency in mice causes 
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ichthyosis, follicular hyperkeratosis and corneal abnormalities we first assumed 
that if CST6 deficiency in humans exist the clinical symptoms might resemble the 
phenotype of the cystatin M/E deficient mice. We were, however, unable to find 
CST6 mutations in a large number of patients with unexplained ichthyoses. Even 
in a patient with a phenotype that included ichthyosis and corneal abnormalities 
we did not find CST6 mutations. In order to predict the epidermal phenotype of 
CST6 deficiency in humans, we here examined the phenotype of cystatin M/E 
deficiency in human epidermis using in vitro 3D reconstructed skin equivalents. 
Surprisingly, we did not observe an expected ichthyosis-like phenotype, but rather 
an atrophic epidermis, which, we speculate, might lead to embryonic lethality in 
humans.
 Recently, the use of synthetic siRNA or lentiviral-delivered transgenes has 
been described in reconstructed skin models12,13. In pilot experiments with synthetic 
siRNAs directed against the CST6 gene we have previously succeeded in gene-
specific (>90%) knockdown of cystatin M/E at the protein level in a submerged 
culture system (unpublished data). Although delivery of synthetic siRNA has been 
used successfully in a 3D reconstructed skin model for several target genes13,14, 
we found that this approach was not suitable for the CST6 gene (data not shown). 
Therefore we decided to use lentiviral vectors for gene knockdown (by delivery of 
shRNA). We succeeded to design four shRNA-CST6 constructs that resulted in a 
satisfying knockdown of cystatin M/E expression at the mRNA level as well as at 
Figure 6.3  Cystatin M/E knockdown by lentiviral delivery of shRNA impairs epidermis for-
mation in a human skin equivalent. Hematoxylin & Eosin staining showed the morphology of the 
human skin equivalents (left column). The control and mock (scrambled shRNA) showed a normal 
developed skin equivalent (a and b), whereas the formation of a multilayered epidermis is prevented 
by cystatin M/E knockdown (c and d). The use of lower shRNA-CST6 virus concentrations showed 
incomplete cystatin M/E knockdown (e and f). Scale bar: 100 µm
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the protein level in submerged keratinocyte cultures. These lentiviral constructs 
did not induce significant changes in expression levels of genes that are known to 
be expressed in human epidermis. However, we detected a modest induction of 
IVL expression as a result of cystatin M/E deficiency. It is known that interferon-γ 
can stimulate human involucrin gene expression15, though we found no dramatic 
interferon responses compared to the mock control as measured by STAT1 and 
OAS2 mRNA expression levels. From this we conclude that the induction of IVL 
expression is a specific consequence of CST6 knockdown, rather than an off-
target effect16,17.
 Deficiency of cystatin M/E in 3D skin constructs resulted in an unexpected 
disturbance of epidermal development, which made it impossible to study 
the involvement of cystatin M/E in the pathway of epidermal differentiation 
and stratum corneum formation and maintenance. We were unable to extract 
epidermal proteins to study protease- and transglutaminase activity, nor could 
we measure consequences of cystatin M/E deficiency on the expression levels of 
genes involved in epidermal differentiation and cornification.
 The phenotypic discrepancy between mouse and human may be explained 
by several factors. First, human legumain is strongly inhibited by human cystatin 
M/E, whereas mouse cystatin M/E is unable to inhibit legumain due to an 
aspartate residue (D64) in the proposed legumain inhibitory site instead of the 
important asparagine (N64)1,7. Therefore we do not exclude that legumain has a 
function in human skin (e.g. processing of cathepsins) that is controlled directly 
by cystatin M/E, which might be essential for normal epidermal development. 
Furthermore, no orthologue of cathepsin V in mice has been discovered yet and 
differences exist between the mouse and human cathepsin L orthologues. In fact, 
human cathepsin V is phylogenetically more closely related to murine cathepsin 
L than to human cathepsin L18. Phenotypical differences between man and mice 
exist. For example, it was shown that cystatin A, a cysteine protease inhibitor like 
cystatin M/E found in the upper layers of the skin, has a role in cell-cell adhesion 
and loss-of-function mutations in CSTA underlie exfoliative ichthyosis19. However, 
no specific phenotype was observed in mice that lack the Csta gene20.
The results of cystatin M/E knockdown in our reconstructed skin model showed 
an impaired epidermal morphogenesis rather than ichthyosis-like features. The 
lack of a well-formed suprabasal compartment precluded further analysis of the 
cystatin M/E regulated processes as we did before using our mouse models, 
e.g. in situ activities of transglutaminases and proteases7. From this study we 
conclude that cystatin M/E is indispensable for human skin development, and 
deficiency of this molecule may be incompatible with normal foetal development.
Materials and Methods
DNA samples
The study was conducted according to Declaration of Helsinki principles 
and approved by the medical ethical committee (Commissie Mensgebonden 
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Onderzoek Arnhem-Nijmegen), the ethical committee of the Medical Faculty of 
the University of Cologne, and the institutional review board of the University 
Hospital of Münster. In advance, approval and individual written informed consent 
were obtained. 
Mutation analysis
 Mutation analysis of all three CST6 exons including exon/intron boundaries 
was performed in genomic DNA by direct sequencing of amplified DNA. Primers 
sequences and sequencing reactions are performed as described previously6,21.
Keratinocyte isolation
 Cells from the mouse fibroblast cell line 3T3 were cultured in Dulbecco’s 
modified Eagle’s medium (Life Technologies, Grand Island, NY) supplemented 
with 50 IU/ml penicillin/streptomycin (ICN Biomedicals, Zoetermeer, The 
Netherlands) and 10% calf serum with iron (Hyclone, Logan, UT). Keratinocytes 
were obtained from human abdominal skin derived from donors who underwent 
surgery for abdominal wall correction. After isolation by trypsin treatment for 16 
to 20 hours at 4°C, keratinocytes were cultured in the presence of irradiated 
(3295 cGy for 4.10 minutes) cells from the 3T3 cell line. 3T3 cells were seeded 
at a concentration of 3x104 cells per cm2 in Greens medium, which consisted of 
two parts Dulbecco’s modified Eagle’s medium (Life Technologies) and one part 
of Ham’s F12 medium (Life Technologies) supplemented with 10% fetal bovine 
serum (Hyclone), 4 mmol/L l-glutamine (Life Technologies), 50 IU/ml penicillin/
streptomycin (Life Technologies), 24.3 μg/ml adenine (Calbiochem, San Diego, 
CA), 5 μg/ml insulin (Sigma, St. Louis, MO), 0.4 μg/ml hydrocortisone (Merck, 
Darmstadt, Germany), 1.36 ng/ml triiodothyronine (Sigma) and 10−10 mol/L 
cholera toxin (Sigma). The next day keratinocytes were added at a concentration 
of 5x104 cells per cm2. After three days, medium was replaced by Greens medium 
containing 10 ng/ml epidermal growth factor (EGF, Sigma). The cells were then 
refreshed every two to three days, and upon confluency, cells were trypsinized 
and stored in liquid nitrogen.
Lentiviral constructs
The generation of recombinant lentiviral particles were based on the third-
generation self-inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN in 
which the PGK promoter was replaced by the RNA polymerase III U6 promoter 
(referred as pSIN-U6) to allow expression of short hairpin RNAs (shRNAs) (a kind 
gift from Dr. Fons van de Loo, Department of Rheumatology, Radboud University 
Nijmegen Medical Centre, The Netherlands). A total of four different hairpins 
directed against the CST6 gene were selected based on experiments with 
synthetic siRNAs that were transfected in keratinocytes (data not shown) and 
using the Block-It RNAi designer from Invitrogen (https://rnaidesigner.invitrogen.
com/rnaiexpress/). Sequences for scrambled control hairpins were obtained 
from literature22. Table 6.2 shows location and sequence of the shRNA targets. 
Primers were designed containing the complete shRNA sequence followed by a 
polymerase III termination sequence. 40 µM of both primers were incubated in 
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Table 6.2 Primers used for construction of hairpins
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annealing buffer (10 mM Tris pH 8.0, 20 mM NaCl) at 95°C for 10 minutes and 
cooled down to room temperature overnight. The annealed primers, containing 
HpaI and NsiI compatible ends, were ligated into the HpaI/NsiI digested pSin-U6 
vector with T4 DNA ligase (Invitrogen, Carlsbad, CA) and transformed into TOP10 
cells (Invitrogen). Recombinant clones were selected on LB plates containing 
ampicillin (Invitrogen). Insertion of hairpins into pSin-U6 was confirmed by 
sequencing. Sequencing reactions were performed by the sequence facility of 
the Radboud University Nijmegen Medical Centre, based on the Sanger method 
using the BigDye Terminator version 3 chemics (Applied Biosystems, Foster City, 
CA).
Lentiviral vector production
VSV-G pseudotyped lentiviruses were produced after transient transfection 
of 293T cells. Cells were seeded in a T225 flask at 1x105 cells/cm2 in DMEM 
(Invitrogen) supplemented with 10% bovine calf serum (Hyclone), 100 µg/
ml penicillin (Invitrogen), 100 µg/ml streptomycin (Invitrogen), 1 mM sodium 
pyruvate (Sigma) and 0.01 mM water-soluble cholesterol (Sigma). Prior to 
transfection, the media was replaced with 24 ml DMEM supplemented with 10% 
BCS, 1 mM sodium pyruvate and 0.01 mM water-soluble cholesterol. Per flask 
the following DNA mixture was prepared containing 56.7 µg transfer vector, 42.3 
µg packaging vector pMDL-g/p-RRE, 20 µg expression vector pHIT-G and 14.2 
µg expression vector pRSV-REV in a final volume of 100 µl water. The DNA was 
added to 1.5 ml 0.5 M CaCl2 (Sigma) and subsequently 1.5 ml 2xHBSS (Hepes-
buffered saline solution, Sigma) was added drop wise under constant stirring. 
The formed precipitates were added to the cells immediately afterwards. Sixteen 
hours post transfection the media was refreshed with DMEM supplemented with 
100 µg/ml penicillin, 100 µg streptomycin and 1 mM sodium pyruvate. 48 hours 
post transfection the virus-containing supernatant was collected and cell debris 
was removed by filtration through a 0.45 µm Stericup (Millipore, Billerica, MA). 
Lentiviral particles were dialysed against PBS and concentrated to 1.5 ml using 
an Amicon filter (MWCO 100 kDa, Millipore). Viral stocks are aliquoted and stored 
at -80oC. Viral titres were determined using an enzyme-linked immunosorbent 
assay (ELISA) kit (Abbott, Chicago, IL) targeting the viral envelope protein p24gag 
and expressed as ng p24/µl.
Lentiviral transduction of adult keratinocytes
Keratinocytes from two different donors were grown to 40% confluency in a 
6-wells plate using KGM medium (Lonza, Verviers, Belgium) supplemented with 
10 μM Y-27632 (Sigma), as described previously23. Subsequently, each well was 
incubated with 0.5 or 2 μg of scrambled, shRNA-CST6-1 and shRNA-CST6-3 
lentivirus for 4 hours after which the cells were washed twice with sterile PBS. 
After 24 hours of recovery in KGM supplemented with 10 μM Y-27632, cells were 
harvested for skin equivalent generation or grown to confluency after which they 
were let to differentiate for 48 hours in growth factor depleted KGM, supplemented 
Chapter 6
148
with 5% serum.
Generation of human skin equivalents
Lentiviral transduced human skin equivalents were generated as described 
previously23. Briefly, 8-mm tissue samples of de-epidermized dermis were placed 
in a 24-wells transwell system and seeded with 1.5x105 lentiviral transduced 
keratinocytes. The human skin equivalents were cultured submerged for three 
days in medium containing 5% serum, consisting of two parts Dulbecco’s modified 
Eagle’s medium and one part Ham’s F12 medium (both from Life Technologies) 
supplemented with 5% calf serum (Hyclone), 4 mmol/l l-glutamine and 50 IU/
ml penicillin or streptomycin (both from Life Technologies), 24.3 μg/ml adenine 
(Calbiochem), 1 μmol/l hydrocortisone (Merck), and 50 μg/ml ascorbic acid, 0.2 
μmol/l insulin, 1.36 ng/ml triiodothyronine, 10−10 mmol/l cholera toxin and 10 μM 
Y-27632 (all from Sigma). Thereafter, the human skin equivalents were cultured 
at the air-liquid interface for ten days in medium without serum, consisting of 
two parts Dulbecco’s modified Eagle’s medium and one part Ham’s F12 medium 
(both from Life Technologies) supplemented with 4 mmol/l l-glutamine and 50 IU/
ml penicillin or streptomycin (both from Life Technologies), 24.3 μg/ml adenine 
(Calbiochem), 1 mg/ml l-serine and 2 μg/ml l-carnitine (both from Sigma), 
bovine serum albumin lipid mix (25 μmol/l palmitic acid, 7 μmol/l arachidonic 
acid, 15 μmol/l linoleic acid, and 0.4 μg/ml vitamin E; all from Sigma), 1 μmol/l 
hydrocortisone (Merck), and 50 μg/ml ascorbic acid, 0.1 μmol/l insulin, 1.36 ng/
ml triiodothyronine, 10−10 mmol/l cholera toxin, 5 ng/ml keratinocyte growth factor 
and 2 ng/ml epidermal growth factor (all from Sigma).
Morphological and immunohistochemical analysis
Human skin equivalents were fixed in buffered 4% formalin for 4 hours, and 
processed for routine histology. Skin equivalents were embedded in paraffin, 
and 6-μm sections were stained with haematoxylin and eosin (H&E) (Sigma) or 
processed for immunohistochemical staining using an indirect immunoperoxidase 
technique with avidin-biotin complex enhancement (Vectastain Laboratories, 
Burlingame, CA). To study cystatin M/E knockdown, a polyclonal goat anti-cystatin 
M/E antibody (AF1286, R&D) was used. Detection by 3-amino-9-ethylcarbazole 
(Calbiochem) was followed by nuclei counterstaining with Mayer’s haematoxylin 
solution (Sigma), and sections were mounted using glycerol gelatin (Sigma).
mRNA isolation and real-time qPCR
Lentiviral transduced keratinocytes were harvested after 48 hours and total RNA 
was purified from these cells as previously described24. A DNase I treatment was 
performed according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA). 
First strand cDNA was synthesized using an input of 1 µg of DNase 1 treated 
RNA with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the 
manufacturer’s recommendation. Real-time quantitative PCR was performed with 
the MyiQ Single-Colour Real-Time Detection System for quantification with SYBR 
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Green and melting curve analysis (Bio-Rad) as previously described25. Primer 
validation, qPCR reactions, and determination of relative mRNA expression were 
performed as previously described24. Expression of the target genes (CST6, 
ITGB1, IVL, Ki-67, KRT14, STAT1 and OAS2) was normalized to that of human 
ribosomal phosphoprotein P0 (RPLP0). Relative quantity of gene expression 
was measured with the delta-delta Cycle threshold (∆∆Ct) method26. Primers for 
qPCR (Biolegio, Nijmegen, the Netherlands) were only accepted if their efficiency 
was 100±10%. Corrections were made for primer efficiency. Primer sequences 
and efficiency are shown in Table 6.3.
Cystatin M/E ELISA
Lentiviral transduced keratinocytes were harvested after 48 hours and protein 
was extracted by repeated freeze/thawing of the cells in extraction buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Triton-X-100, and a protease inhibitor 
cocktail) followed by centrifugation for 10 min at 15000 x g. The supernatants that 
harbor the soluble proteins were measured for the presence of cystatin M/E by 
ELISA as described previously27.
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Abstract 
Vanins are enzymes with pantetheinase activity and are presumed to play a 
role in recycling of pantothenic acid (vitamin B5) from pantetheine. Pantothenic 
acid is an essential nutrient required to synthesize coenzyme A, a cofactor 
involved in many biological processes such as fatty acid synthesis and oxidation 
of pyruvate to fuel the citric acid cycle. Hydrolysis of pantetheine also liberates 
cysteamine, a known antioxidant. Vanin-1 is highly expressed in liver and is 
under transcriptional control of PPAR-alpha and nutritional status, suggesting a 
role in energy metabolism. The lack of potent and specific inhibitors of vanins has 
hampered detailed investigation of their function. We hereby report the design, 
synthesis and characterization of a novel pantetheine analog, RR6, that acts as a 
selective, reversible and competitive vanin inhibitor at nanomolar concentration. 
Oral administration of RR6 in rats completely inhibited plasma vanin activity and 
caused alterations of plasma lipid concentrations upon fasting, thereby illustrating 
its potential use in chemical biology research.
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Members of the vanin (VNN) gene family encode proteins with pantetheinase 
activity1,2. In humans, three vanins have been described, two of which have 
confirmed enzymatic activity (vanin-1 and vanin-2)3,4. The natural substrate of 
vanins is pantetheine, which is hydrolyzed to pantothenic acid and cysteamine. 
On the basis of sequence similarities, vanins were classified as members of 
the biotinidase branch of the nitrilase superfamily5. Nitrilases are thiol enzymes 
that perform their hydrolytic reactions through a catalytic triad consisting of Glu, 
Lys and Cys, where the cysteine nucleophile produces a covalent intermediate. 
Although vanins are poorly characterized at the functional level, their primary 
function is assumed to be in pantothenate recycling, which is a necessary factor 
in the synthesis of Coenzyme A (CoA)6. Recent investigations, however, have 
shown that at least murine vanin-1 has additional functions7. Vnn1 knockout mice 
did not have an obvious spontaneous phenotype, but were resistant to intestinal 
inflammation, oxidative stress and experimental colitis7-9. Other conditions with a 
putative role of vanins include malaria susceptibility10, psoriasis11, carcinogenesis12 
and cardiovascular disease13. Vanins are the only known source of pantetheinase 
activity in mammalian tissues. Interestingly, the Vnn1 gene was shown to be one 
of the major targets of PPAR-α in mouse liver14, suggesting a role for vanin-1 in 
metabolism15.
 The lack of selective high-affinity vanin inhibitors has so far hampered 
investigation of vanin biology in vitro and in vivo. Recently, an inhibitor screen 
of Sigma’s Library of Pharmacologically Active Compounds (LOPAC library), 
identified six compounds with anti-pantetheinase activity. These comprised 
widely different chemotypes with IC50 values towards recombinant human vanin-1 
in a range of 4-20 µM16. All these compounds had known other pharmacological 
activities or cytotoxic properties that would preclude their use as specific vanin 
inhibitors. These observations emphasize the need for selective and potent 
vanin inhibitors as tools in chemical biology, to study the role of vanins in human 
biology and to evaluate these enzymes as potentially druggable targets. Herein, 
we report the design of pantetheine analogs as reversible, competitive inhibitors 
of mammalian vanins. It is shown that RR6, our most potent vanin inhibitor, is 
selective and displays excellent bioavailability and potency in vivo. 
 We reasoned that pantetheine analogues lacking the amide bond, but 
containing a warhead that would form a reversible covalent bond with the 
cysteine residue of the catalytic triad, could potentially interfere with vanin 
activity. We synthesized compounds substituting the amide bond by a keto group, 
a known warhead for proteases17, by applying the Weinreb ketone synthesis 
strategy (figure 7.1). Conversion of partially protected pantothenic acid 1 into 
Weinreb amide 2 allowed the addition of a variety of Grignard reagents. After 
acid mediated deprotection of the pantoic acid moiety a series of potential vanine 
inhibitors was obtained. (Table 7.1 and Supplemental Materials and Methods 
for details of chemical structures and synthetic procedures). Compounds were 
tested for vanin inhibition using pantothenate-7-amino-4-methylcoumarin (AMC-
Pan) as a highly sensitive fluorogenic substrate16. As sources of vanin activity 
Chapter 7
158
we used recombinant human vanin-1 as well as serum. Vanin-1, which is highly 
expressed in epithelia as a membrane-bound GPI-anchored ectoenzyme, was 
cloned without the C-terminal GPI-anchoring site, and expressed in a eukaryotic 
system as a 6-His tagged, secreted protein (Supplementary Figure 7.1). Affinity-
purified vanin-1 was used for subsequent inhibitor assays. Attempts to express 
enzymatically active human vanin-2 were unsuccessful. We used serum (human, 
rat and bovine) as a natural, physiological source of pantetheinase activity. Serum 
pantetheinase activity likely represents vanin-2 (originally called GPI-80)18, which 
is known to be present in a secreted form19. From our first series of compounds, 
RR2 was identified as a hit compound, showing IC50 values in the low micromolar 
range. Limited optimization of RR2 (Table 7.1), replacing the alkenyl moiety by 
an aromatic residue (RR6 compound), yielded a 30-fold improvement of the IC50 
value towards recombinant vanin-1 down to the nanomolar range. When serum 
was used, an even lower IC50 (40 nM for human serum) was observed (Figure 
7.2a). Reduction of the keto group to a hydroxyl (CXP14.1-034) caused a strong 
decrease of the potency, supporting the idea that the keto group has a warhead. 
The chain length between the keto group and the phenyl moiety clearly affected 
the potency, as indicated by the reduced potency of CXP14.1-037, RR7 and 
RR8. One carbon atom turned out to be optimal, as increasing the chain length 
showed a decrease in potency, while leaving out the linker led to a similar result 
(Table 7.1).
Figure 7.1 Weinreb ketone synthesis strategy including yields.
Figure 7.2 Characterization of the pantetheinase/vanin inhibitor RR6. (A) Inhibition of pantet-
heinase activity of recombinant human vanin-1 (▼) and bovine serum vanin (■) by RR6, using the 
synthetic substrate AMC-Pan. (B) A Lineweaver-Burk plot of reaction velocities at different substrate 
concentrations and inhibitor concentrations indicates that RR6 is a competitive inhibitor. The kinetic 
constants Km (12 μM) and the Vmax (6 pmol/min) were read from this graph. Bovine serum was 
used as source of vanin activity. (C) Superdex-75 chromatography of fetal bovine serum in the pre-
sence of excess RR6. Complete recovery of vanin activity in the high molecular weight fraction was 
obtained, indicating a reversible binding of RR6. V0: void volume of the column. Molecular mass 
markers: bovine serum albumin (66 kDa), ovalbumin (45 kDa) and cytochrome c (12 kDa). FU: 
fluorescence units.
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Table 7.1 Structures of pantothenate derivatives and IC50 values for pantetheinase and bioti-
nidase inhibition
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 In a next step we sought to characterize the mechanism of binding. As the 
inhibitor is an analogue of its natural substrate we assumed that inhibition would 
be competitive. Figure 7.2b shows that, using RR6 as an inhibitor, this is indeed 
the case. A Lineweaver-Burk plot of the data indicated that RR6 did not change 
Vmax, but caused an increase of the apparent Km. To investigate the reversibility 
of binding, we used serum diluted in PBS with excess RR6 (100 µM) to achieve 
complete inhibition of vanin activity. Gel permeation chromatography of this 
sample showed complete recovery of serum vanin activity in the high molecular 
weight fractions, indicating a reversible binding of RR6 (Figure 7.2c).
 To characterize the selectivity of RR6 we first tested biotinidase, an enzyme 
that has the highest structural similarity to vanins. Only RR2 has significant 
biotinidase inhibiting activity (IC50 = 30 µM), whereas none of the other compounds 
showed activity up to the highest concentration tested (200 µM) (Table 7.1). 
As the scissile bond between pantothenate and the AMC group resembles a 
peptide bond, and knowing that nitrilases use a cysteine in their active site, we 
considered the possibility that cysteine proteases could hydrolyze the AMC-Pan 
substrate. None of the ubiquitous human cysteine proteases cathepsin B and 
L, nor the plant cysteine protease papain hydrolyzed the AMC-pan substrate. 
RR6, up to the highest concentration tested (200 µM) did not inhibit the activity of 
any of these cysteine proteases towards their own specific synthetic substrates. 
Similarly, we did not observe any inhibition of serum vanin activity by the generic 
cysteine protease inhibitor E-64 or the generic serine protease inhibitor PMSF.
 To investigate the in vivo potency of our lead compound RR6 on vanin 
inhibition and subsequent downstream biological effects, we first investigated its 
pharmacodynamic properties. Oral administration in rats showed a strong dose-
dependent inhibition of plasma vanin activity (Figure 7.3a). After a single oral 
dose of 50 mg/kg, a prolonged complete inhibition of plasma vanin activity was 
achieved which lasted up to 8 hours after the initial dose. No adverse effects on 
the animals were noted at any dose given. These data suggested that RR6 could 
be used as a tool to study in vivo biological processes that involved vanin activity. 
In order to facilitate animal-friendly and easy experimentation we investigated 
Figure 7.3 Pharmacodynamics of RR6 in rats. (A) Inhibition of plasma pantetheinase activity by 
RR6 following oral administration to rats at the indicated doses. Plasma vanin activity is dose-depen-
dently inhibited, as determined by hydrolysis of the synthetic AMC-Pan substrate ex vivo. (B) RR6 in 
drinking water (3 mg/mL) increases plasma free fatty acid levels in rats after a 24h fast as compared 
with rats without RR6 in the drinking water (control). Values are means ± SD (n=7). (C) RR6 in drin-
king water (3 mg/mL) reduced plasma cholesterol levels after a 24h fast in rats as compared with 
rats without RR6 in the drinking water (control). Values are means ± SD (n=7). *P<0.05 **P<0.01.
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whether RR6 could be given in the drinking water of rats to achieve prolonged 
complete vanin inhibition without the need of multiple daily drug administrations. 
We found that dosing of RR6 at 3 mg/mL in rats caused a nearly complete 
inhibition of plasma vanin activity (Supplementary Figure 7.2).
 Finally, we investigated if vanin inhibition by RR6 could affect a biological 
process. It is not known if vanins have non-redundant biological functions in 
normal physiology, as the Vnn1 knockout mouse only displays a phenotype upon 
challenge (infection, inflammation, cancer). Previous studies have shown that 
pantethine the dimer of pantetheine, the presumed natural substrate of vanins 
is involved in lipid metabolism20,21. This suggested to us that pharmacological 
modulation of vanin activity could have an effect on lipid homeostasis. Similary, 
a number of studies have shown that vanin-1 expression in liver is induced by 
peroxisome proliferator activated receptor (PPAR)-α agonists. PPARs are ligand 
activated transcription factors and play an important role in nutrient homeostasis. 
Oral administration of triglycerides or PPAR-α ligands such as WY14643 and 
fenofibrate caused a strong increase of vanin-1 expression in mouse liver14. 
Although the functional effect of vanin-1 upregulation in PPAR-α dependent 
metabolic changes is completely unknown and unexplored, these findings also 
suggested a possible role of vanin-1 in lipid homeostasis. Moreover, a recent 
study has shown that fasting induces a huge increase in liver vanin-1 expression 
in wild type mice15. We therefore investigated the effect of RR6 administration on 
lipid metabolism following fasting. Rats were given RR6 for 4 days in the drinking 
water (3 mg/mL) and were subjected to fasting for 24 hours at day 4. Analysis of 
a limited set of metabolites in plasma showed modest but statistically significant 
changes such as an increase in plasma free fatty acids (FFA) and a decrease of 
plasma cholesterol (Figure 7.3b and 7.3c) as compared with rats without RR6 in 
drinking water (control). Plasma glucose levels were not altered. Upon fasting, 
lipids are mobilized from tissue fat stores as a source of energy, thereby causing 
an increase of plasma FFA and liver steatosis. At the same time fasting will induce 
high levels of liver vanin-1 activity in a PPAR-α dependent manner. This suggests 
a role of vanin-1 in mobilization and/or conversion of triglycerides, fatty acids and 
cholesterol. Detailed investigation of these metabolic changes was beyond the 
scope of this report, but these findings clearly offer a starting point to study the 
physiological role of vanins in lipid metabolism.
 Based on its potency, selectivity and bioavailability, RR6 represents a novel 
biological chemistry tool that will greatly facilitate the study of vanin function in 
health and disease. It is assumed that pantetheine is the major vanin substrate 
and hence a role in vitamin B5 recycling (pantothenate release) and antioxidant 
production (cysteamine release) has been proposed. The fact that vanin-1 is 
a PPAR-α target and appears to have a role in nutrient or lipid metabolism as 
witnessed by the current study, suggests that enzymatic activity of vanins may not 
be restricted to pantetheine alone. We propose that RR6 and optimized versions 
of this novel chemotype constitute a promising starting point for a platform of 
vanin inhibitors which may open up a new field of research.
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Materials and methods
Synthesis of probes
The detailed description of the synthesis of the vanin inhibitors can be found in 
the supplementary information.
Pantothenate-7-amino-4-methylcoumarin (AMC-Pan)
AMC-Pan was synthesized according to the published method by Ruan et al.16
Assay of pantetheinase activity and pantetheinase inhibition
Pantetheinase activity was measured largely as described by Ruan et al.16 
Samples (10 µL volume) with pantetheinase activity (recombinant human vanin-1 
or diluted serum from different origin) were added to the substrate AMC-Pan (10 
µM final concentration) in a 100 µL final volume, in PBS at pH 7.4. Five hundred 
ng of recombinant vanin-1 was used per reaction. Human serum was diluted 2.5 
times, FBS was diluted 100 times and rat serum was diluted two times before 
addition to the reaction (all in PBS at pH 7.4). In the case that inhibition was 
measured, 10 µL of inhibitor solution was added to 10 µL of sample (recombinant 
vanin or diluted serum) and allowed to equilibrate for 10 min, whereafter substrate 
was added. From these reaction mixtures 10 µL was taken after 10 minutes 
incubation, diluted 10-fold in PBS and measured in a 96-well plate fluorescence 
reader (Perkin Elmer LS55) at excitation 360 nm and emission 450 nm. IC50 
determinations were made in duplicate, by measuring the inhibition of inhibitors 
in a 10-10 to 10-3 M dilution range. IC50 values were calculated from the fit of 
the % inhibition of the dose response curve (Graphpad Prism version 4.0). The 
mode of inhibition was investigated by assaying RR6 inhibition of plasma vanin 
activity in the presence of varying substrate concentrations, from 300 µM to 1 
µM (Graphpad Prism version 4.0). When we wished to determine pantetheinase 
activity under near physiological conditions, like in undiluted rat plasma taken 
from animals that received oral RR6, we used the following procedure. A buffered 
substrate solution (20 µL) was put in 96-well plates and evaporated to dryness. 
The rat plasma samples were added and substrate hydrolysis was allowed to 
proceed. Substrate hydrolysis and inhibition by our experimental compounds was 
measured as described above.
Biotinidase and cysteine protease assays
Biotinidase activity was assayed by the hydrolysis of 6-amidoquinoline (Apollo 
Scientific) as a fluorimetric substrate22, and IC50 for biotinidase was determined 
as described for vanin activity. Cathepsins B and L (R&D Systems) and papain 
(Sigma) were assayed as described previously, using the substrates Z-Leu-
Arg-AMC (R&D Systems) for the cathepsins and Z-Phe-Arg-AMC (Bachem) for 
papain23.
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Cloning and expression of recombinant human vanin-1
Human vanin-1 cDNA was obtained from image clone 40006204 (Geneservice)24. 
Using PCR the vanin-1 ORF (aa 1-483) was amplified without its GPI-anchor and 
cloned into the eukaryotic expression vector pHLsec25. Transfection of pHLsec-
VNN1 into 293T cells using PEI transfection reagent results in the producion of 
His-tagged recombinant human vanin-1 protein. Media containing the secreted 
recombinant protein were collected 72 hours post transfection and recombinant 
protein was affinity purified using Ni-NTA agarose beads. After the protein was 
eluted from the column it was concentrated and dialysed to PBS using Microcon 
YM-10 filters (Millipore). 
Gel permeation chromatography
Bovine serum diluted 1:3 with PBS was used and incubated with 100 µM RR6 
for 2 h. At this concentration a complete inhibition of serum vanin activity is 
achieved. A 50 µL sample was injected on a Superdex-75 HR 10/30 SMART 
column (GE Health Sciences) in PBS at a flow rate of 40 µL per min. The column 
was calibrated with bovine serum albumin (66 kDa), ovalbumin (45 kDa) and 
cytochrome c (12 kDa), all obtained from Sigma. Eluted proteins were monitored 
at 280 nm using a microflow cell. Fractions (40 µL) were collected and measured 
for pantetheinase activity.
Pharmacodynamic studies
Female Wistar rats (Harlan), weighing 200-250 gram were housed in groups of 
two or three animals in the Central Animal Laboratory of the Radboud University 
and given water and chow ad libitum. Protocols were approved by our local 
committee for animal experiments (DEC). Rats (2-3 per group) were given RR6 
by a single oral administration (dissolved in 10% DMSO in PBS at doses of 2, 10 
and 50 mg/kg) or via their drinking water (dissolved at doses of 0.3, 1 and 3 mg/
mL in water). Heparinized blood samples were drawn at several time points, and 
plasma was obtained by centrifugation of the blood samples for 20 minutes at 
465 g at 4o C, for pantetheinase activity determination as indicated above. 
Metabolic studies
Male Wistar rats (Harlan), weighing 150-200 gram were housed in groups of two 
or three animals in the Central Animal Laboratory of the Radboud University and 
given water and chow ad libitum. Protocols were approved by our local committee 
for animal experiments (DEC). Rats were given RR6 via drinking water (3 mg/mL) 
for 4 days. Blood was collected after a 24 h period of fasting and placed on ice, 
centrifuged and plasma was assayed for free fatty acids (FFA) using the NEFA-C 
kit (Wako Diagnostics). Glucose and cholesterol were determined using kits from 
Human Diagnostics. 
Data analysis
Data were analyzed using Graphpad Prism version 4. Kinetic constants were 
Chapter 7
164
determined with the non-linear regression analysis module. Statistical analysis 
of FFA and cholesterol measurements was performed using a Student’s T-test 
(SPSS Inc). P<0.05 was considered statistically significant.
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Supplemantary information
Synthesis of probes: general remarks
All reactions were performed under a nitrogen atmosphere, unless stated 
otherwise. Solvents were distilled from appropriate drying agents prior to use. 
Standard syringe techniques were applied for the transfer of air sensitive reagents 
and dry solvents. All other chemicals were purchased from commercial suppliers 
and were used without further purification, unless stated otherwise. Reactions 
Supplementary figure 7.1 SDS-PAGE of purified recombi-
nant human vanin-1. (a) Coomassie Brilliant Blue staining of an 
SDS-PAGE gel loaded with a sample of the culture medium medi-
um 72 hours post transfection (lane 1) and affinity purified recom-
binant human vanin-1 (lane 2). (b) Western blot analysis of purified 
recombinant human vanin-1 detected with a Penta-His monoclonal 
antibody.
Supplementary figure 7.2 Vanin inhibition in 
rat plasma following administration of RR6 
in the drinking water. Rats were given RR6 
dissolved in the drinking water at concentrati-
ons of 0.3, 1 and 3 mg/mL for 3 days. Every 
morning and evening, blood samples were ta-
ken and the pantetheinase activity was measu-
red. A dose-dependent pantetheinase inhibition 
was found with a stable (>95%) pantetheinase 
inhibition at 3 mg/mL. 
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were followed, and Rf values are obtained using thin layer chromatography 
(TLC) on silica gel-coated plates (Merck 60 F254) with the indicated eluent 
and compounds were detected with UV-light and/or by charring at ca. 150 °C 
after dipping into a solution of potassium permanganate, or ninhydrin. Column 
chromatography was carried out using ACROS silica gel (0.035-0.070 mm, pore 
diameter ca. 6 mm). IR spectra were recorded on an ATI Mattson Genesis Series 
FTIR spectrometer. High-resolution mass spectra were recorded on a JEOL 
AccuTOF (ESI) or a MAT900 (EI, CI, and ESI). NMR spectra were recorded at 
298 K on a Bruker DMX 300 (300 MHz) and a Varian 400 (400 MHz) spectrometer 
in the solvent indicated. Chemical shifts are given in parts per million (ppm) with 
respect to tetramethylsilane (0.00 ppm), or CHD2OD (3.31 ppm) as internal 
standard for 1H NMR; and CDCl3 (77.16 ppm), or CD3OD (49.00 ppm) as internal 
standard for 13C NMR. Coupling constants are reported as J values in hertz (Hz). 
All compounds used for assays/metabolic studies were obtained with a chemical 
purity >97% based on 1H NMR.
Synthetic scheme for vanin inhibitors
(R)-3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanoic acid [(R)-pantothenic acid]
OHN
H
OO
OH OH
A suspension of calcium (R)-pantothenate (1) (25.0 g, 52.6 mmol) 
in 1M aqueous HCl (125 mL) was stirred vigorously until the 
starting material was completely dissolved. The solution was 
saturated by the addition of NaCl and the resulting suspension 
was extracted with EtOAc (3 × 250 mL). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo to yield (R)-pantothenic acid as a colorless oil (20.8 g, 
90%). Spectral data were in correspondence with reported data in literature26.
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(R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid (2)
OHN
H
OO
O O
To a cooled solution (0 °C) of (R)-pantothenic acid (20.8 g, 94.0 
mmol) in acetone (500 mL) were added subsequently 
2-methoxyprop-1-ene (27.1 mL, 283 mmol) and pTsOH·H2O (0.89 
g, 4.72 mmol). After 15 min the temperature was raised to room 
temperature and the mixture was stirred for another 30 min. The 
mixture was diluted with saturated aqueous NaHCO3 (10 mL) and concentrated in vacuo 
to yield 2 as a yellow solid, which was used without purification. TLC (CH2Cl2:MeOH, 9:1 
v/v): Rf = 0.67. Spectral data were in correspondence with reported data in literature
26.
(R)-N-{3-[methoxy(methyl)amino]-3-oxopropyl}-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamide (3)
NN
H
OO
O O
OMe
To a solution of 2 (1.80 g, 6.92 mmol) in dry CH2Cl2 (65 mL) at 
room temperature were added EDC·HCl (2.09 g, 10.9 mmol), 
N,O-dimethylhydroxylamine·HCl (1.04 g, 10.7 mmol) and 
DIPEA (3.43 mL, 19.6 mmol), followed by DMAP (483 mg, 
3.95 mmol). The reaction mixture was stirred overnight at 
room temperature, quenched with saturated aqueous NH4Cl (40 mL), extracted with 
CH2Cl2 (3 × 50 mL), dried over Na2SO4 and concentrated in vacuo. The product was 
purified by flash column chromatography (MeOH:CH2Cl2, 0:1→1:4 v/v) to afford 3 (1.90 g, 
91%) as a colorless oil. TLC (MeOH:CH2Cl2, 1:9 v/v): Rf = 0.56; [α]D = +44.5 (c 1.32, 
CH2Cl2); IR (ATR): 3417, 3334, 2980, 2940, 2871, 1661, 1520, 1378, 1196, 1095, 873 
cm−1; 1H NMR (400 MHz, CDCl3): δ 7.13 (t, J = 5.7 Hz, 1H), 4.07 (s, 1H), 3.68 (d, J = 11.7 
Hz, 1H), 3.67 (s, 3H), 3.64-3.48 (m, 2H), 3.27 (d, J = 11.7 Hz, 1H), 3.18 (s, 3H), 2.76-2.59 
(m, 2H), 1.46 (s, 3H), 1.42 (s, 3H), 1.03 (s, 3H), 0.96 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
172.9, 169.9, 99.0, 77.1, 71.5, 61.2, 34.0, 33.0, 32.1, 31.8, 29.4, 22.1, 18.8, 18.7; HRMS 
(ESI) m/z: [M+Na]+ calcd. for C14H26N2O5Na, 325.1739; found, 325.1746.
(R)-2,2,5,5-tetramethyl-N-(3-oxohept-6-en-1-yl)-1,3-dioxane-4-carboxamide (4a)
N
H
OO
O O
To a solution of 3 (2.10 g, 6.95 mmol) in a mixture of dry 
Et2O/THF (70 mL, 1:1 v/v) at 0 °C, was added dropwise 
3-butenylmagnesium bromide (28.0 mL of a 0.5 M solution in 
THF, 13.9 mmol). After 15 min the reaction mixture was 
allowed to warm to rt and stirred for 4 h. Next, saturated 
aqueous NH4Cl was added to quench the reaction, followed by extraction with CH2Cl2 (3 × 
70 mL). The organic layers were combined, dried (Na2SO4), and concentrated in vacuo. 
The product was purified by flash column chromatography (EtOAc/heptane, 0:1→1:2) to 
afford 4a (1.23 g, 59%) as a colorless oil. TLC (MeOH:CH2Cl2, 1:9 v/v): Rf = 0.86; [α]D = 
+44.1 (c 1.38, CH2Cl2); IR (ATR) 3421, 2915, 2849, 1709, 1666, 1519, 1377, 1092, 871, 
701 cm−1; 1H NMR (400 MHz, CDCl3): δ 6.96-6.87 (m, 1H), 5.79 (ddt, J = 16.7, 10.2, 6.5 
Hz, 1H), 5.05-4.96 (m, 2H), 4.05 (s, 1H), 3.68 (d, J = 11.7 Hz, 1H), 3.58-3.42 (m, 2H), 3.27 
(d, J = 11.7 Hz, 1H), 2.68 (t, J = 6.0 Hz, 2H), 2.53-2.49 (m, 2H), 2.36-2.30 (m, 2H), 1.46 (s, 
3H), 1.41 (s, 3H), 1.04 (s, 3H), 0.95 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 209.2, 169.9, 
136.9, 115.6, 99.1, 77.3, 71.6, 42.3, 42.1, 33.4, 33.1, 29.6, 27.8, 22.3, 19.0, 18.8; HRMS 
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(ESI) m/z: [M+Na]+ calcd. for C16H27NO4Na, 320.1838; found, 320.1837.
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxohept-6-en-1-yl)butanamide (RR2)
N
H
OO
OH OH
To a solution of 4a (30 mg, 0.10 mmol) in MeCN (1.0 mL) 
was added, BiCl3 (6.5 mg, 20 mol%), followed by 
demineralized H2O (36 μL, 20 equiv). The reaction was 
stirred at room temperature for 4 h, then filtered and 
concentrated in vacuo. After dilution with EtOAc (10 mL), the reaction mixture was washed 
with saturated aqueous NaHCO3 (2 × 8 mL) and the aqueous layer was extracted with 
EtOAc (3 × 8 mL). The organic layers were combined, dried over Na2SO4 and concentrated 
in vacuo. The product was purified by flash column chromatography (EtOAc/heptane, 
1:1→1:0) to afford RR2 (24 mg, 92%) as a colorless oil. TLC (MeOH:CH2Cl2, 1:9 v/v): Rf = 
0.52; [α]D =  +32.6 (c 1.18, CH2Cl2); IR (ATR) 3347, 2955, 2872, 1706, 1646, 1532, 1079, 
1041, 919 cm−1; 
1H NMR (400 MHz, CDCl3): δ 7.25 (t, J = 6.0 Hz, 1H), 5.78 (ddt, J = 16.7, 
10.2, 6.5 Hz, 1H), 5.03 (ddd, J = 16.7, 3.4, 1.3 Hz, 1H), 4.99 (ddd, J = 10.2, 3.4, 1.3 Hz, 
1H), 4.16 (d, J = 4.5 Hz, 1H), 3.98 (d, J = 4.3 Hz, 1H), 3.66 (bs, 1H), 3.59-3.45 (m, 4H), 
2.70 (t, J = 5.9 Hz, 2H), 2.53 (t, J = 7.4 Hz, 2H), 2.35-2.30 (m, 2H), 0.98 (s, 3H) 0.89 (s, 
3H); 13C NMR (75 MHz, CDCl3): δ 209.6, 173.4, 136.8, 115.6, 77.6, 71.2, 42.2, 42.0, 39.4, 
33.8, 27.7, 21.4, 20.4; HRMS (ESI) m/z: [M+H]+ calcd. for C13H24NO4, 258.1705; found, 
258.1699.
(R)-2,2,5,5-tetramethyl-N-(3-oxo-3-phenylpropyl)-1,3-dioxane-4-carboxamide (4b)
N
H
OO
O O
 To a cooled (0 °C) solution of 3 (266 mg, 0.88 mmol) in dry THF 
(5.0 mL) was added phenylmagnesium bromide (0.88 mL, 2.6 
mmol, 3M solution in Et2O) over a period of 5 min. The mixture 
was allowed to warm to room temperature and after 2 h more 
phenylmagnesium bromide (1 equiv.) was added. The reaction 
mixture was stirred for an additional hour and then quenched with a mixture of saturated 
aqueous NH4Cl (25 mL) and water (5 mL) and extracted twice with EtOAc (30 and 10 mL). 
The combined organic phases were washed with saturated aqueous NH4Cl (20 mL) and 
brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (EtOAc/heptane = 1:2→1:1→2:1) yielding 4b as 
a colorless oil (209 mg, 74%). TLC (EtOAc:heptane, 3:1 v/v): Rf = 0.61; [α]D =  +53.4 (c 
0.98, CH2Cl2); IR (ATR) 3429, 2993, 2945, 2872, 1674, 1521, 1377, 1218, 1197, 1159, 
1096, 873, 755, 690, 615 cm−1; 1H NMR (400 MHz, CDCl3): δ 7.95 (m, 2H), 7.58 (m, 1H), 
7.47 (m, 2H), 7.05 (br s, 1H), 4.07 (s, 1H), 3.76-3.62 (m, 3H), 3.27-3.22 (m, 3H), 1.47 (s, 
3H); 1.41 (s, 3H), 1.04 (s, 3H), 0.92 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 198.8, 169.8, 
136.5, 133.3, 128.6, 127.9, 98.9, 77.1, 71.4, 38.1, 33.6, 32.9, 29.4, 22.1, 18.8, 18.6; HRMS 
(ESI) m/z: [M+Na]+ calcd. for C18H25NO4Na, 342.1681; found, 342.1689.
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(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-3-phenylpropyl)butanamide (CXP14.1-037)
N
H
OO
OH OH
A solution of 4b (236 mg, 0.739 mmol) in AcOH (3 mL) and H2O 
(1.5 mL) was stirred for 5 h at room temperature. The solution 
was poured carefully into a stirring mixture of saturated aqueous 
NaHCO3 (60 mL) and EtOAc (100 mL). The organic layer was 
washed with saturated aqueous NaHCO3 (30 mL) and brine (30 mL), dried over Na2SO4 
and concentrated in vacuo. Purification was performed by flash column chromatography 
(EtOAc), yielding CXP14.1-037 as a colorless oil (159 mg, 77%). TLC (EtOAc:heptane, 
3:1 v/v): Rf = 0.21; [α]D = +34.5 (c 0.32, CH2Cl2)
27 [α]D = +37.1 (c 1.00, EtOH); IR (ATR) 
3356, 2962, 2876, 1674, 1644, 1527, 1441, 1359, 1212, 1069, 1043, 750, 685 cm−1; 
1H 
NMR (400 MHz, CDCl3): δ 7.96 (m, 2H), 7.59 (m, 1H), 7.48 (m, 2H), 7.22 (br s, 1H), 4.00 
(d, J = 5.2 Hz, 1H), 3.73 (AB d, J = 6.0 Hz, 2H), 3.49 (AB dd, J = 11.2, 5.8 Hz, 2H), 3.30 
(d, J = 5.2 Hz, 1H), 3.26 (dd, J = 6.0,  5.2 Hz, 2H), 2.87 (t, J = 5.8 Hz, 1H), 1.00 (s, 3H), 
0.88 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 199.1, 173.4, 136.2, 133.5, 128.6, 127.9, 77.4, 
71.0, 39.2, 38.0, 34.0, 21.1, 20.1; HRMS (ESI) m/z: [M+Na]+ calcd. for C15H21NO4Na, 
302.1368; found, 302.1366.
(R)-2,2,5,5-tetramethyl-N-(3-oxo-5-phenylbutyl)-1,3-dioxane-4-carboxamide (4c)
N
H
OO
O O
Prepared as described for 4a, starting from 3 (412 mg, 1.36 
mmol) and benzylmagnesium chloride (3.41 mL of a 2.0 M 
solution in THF, 6.81 mmol). Purification by flash column 
chromatography (EtOAc/heptane, 1:2→2:1) afforded 4c 
(384 mg, 85%) as a colorless oil. TLC (EtOAc): Rf = 0.69; [α]
D = +41.1 (c 1.15, CH2Cl2); IR (ATR) 3430, 2993, 2950, 2868, 2358, 1713, 1670, 1522, 
1377, 1196, 1095 cm−1; 1H NMR (300 MHz, CDCl3): δ 7.35-7.17 (m, 5H), 6.88 (m, 1H), 4.02 
(s, 1H), 3.68 (s, 2H), 3.65 (d, J = 11.7 Hz, 1H), 3.55-3.38 (m, 2H), 3.25 (d, J = 11.7 Hz, 1H), 
2.73-2.64 (m, 2H), 1.45 (s, 3H), 1.40 (s, 3H), 1.01 (s, 3H), 0.88 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 207.4, 169.8, 133.8, 129.4, 128.9, 127.3, 99.1, 77.1, 71.5, 50.3, 41.5, 33.3, 33.0, 
29.5, 22.2, 18.9, 18.8; HRMS (ESI) m/z: [M+H]+ calcd. for C19H28NO4, 334.2018; found, 
334.2017.
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-5-phenylbutyl)butanamide (RR6)
N
H
OO
OH OH
Prepared as described for RR2, starting from 4c (367 mg, 
1.10 mmol). Flash column chromatography (EtOAc/heptane, 
0:1→1:0) afforded RR6 (197 mg, 61%) as a colorless oil. 
TLC (EtOAc): Rf = 0.30; [α]D = +28.7 (c 1.17, CH2Cl2); IR 
(ATR) 3372, 3058, 3036, 2960, 2868, 1710, 1643, 1530, 1496, 1453, 1366, 1287, 1076, 
1041 cm−1; 
1H NMR (300 MHz, CDCl3): δ 7.36–7.18 (m, 5H), 7.04 (m, 1H), 3.93 (d, J = 4.5 
Hz,  1H), 3.69 (s, 2H), 3.52–3.45 (m, 2H), 3.47-3.30 (m, 3H), 2.90 (br s, 1H), 2.73 (t, J = 
5.8 Hz, 2H), 0.96 (s, 3H), 0.83 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 207.9, 173.2, 133.7, 
129.5, 129.0, 127.4, 77.6, 71.3, 50.3, 41.4, 39.4, 33.8, 21.5, 20.3. HRMS (ESI) m/z: [M+H]+ 
calcd. for C16H24NO4, 294.1705; found, 294.1694.
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(R)-2,2,5,5-tetramethyl-N-(3-oxo-5-phenylpentyl)-1,3-dioxane-4-carboxamide (4d)
N
H
OO
O O
Prepared as described for 4a, starting from compound 3 
(1.03 g, 3.40 mmol) and phenethylmagnesium chloride 
(1.0 M solution in THF) (6,96 mL, 6.96 mmol). The reaction 
was completed in 2 h. Purification by flash column 
chromatography yielded 4d (754 mg, 64%) as colorless 
oil. TLC (EtOAc): Rf = 0.71; [α]D = +37.7 (c 1.07, CH2Cl2); IR (ATR): 3426, 3334, 2989, 
2952, 2870, 2362, 2332, 1712, 1671, 1521, 1377, 1197, 1095 cm-1; 1H NMR (300 MHz, 
CDCl3): δ 7.30-6.94 (m, 5H), 6.94-6.90 (m, 1H), 4.05 (s, 1H), 3.67 (d, J = 11.7 Hz, 1H), 
3.58-3.39 (m, 2H), 3.27 (d, J = 11.7 Hz, 1H), 2.90 (m, 2H), 2.76-2.70 (m, 2H), 2.65 (t, J = 
6.0 Hz, 2H), 1.47 (s, 3H), 1.41 (s, 3H), 1.03 (s, 3H), 0.93 (s, 3H); 13C NMR (75 MHz. 
CDCl3): δ 209.0, 169.9, 140.9, 128.7, 128.4, 126.3, 99.2, 77.3, 71.6, 44.5, 42.4, 33.4, 33.1, 
29.8, 29.6, 22.3, 19.0, 18.8; HRMS (ESI) m/z: [M+H]+ calcd. for C20H30NO4, 348.2175; 
found, 348.2175.
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-5-phenylpentyl)butanamide (RR7)
N
H
OO
OH OH
Prepared as described for RR2, starting from compound 
4d (366 mg, 1.05 mmol), yielding RR7 (260 mg, 80%) as 
colorless oil. TLC (EtOAc): Rf = 0.33; [α]D = +28.6 (c 1.61, 
CH2Cl2); IR (ATR): 3354, 2933, 2859, 1708, 1644, 1529, 
1452, 1369, 1287, 1075, 1041 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.31-7.15 (m, 5H), 7.09 
(m, 1H), 3.96 (s, 1H), 3.58 (br s, 1H), 3.54-3.42 (m, 4H), 3.12 (br s, 1H), 2.92-2.87 (m, 2H), 
2.78-2.72 (m, 2H), 2.66 (t, J = 5.8 Hz, 2H), 0.99 (s, 3H), 0.87 (s, 3H). 13C NMR (75 MHz, 
CDCl3): δ 209.4, 173.1, 140.8, 128.7, 128.4, 126.4, 77.7, 71.3, 44.4, 42.3, 39.5, 33.9, 29.7, 
21.6, 20.3. HRMS (ESI) m/z: [M+H]+ calcd. for C17H26NO4, 308.1861; found 308.1851.
(R)-2,2,5,5-tetramethyl-N-(3-oxo-6-phenylhexyl-1,3-dioxane-4-carboxamide (4e)
N
H
OO
O O
Magnesium (1.00 g, 41.2 mmol, 12.0 equiv) was stirred 
in Et2O (20 mL) with three drops 1,2-dibromoethane 
and heated briefly. (3-bromopropyl)benzene (3.08 mL, 
20.2 mmol, 6.0 equiv) was dissolved in Et2O (20 mL) 
and added dropwise to the magnesium over a period of 
15 min. The hazy solution was stirred at room temperature for 2 h. The Grignard reagent 
was added dropwise to a cooled (0 °C) solution of compound 3 (1.02 g, 3.37 mmol) in THF 
(20 mL) and stirred at 0 °C for 3.5 h. The reaction mixture was quenched with saturated 
aqueous NH4Cl (100 mL) and extracted with CH2Cl2 (3 × 70 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. The crude product was purified 
by flash column chromatography (heptane/EtOAc, 1:0→1:1), yielding compound 4e (950 
mg, 78%) as a colorless oil. TLC (EtOAc): Rf = 0.70; [α]D = +34.4 (c 1.23, CH2Cl2); IR 
(ATR): 3421, 2997, 2947, 2872, 1710, 1672, 1522, 1454, 1377, 1260, 1222, 1197, 1159, 
1096 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.31-7.14 (m, 5H), 6.92 (m, 1H), 4.05 (s, 1H), 
3.67 (d, J = 11.7 Hz, 1H), 3.56-3.41 (m, 2H), 3.27 (d, J = 11.7 Hz, 1H), 2.64 (t, J = 6.1 Hz, 
2H), 2.61 (t, J = 6.0 Hz, 2H), 2.41 (t, J = 7.3 Hz, 2H), 1.91 (app. quintet, J = 7.7 Hz, 2H), 
1.45 (s, 3H), 1.40 (s, 3H), 1.03 (s, 3H), 0.94 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 209.8, 
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169.9, 141.5, 128.6, 128.5, 126.2, 99.2, 77.3, 71.6, 42.2, 42.1, 35.1, 33.5, 33.1 29.6, 25.3, 
22.3, 19.0, 18.8. HRMS (ESI) m/z: [M+H]+ calcd. for C21H32NO4, 362.2331; found, 362,2352. 
 
(R)-2,4-dihydroxy-3,3-dimethyl-N-(3-oxo-6-phenylhexyl)butanamide (RR8)
N
H
OO
OH OH
Prepared as described for RR2, starting from compound 
4e (380 mg, 1.05 mmol), yielding RR8 (268 mg, 79%) 
as colorless oil. TLC (EtOAc): Rf = 0.36; [α]D = +26.6 (c 
1.16, CH2Cl2); IR (ATR): 3358, 3028, 2946, 2868, 1708, 
1643, 1530, 1453, 1368, 1269 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.31-7.05 (m, 6H), 3.98 
(s, 1H), 3.54-3.43 (m, 5H), 3.04 (br s, 1H), 2.66-2.59 (m, 4H), 2.42 (t, J = 7.4 Hz, 2H), 1.91 
(app. quintet, J = 7.5 Hz, 2H), 1.00 (s, 3H), 0.88 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
210.2, 173.1, 141.5, 128.6, 126.2, 77.7, 71.3, 42.2, 42.1, 39.5, 35.1, 33.9, 25.2, 21.5, 20.3; 
HRMS (ESI) m/z: [M+H]+ calcd. for C18H28NO4, 322.2018; found, 322.2009.
(2R/S)-2,4-dihydroxy-N-(3-hydroxy-4-phenylbutyl)-3,3-dimethylbutanamide (CXP14.1-
034)
N
H
OHO
OH OH
To a cooled solution (0 °C) of RR6 (108 mg, 0.37 mmol) in 
MeOH (3 mL) was carefully added NaBH4 (27.9 mg, 0.74 
mmol) over a period of 10 min. The mixture was stirred for 15 
min at 0 °C, followed by 15 min at room temperature, before 
it was diluted with EtOAc (15 mL) and washed with a mixture of saturated aqueous NH4Cl 
(15 mL) and H2O (2 mL). The aqueous phase was extracted with EtOAc (2 × 10 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography (EtOAc/MeOH, 
40:1→20:1→9:1→5:1 v/v)) yielded CXP14.1-034 as a 1:1 mixture of diastereomers as a 
colorless oil (89 mg, 75%). TLC (EtOAc): Rf = 0.11; IR (ATR) 3308, 2928, 2872, 1636, 
1532, 1454, 1272, 1216, 1078, 1039, 737, 702 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.33-
7.18 (m, 2 × 5H), 7.10 (br s, 2 × 1H), 4.02 (s, 2 × 1H), 3.87 (s, 2 × 1H), 3.71 (m, 2 × 1H), 
3.49 (m, 2 × 3H), 3.25 (m, 2 × 1H), 2.96-2.84 (m, 2 × 2H), 2.78 (m, 2 × 2H), 1.75 (m, 2 × 
1H), 1.61 (m, 2 × 1H), 1.04 (s, 3H), 1,02 (s, 3H), 0.94 (s, 3H), 0.92 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 173.9, 173.8, 138.2 (2C), 129.4 (2C), 129.3 (2C), 128.5 (4C), 126.4 (2C), 
77.4 (2C), 71.0 (2C), 70.6 (2C), 43.9, 43.8, 39.3, 39.2, 36.4, 36.3, 36.0 (2C), 21.2, 21.2, 
20.4, 20.3; HRMS (ESI) m/z: [M+Na]+ calcd. for C16H25NO4Na, 318.1681; found, 318.1681.
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1H NMR spectra of RR2
1H NMR spectra of CXP14.1-037
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1H NMR spectra of RR6
1H NMR spectra of RR7
Vanin inhibitors
173
1H NMR spectra of RR8 
1H NMR spectra of CXP14.1-034
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Abstract
The emergence of resistance against current antibiotics calls for the development 
of new compounds to treat infectious diseases. Synthetic pantothenamides are 
pantothenate analogs that possess broad spectrum antibacterial activity in vitro 
in minimal media. Pantothenamides were shown to be substrates of the bacterial 
coenzyme A (CoA) biosynthetic pathway, causing cellular CoA depletion and 
interference with fatty acid synthesis. In spite of their potential use and selectivity 
for bacterial metabolic routes, these compounds have never made it to the clinic. 
In the present study we show that pantothenamides are not active as antibiotics 
in the presence of serum, and we found that they were hydrolyzed by ubiquitous 
pantetheinases of the vanin family. To address this further, we synthesized a 
series of pantetheinase inhibitors based on a pantothenate scaffold that inhibited 
serum pantetheinase activity in the nanomolar range. Mass spectrometric 
analysis showed that addition of these pantetheinase inhibitors prevented 
hydrolysis of pantothenamides by serum. We found that combination of these 
novel pantetheinase inhibitors and prototypic pantothenamides like N5-Pan and 
N7-Pan exerted antimicrobial activity in vitro particularly against gram-positive 
bacteria (Staphylococcus aureus, Streptococcus pneumoniae) even in the 
presence of serum. These results indicate that pantothenamides, when protected 
against degradation by host pantetheinases, are potentially useful antimicrobial 
agents. 
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Introduction
There is a continuous battle between humans and microorganisms, and the 
development of resistance against current antibiotics creates a need to develop 
new drug scaffolds and targets1. There are several classes of antibiotic-resistant 
pathogens that emerge as major threats. Methicillin-resistant and vancomycin-
resistant Staphylococcus aureus strains (MRSA and VRSA), and multidrug-
resistant Streptococcus pneumoniae are a serious health problem in both 
hospital settings and the community. Multidrug-resistant gram-negative bacteria 
(e.g. Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa) are 
a second group of organisms that pose a threat of untreatable infections. Finally, 
poverty-related conditions such as tuberculosis and parasitic diseases, particularly 
important in developing countries are a cause of great concern, as the already 
limited number of treatment modalities is decreasing because of resistance. The 
development of new antibiotics has been slow, and most compounds to date 
have been derived from a limited number of molecular scaffolds targeting a 
few microbial molecular pathways. Discovery of new scaffolds and new targets 
should clearly be a priority, although the commercial prospects of antibiotics 
development are unfavorable1.
 In 1970, amides derived from pantothenic acid (vitamin B5), were reported 
to possess antibiotic activity in vitro2. During the last decades many of these 
pantothenamides have been synthesized and the putative modes of action have 
been studied in detail3-10. Pantothenamides, of which N-pentylpantothenamide 
(N5-Pan) and N-heptylpantothenamide (N7-Pan) are the prototypes, are active 
against gram-negative2 and gram-positive11 bacteria, but they have also been 
shown to possess activity against fungi and malaria parasites2,8. Pantothenamides 
were found to be substrates of the key rate-controlling enzyme pantothenate 
kinase (CoaA), and the rate of conversion of N5-Pan was found to be more rapid 
than that of pantothenate itself. This led to the conclusion that the mechanism 
for toxicity towards E. coli is due to the formation of CoA analogs that lead to the 
transfer of an inactive 4’-phosphopantothenamide moiety to acyl carrier protein 
(ACP) which is the first step in the bacterial type II route (FASII) of fatty acid 
synthesis10,12. A recent study showed that N5-Pan causes a 10-fold reduction of 
cellular CoA levels in E. coli7. The same study also showed that ethyldethia-ACP, 
is readily hydrolyzed by ACP-phosphodiesterase (AcpH). Neither overexpression 
of CoA biosynthetic enzymes or pantothenate supplementation could relieve 
growth inhibition by N5-Pan. These findings indicate that the mechanisms by 
which pantothenamides inhibit bacterial viability are not yet completely resolved. 
 Mammalian pantetheinases have only recently been discovered. The first 
one that was cloned was the mouse vanin-1 (Vnn1) gene, which encoded a GPI-
anchored leukocyte cell surface protein of unknown function13. Analysis of human 
vanins revealed three family members named VNN1, 2 and 3, clustered on 
chromosome 614. The encoded proteins were shown to possess pantetheinase 
activity by the hydrolysis of pantetheine into pantothenic acid (vitamin B5) and 
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the low molecular weight thiol cysteamine15. We found vanin family members to 
be broadly expressed in nearly all human tissues16. On the basis of sequence 
similarities, vanins were classified as members of the biotinidase branch of 
the nitrilase superfamily17. The most obvious function of biotinidases and 
pantetheinases is that of amidases involved in vitamin recycling. 
 In the present paper we address the possible application of pantothenamides 
as antibiotics, considering the current knowledge on human pantetheinases. Based 
on the fact that vanins are active on the carbon-nitrogen bond of pantetheine, 
we hypothesized that antibiotic pantothenamides could also be hydrolyzed by 
pantetheinase activity, which was indeed found to be the case. We further show 
that inhibition of pantetheinase activity by novel chemotypes that we recently 
developed18, protects pantothenamides against hydrolysis thereby preserving 
their antibiotic activity. We thereby provide proof of concept that combination of 
pantetheinase inhibitors with pantothenamides might be a novel antimicrobial 
strategy.
Results
Pantothenamides are inactive as antibiotics in serum-containing medium
To test whether pantothenamides have antibiotic activity under physiological 
conditions, E. coli was cultured in minimal medium in the presence of complement-
inactivated serum (in this case fetal bovine serum, but human serum gives 
similar results). Addition of the prototypic pantothenamide N5-Pan to log phase 
cultures of E. coli in the absence of serum shows the expected growth inhibiting 
properties as described before2 (Figure 8.1). Addition of 1% and 10% serum 
dose-dependently abolishes the inhibitory effect of N5-Pan. 
 We next investigated if the effect of serum on pantothenamides was due to 
a heat-labile factor. Figure 8.2A shows that heat-inactivated serum (5 minutes at 
100o C) is unable to interfere with N5-Pan mediated growth inhibition of E.coli. 
This made is very likely that the effect was due to one or more proteins present in 
serum. 
Figure 8.1 The effect of serum on pantothenamides. Growth inhibiting effect of N5-Pan on E. 
coli in media containing increasing amounts of serum. In serum-free medium a low concentration of 
N5-Pan is sufficient to inhibit bacterial growth, while in a 1% serum medium, a high concentration 
N5-Pan is needed for bacterial growth inhibition. In 10% serum a high concentration of N5-Pan is 
insufficient to be antibiotic. All samples N=4. 
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Pantothenamides are hydrolyzed in serum
Based on structural homology of pantothenamides with pantetheine and the 
knowledge that pantetheine is hydrolyzed by pantetheinases of the vanin family 
into pantothenic acid and cysteamine, we hypothesized that this class of enzymes 
could also hydrolyze pantothenamides. In a previous study we have shown that 
vanins are ubiquitously expressed16. Using an aminomethylcoumarine derivative 
of pantothenic acid, which is a pantothenamide with a fluorescent leaving group 
as a substrate19 pantetheinase activity in serum is readily detected. We found that 
this hydrolytic activity was completely abolished by heat-inactivation of the serum 
(Figure 8.2B). 
 Subsequently, we analyzed if known antibiotic pantothenamides are also 
hydrolyzed in the presence of serum. Mass spectrometric analysis of N7-Pan 
incubated in 1% serum for 24 h revealed a complete disappearance of the 
N7-Pan peak, whereas a clear peak of heptylamide, the expected hydrolysis 
product, appears (Figure 8.3A). This indicates that pantothenamides are indeed 
hydrolyzed in the presence of serum.
Pantetheinase inhibitors prevent degradation of antibiotic pantothenamides in 
serum
We reasoned that inhibitors of serum pantetheinases could prevent degradation 
of pantothenamides in biological fluids thereby preserving their antibiotic 
activity. As there were no selective high-affinity (sub-nanomolar) pantetheinase 
inhibitors available, we designed and synthesized a number of new inhibitors 
starting from pantetheine, the natural substrate of pantetheinases, as a scaffold. 
Synthesis and characterization of these new chemotypes, pantetheine analogs 
lacking the hydrolysable amide bond, has recently been published elsewhere18. 
The most potent and selective inhibitor (RR6) showed an IC50 of 40 nM against 
pantetheinase activity present in human or bovine serum. See Table S8.1 for the 
structures and IC50 values of all compounds used here.
 We next investigated if these pantetheinase inhibitors could protect 
pantothenamide antibiotics from hydrolysis by serum pantetheinase activity. 
Figure 8.3B shows mass spectrometric analysis of N7-Pan incubated in 1% serum 
Figure 8.2 Inactivation of N5-Pan by serum is heat-labile (A) N5-Pan (64 µg/ml) (filled bars) does 
not inhibit growth of E. coli in the presence of FBS. Upon heat-inactivation of serum (5 min at 100o C) 
N5-Pan effectively inhibit bacterial growth. Open bars: bacterial growth without N5-Pan. All samples 
N=4. (B) Pantetheinase activity assay shows pantetheinase activity in serum (×), but none in inacti-
vated serum (+), confirming that pantetheinases might be involved in pantothenamide inactivation. 
Chapter 8
182
for 24 h in the presence of 256 μg/ml RR6. Whereas in Figure 8.3A a complete 
disappearance of the N7-Pan peaks is observed and only the hydrolysis product 
heptylamine can be identified, Figure 8.3B shows that in the presence of RR6 the 
N7-Pan peaks are still present. Although we found a minor peak corresponding 
to heptylamide, we conclude that N7-Pan is clearly protected against hydrolysis 
by the addition of a pantetheinase inhibitor. 
In vitro antibiotic effects of combinations of pantothenamides and pantetheinase 
inhibitors
We next examined if inhibition of serum pantetheinase could preserve the 
antibiotic effect of the pantothenamides N5-Pan and N7-Pan which were 
previously reported to be active against bacterial strains of E. coli and S. aureus 
respectively. Figure 8.4 shows the effects of pantothenamides or a pantetheinase 
inhibitor (RR6) alone, and combinations of these. Addition of pantothenamides 
had no antibacterial effect in media with 10% FBS as shown before for N5-
Pan (see Figure 8.1). Similarly, the pantetheinase inhibitor RR6 on its own did 
not affect bacterial growth of E. coli or S. aureus. Combination of RR6 with 
pantothenamides, however, showed a clear antimicrobial effect for N5-Pan on 
E. coli (Figure 8.4A) and for N7-Pan on S. aureus (Figure 8.4B). We performed 
checkerboard titration of pantothenamides and the pantetheinase inhibitor 
RR6 to obtain a range of MIC (minimum inhibitory concentration) values for the 
combined compounds as shown in Figure 8.4C. The protective effect of RR6 
towards pantothenamides is clearly visible for both E. coli and S. aureus. The 
amount of pantothenamides decreased to MIC values in cultures without serum 
and RR6 (Figure 8.4D).
Specificity and toxicity of pantothenamide antibiotics and vanin inhibitors
The efficacy of pantothenamides has so far only been studied in vitro on a limited 
Figure 8.3 Hydrolysis of N7-Pan is inhibited RR6 (A) Mass spectrometric analysis of a sample 
containing 1% serum and N7-Pan after 24 hours incubation showed a heptylamine peak, but no N7-
Pan-peak. Note that the produced pantothenic acid will only be partially visualized under the used 
settings. (B) Pantetheinase inhibitor RR6 is able to protect N7-Pan against hydrolysis as clear peaks 
corresponding to the N7-Pan adducts are shown on the mass spectrum. Also the RR6 adducts and 
a very small peak corresponding to heptylamine are detected. The reaction was performed in the 
same way as in (A).
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Figure 8.4 Pantetheinase inhibition preserves the antibiotic effect of pantothenamides (A) 
Growth curves of respectively E. coli and S. aureus in 1% tryptone with 10% FBS alone (■), or sup-
plemented with 64 µg/ml N5-Pan (●), 256 µg/ml RR6 (○) or a combination of N5-Pan and RR6 (□). 
Only the combination of RR6 and N5-Pan showed long-term bacterial growth inhibition of E. coli. 
All samples N=3. (B) Same conditions as in (A), but N7-Pan instead of N5-Pan was added. Only 
the combination of RR6 and N7-Pan results in S. aureus growth inhibition. All samples N=3. (C) 
Bacterial growth of E. coli and S. aureus in 1% tryptone with 10% decomplemented human serum 
in the presence of different concentrations of RR6 and N5-Pan (E. coli) and N7-Pan (S. aureus). 
The checkerboard titration shows that addition of RR6 increased the potency of pantothenamides 
in serum-containing media to concentrations comparable to cultures without serum as shown in (D). 
N=2. (D) Bacterial growth of E. coli and S. aureus in 1% tryptone without serum in the presence of 
different concentrations of N5-Pan and N7-Pan respectively. N=2.
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number of bacterial species2,11. To delineate the taxa that are potential targets 
for antibiotic therapy we determined the MIC values for a number of clinically 
relevant species. Table 8.1 shows that only gram-positive bacteria are sensitive 
to pantothenamides in pharmaceutically realistic concentrations (8 µg/ml). 
Sensitive species include S. aureus, S. pneumoniae and S. epidermidis. Within 
one genus (Streptococcus), there is differential sensitivity, as S. agalactiae and 
S. pyogenes were resistant as opposed to pneumococci. We tested 18 strains of 
S. pneumoniae and these were all found to be sensitive to N5-Pan (Table S8.2).
 As the putative mode of action of pantothenamides is at the level of CoA-
dependent biochemical pathways, this raised the question of selectivity for 
microbial versus host targets. We therefore investigated if pantothenamides and 
pantetheinase inhibitors were tolerated by mammalian cells. Using concentrations 
of N5-Pan, N7-Pan and RR6 up to 200 µM, no effects on cell growth or viability 
were observed in a human cell line (293T kidney cells) (Figure 8.5).
Discussion
We here provide detailed experimental evidence for the concept that pantetheinase 
inhibitors can prevent the enzymatic degradation of pantothenamide antibiotics. 
Combination of a pantetheinase inhibitor with pantothenamides could be a 
successful strategy to preserve the antibiotic properties of pantothenamides in 
the presence of host pantetheinases. We propose that our data provide proof 
of concept for a novel antibiotic strategy that could be used against clinically 
relevant gram-positive bacteria. 
 Since pantothenic acid was first described as a nutritional requirement 
for almost, if not, all organisms, its potential for antibiotic drug design has 
Figure 8.5 In vitro toxicity of compounds Cytotoxicity was measured on human embryonic kidney 
293T cells treated with or without N5-Pan, N7-Pan or RR6. None of the tested compounds resulted 
in increased cell death up to 2000 μM. The dotted line represents the percentage cell death in un-
treated cells (N=3).
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been investigated. The different mechanisms by which organisms were able to 
obtain pantothenic acid for CoA biosynthesis and the relatively low homology 
between enzymes involved in pantothenic acid processing opened the field to 
design growth inhibiting molecules specific for pathogens. Based on pantothenic 
acid, different classes of molecules were described to posses anti-bacterial, 
anti-fungal and anti-parasitic activity in vitro, including N-pantoyl-substituted 
amines, pantoylhydrazides, pantothenones and pantothenamides20. Most of 
these analogues were expected to be competing with endogenous pantothenic 
acid for the first enzyme of the CoA biosynthesis, CoaA. In contrast, the working 
mechanism of pantothenamides is expected to be different. Strauss and Begley10 
showed that N-pentylpantothenamide is rather a substrate for CoA than an 
inhibitor. They showed that the pantothenamide is completely processed to a 
CoA analogue, called ethyldethia-CoA and that the conversion is over 10 times 
faster than pantothenic acid processing. Subsequently Zhang et al. showed 
that acyl carrier protein (ACP) is the cellular target, which results in an inactive 
ACP analogue, that lacks the sulfydryl group for the attachment of acyl chains 
for fatty acid synthesis3. Mercer et al. have shown that pantothenamide azido-
pantetheine could be processed to ACP via FAS type II in bacteria, while it 
cannot be processed via FAS type I in human SKBR3 cell-line21. Apparently, CoA 
analogues are only recognized by type II fatty acid synthase, which is found in 
most bacteria, while FAS type I system is present in mammals and fungi. Because 
the structural arrangement of fungal and mammalian synthases differs, selective 
pantothenamides could theoretically also target fungal FAS type I. Assuming that 
pantothenamides target the bacterial FASII pathway, administration of exogenous 
fatty acids could potentially overcome the antibiotic effects of pantothenamides. 
Work by Zhang et al. showed that this is not the case for E. coli. The MIC for S. 
pneumoniae, however, was increased 4-fold, suggesting that pantothenamides 
Organism Gram staining Strain Most effective pantothenamide
MIC 
(µg/ml)
S. aureus positive ATCC6538 N7-Pan 0.5
S. pneumoniae positive R6 N5-Pan 0.25
S. epidermidis positive ATCC12228 N7-Pan 1
S. agalactiae positive RIVM861352 none >256
S. pyogenes positive ATCC43202 N7-Pan 64
E. coli negative ATCC25922 N5-Pan 64
K. pneumoniae negative ATCC43816 N5-Pan 32
M. catarrhalis negative RH4 N7-Pan 128
P. aeruginosa negative Xen41 none >256
Table 8.1 MIC values of most potent pantothenamide against various bacterial strains
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target FASII but may also have other effects3. A recent paper by Parsons et 
al. elucidated the basis of differential susceptibility of gram-positive bacteria to 
fatty acid synthesis inhibitors like cerulinin and platensimycin22. From this work 
it was concluded that fatty acids cannot overcome FASII inhibition in S. aureus 
in contrast to S. pneumoniae. Whether this also holds for pantothenamides 
remains to be investigated, as they are likely to inhibit other pathways in addition 
to FASII. This is supported by recent findings describing that, at least in E. coli, 
both holo-ACP and ethyldethia-ACP can be hydrolysed to Apo-ACP by ACP 
phosphodiesterase (AcpH)7. Their data suggest that the antibacterial effect of 
N5-Pan is due to cellular depletion of CoA7. 
 The first step in CoA biosynthesis is the phosphorylation of pantothenic 
acid by pantothenate kinase (PanK), the key regulatory enzyme that is subject to 
selfregulation through feedback inhibition by CoA. Structures of PanK enzymes 
among different species have been investigated, which showed differences in 
binding capacity for pantothenic acid23,24. This might explain why N5-Pan is more 
active against E. coli and N7-Pan has specificiy for S. aureus. Binding features of 
human PanK family members with pantothenic acid have not been investigated. 
Although structures of human PanK1α en PanK3 in complex with acetyl-CoA 
have been analyzed, the structure of human PanK isoforms in complex with 
pantothenic acid would further facilitate the knowledge of binding properties 
of PanK, and thus would provide more insight into possible modifications of 
pantothenic acid to aid medicinal chemistry efforts.
 We have no data whether our pantetheinase inhibitors are PanK substrates. 
We have shown that pantetheinase inhibitors by themselves are not antibiotic, 
which suggests that they are not a substrate for the CoA biosynthetic machinery. 
This may be caused by the loss of the amide bond which is likely to be a necessary 
structural requirement for entering the first step of CoA synthesis leading to CoA 
antimetabolites, as recently suggested in a study by Mercer et al.5
 A recent publication has identified pantetheinase inhibitors derived from 
various chemical scaffolds in the LOPAC library, via a high-throughput approach19. 
These compounds are all non-selective and have modest potency. As they are 
known to target various mammalian cellular pathways at concentrations that are 
lower than required for vanin inhibition, it is unlikely that these compounds are 
useful in pharmacology or biological chemistry approaches25,26.
 The antibiotic strategy described here includes a combination of an 
enzyme inhibitor and a molecule that interferes with bacterial growth. Although 
a dual compound formulation is not a preferred pharmaceutic approach, it is not 
unprecedented as witnessed by the use of beta lactamase inhibitors (combined 
with penicillin) and a dehydropeptidase inhibitor (combined with iminipem)27. 
Here, we provide detailed experimental data of a concept that we previously put 
forward28,29. Recently, indirect evidence for this concept was found in the case of 
Plasmodium falciparum growth inhibition by pantothenamides30.
 Obviously, a number of steps need to be taken before combination therapy 
of pantothenamide antibiotics and vanin inhibitors can enter drug development. 
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As witnessed by Figure 8.4C, the potency of our current vanin inhibitors needs 
to be improved to achieve complete protection of pantothenamides in serum and 
to maintain the required MIC values31 (e.g. around 1 μg/ml for S. aureus). We 
found a good bioavailability and pharmacodynamic profile of the vanin inhibitor 
RR618, which is encouraging to explore this further. Clearly, an increase of the 
potency of current pantothenamides (N5-Pan and N7-Pan) is required. If this can 
be achieved, their application and may even extend the sensitivity beyond the 
gram-positive species that we have identified here. 
Materials and methods
Bacterial growth assays
Bacterial strains of Escherichia coli, Staphylococcus aureus, Staphylococcus 
epidermidis, Streptococcus agalactiae, Streptococcus pyogenes, Moraxella 
catarrhalis, Klebsiella pneumonia  and Pseudomonas aeruginosa  were grown 
overnight in 1% Bacto Tryptone media (BD, Sparks, MD). Cultures were then 
diluted 1:1000 in fresh assay media supplemented with or without 20% FBS 
(HyClone, Celbio, Logan, UT) or 20% decomplemented human serum (Sanquin, 
Bloodbank, NL) and added to 96 well sterile ELISA plate (100 µl per well). The 
compounds to be tested were diluted in the media without serum and added to 
the bacteria (100 µl per well). Plates were incubated at 37 oC and bacterial growth 
was followed in time by reading the optical density at 490 nm using a microplate-
reader (Model 450, Bio-Rad Laboratories Inc., Hercules, CA). Pantothenic acid 
was purchased from Sigma Aldrich (Dorset, UK). Streptococcus pneumonia were 
grown till mid-log phase (OD620 = 0,3) and stored in 15% glycerol at -80
oC till 
further use. Bacteria were diluted 10-fold in Mueller Hinton media (BD, Sparks, 
MD) and added to 96 well sterile ELISA plate (150 µl per well). The compounds to 
be tested were diluted in the media without serum and added to the bacteria (150 
µl per well). Plates were incubated overnight at 37 oC, 5% CO2. MIC was defined 
as the lowest concentration of pantothenamide where no growth was visible.
Synthesis of pantothenamides and pantetheinase inhibitors
All reactions were performed under an argon atmosphere, unless stated 
otherwise. Solvents were distilled from appropriate drying agents prior to use. 
Et3N was distilled and stored over KOH. Reactions were followed, and Rf values 
are obtained using thin layer chromatography (TLC) on silica gel-coated plates 
(Merck 60 F254) with the indicated eluent and compounds were detected 
with UV-light and/or by charring at ca. 150 °C after dipping into a solution of 
potassium permanganate, or ninhydrin. Column or flash chromatography was 
carried out using ACROS silica gel (0.035-0.070 mm, pore diameter ca. 6 mm). 
IR spectra were recorded on an ATI Mattson Genesis Series FTIR spectrometer. 
High-resolution mass spectra were recorded on a JEOL AccuTOF (ESI) or a 
MAT900 (EI, CI, and ESI). Melting points were analyzed with a Büchi melting 
point B-545 and are not corrected. NMR spectra were recorded at 298 K on a 
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Bruker DMX 300 (300 MHz) and a Varian 400 (400 MHz) spectrometer in the 
solvent indicated. Chemical shifts are given in parts per million (ppm) with respect 
to tetramethylsilane (0.00 ppm), or CHD2OD (3.31 ppm) as internal standard for 
1H-NMR; and CDCl3 (77.16 ppm), or CD3OD (49.00 ppm) as internal standard 
for 13C-NMR. Coupling constants are reported as J values in hertz (Hz). See 
Supplementary Information for detailed synthesis of pantothenamides. Details 
on the synthesis of pantetheinase inhibitors are described previously by Jansen 
et al18.
Pantheteinase activity
Pantetheinase activity was measured by the amount of free 7-amino-4-
methylcoumarin (AMC) released by the hydrolysis of the pantetheine-analogue 
pantothenate-AMC19. Pantothenate-AMC (final concentration 10 µM) was 
incubated in phosphate buffer (100 mM potassium phosphate buffer pH 8.0) in 
the presence of serum (1%) as pantetheinase source with or without a potential 
pantetheinase inhibitor. In time, samples were taken and the reaction was 
terminated by addition of 180 µl 100 mM CaCO3 pH 10.5. Fluorescence was 
measured using a luminescence spectrometer (LS55, Perkin Elmer, EX 350 ± 
2.5 nm, EM 450 ± 2.5 nm) against samples without serum as negative control. 
 For mass spectrometric analysis 64 μg/ml N7-Pan was incubated for 24 
hours at room temperature with 1% fetal bovine serum diluted in phosphate 
buffer (500 μM potassium phosphate buffer pH 8.0) with and without the addition 
of 256 μg/ml RR6.
Mass spec analysis
Mass spectrometry was performed on a JEOL JMS-T100CS (AccuTOF CS) 
connected to a Agilent 1100 series HPLC system. Analysis was performed in 
infusion mode, 3 µl of sample 1% of sample in methanol (HPLC grade, Fisher 
Scientific) was injected into a stream of methanol (HPLC grade, Fisher Scientific) 
containing 0.1% formic acid (puriss. Pa for mass spectrometry, Fluka) and 50 
nanomolar PPG425 (polypropylene glycol, average M.W. 425, Sigma-Aldrich 
Chemie GmbH) for use as an internal mass drift compensator. Total analysis time 
with a flow rate of 100 µl/min was 2.5 minutes per sample. Sample information 
elutes between 0.3 and 1.0 minutes. Data between 0 and 0.3 minutes was used 
to mass drift compensate the calibration against PPG425 peaks resulting in a 
mass precision better than 2 ppm. 
In vitro toxicity
Human embryonic kidney 293T cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM-Glutamax, Gibco Invitrogen) containing 10% FBS (HyClone, 
Celbio, Logan, UT), 100 µg/ml penicillin-streptomycin, 1% pyruvate (Gibco 
Invitrogen) at 37˚C and 5% CO 2. Pantothenamide or pantetheinase inhibitors 
were added to these cultures for 48 hours and effect on growth and toxicity was 
determined microscopically. Cytotoxicity was detected using the LDH cytotoxicity 
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detection kit according to the manufacturer’s protocol (Roche Applied Science, 
Indianapolis, IN).
Statistics
Data were analyzed using Graphpad Prism version 5. Data are expressed as 
mean ± standard deviation. 
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Supplementary information
Synthesis of N5-Pan and N7-Pan
(R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid (1)
To a cooled solution (0 °C) of (R)-pantothenic acid (20.8 g, 
94.0 mmol) in acetone (500 mL) were added subsequently 
2-methoxyprop-1-ene (27.1 mL, 283 mmol) and pTs-
OH•H2O (0.89 g, 4.72 mmol). After 15 min the temperature 
was raised to room temperature and the mixture was stirred for another 30 min. The 
mixture was diluted with saturated aqueous NaHCO3 (10 mL) and concentrated 
in vacuo to yield 1 as a yellow solid, which was used without purification. TLC 
(CH2Cl2:MeOH, 9:1 v/v): Rf = 0.67. Spectral data were in correspondence with 
reported data in literature32.
(R)-N-{3-[methoxy(methyl)amino]-3-oxopropyl}-2,2,5,5-tetramethyl-1,3-dioxane-
4-carboxamide (2) 
To a solution of 1 (1.80 g, 6.92 mmol) in dry CH2Cl2 
(65 mL) at rt were added, EDC (2.09 g, 1.5 equiv), 
N,O-dimethylhydroxylamine hydrochloride (1.04 g, 1.5 
equiv) and DIPEA (3.43 mL, 3.0 equiv), followed by 
DMAP (483 mg, 0.5 equiv). The reaction mixture was stirred over night at rt, 
quenched with saturated aqueous NH4Cl (40 mL), extracted with CH2Cl2. (3 × 
50 mL), dried (Na2SO4), and concentrated in vacuo. The product was purified by 
column chromatography (MeOH/CH2Cl2, 0:1→1:4) to afford 2 (1.90 g, 91% yield) 
as a colorless oil. Rf 0.56 (MeOH/CH2Cl2, 1:9). [α]D
20+44.5 (c 1.32, CH2Cl2). IR 
(ATR) 3417, 3334, 2980, 2940, 2871, 1661, 1520, 1378, 1196, 1095, 873 cm−1. 
1H NMR (CDCl3, 400 MHz): δ 7.13 (t, J = 5.7 Hz, 1H), 4.07 (s, 1H), 3.68 (d, J = 
11.7 Hz, 1H), 3.67 (s, 3H), 3.64-3.48 (m, 2H), 3.27 (d, J = 11.7 Hz, 1H), 3.18 (s, 
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3H), 2.76-2.59 (m, 2H), 1.46 (s, 3H), 1.42 (s, 3H), 1.03 (s, 3H), 0.96 (s, 3H). 13C 
NMR (CDCl3, 75 MHz): δ 169.9, 99.1, 77.3, 71.6, 61.4, 34.2, 33.1, 32.3, 31.9, 
29.6, 22.3, 19.0, 18.8. HRMS (ESI) m/z calcd for C14H26N2O5 (M+Na)
+: 325.1739, 
found: 325.1746.
(R)-2,2,5,5-tetramethyl-N-[3-oxo-3-(pentylamino)propyl]-1,3-dioxane-4-
carboxamide (3)
Prepared as described for 2, starting from 1 (3.40 
g, 13.1 mmol) and n-amylamine (2.30 mL, 1.5 
equiv). Column chromatography (EtOAc/heptane, 
0:1→4:1) afforded 3 (1.89 g, 44% yield) as a white 
solid. Rf 0.56 (MeOH/CH2Cl2, 1:9). Mp 81.5 °C. [α]D
20+41.6 (c 1.01, CH2Cl2). IR 
(ATR) 3430, 3317, 3300, 2954, 2931, 2868, 1649, 1526, 1463, 1377, 1197, 1098, 
873 cm−1. 
1H NMR (CDCl3, 400 MHz): δ 7.02 (t, J = 5.2 Hz, 1H), 5.88-5.84 (m, 1H), 
4.07 (s, 1H), 3.68 (d, J = 11.7 Hz, 1H), 3.64-3.46 (m, 2H), 3.28 (d, J = 11.7 Hz, 
1H), 3.26-3.21 (m, 2H), 2.43 (t, J = 6.2 Hz, 2H), 1.49 (dt, J = 7.3, 14.6 Hz, 2H), 
1.46 (s, 3H), 1.42 (s, 3H), 1.38-1.24 (m, 4H), 1.04 (s, 3H), 0.97 (s, 3H), 0.90 (t, J 
= 6.8 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 170.9, 170.3, 99.2, 77.3, 71.6, 39.7, 
36.4, 35.1, 33.1, 29.6, 29.4, 29.2, 22.5, 22.3, 19.0, 18.8, 14.1. HRMS (ESI) m/z 
calcd for C17H33N2O4 (M+H)
+: 329.2440, found: 329.2426. 
(R)-N-[3-(heptylamino)-3-oxopropyl]-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamide (4)
Prepared as described for 2, starting from 1 
(4.50 g, 17.4 mmol) and n-heptylamine (3.90 
mL, 1.5 equiv). Column chromatography 
(EtOAc/heptane, 1:2→1:0) afforded 4 (3.15 
g, 51% yield) as a colorless oil. Rf 0.56 (MeOH/CH2Cl2, 1:9). [α]D
20+39.4 (c 1.00, 
CH2Cl2). IR (ATR) 3425, 3321, 2927, 2863, 1650, 1526, 1459, 1377, 1196, 1098, 
875 cm−1. 
1H NMR (CDCl3, 400 MHz): δ 7.04 (t, J = 5.9 Hz, 1H), 6.03 (t, J = 4.9 
Hz, 1H), 4.06 (s, 1H), 3.68 (d, J = 11.7 Hz, 1H), 3.63-3.46 (m, 2H), 3.28 (d, J = 
11.7 Hz, 1H), 3.26-3.20 (m, 2H), 2.42 (t, J = 6.2 Hz, 2H), 1.53-1.47 (m, 2H), 1.46 
(s, 3H), 1.41 (s, 3H), 1.32-1.24 (m, 8H), 1.03 (s, 3H), 0.97 (s, 3H), .88 (t, J = 6.9 
Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ 170.8, 170.2, 99.1, 77.1, 71.5, 39.6, 36.2, 
35.0, 33.0, 31.7, 29.6, 29.5, 29.0, 26.9, 22.6, 22.2, 18.9, 18.7, 14.1. HRMS (ESI) 
m/z calcd for C19H37N2O4 (M+H)
+: 357.2753, found: 357.2747.
(R)-2,4-dihydroxy-3,3-dimethyl-N-[3-oxo-3-(pentylamino)propyl]butanamide (N5-
Pan, 5)
To a solution of 3 (30 mg, 0.10 mmol) in MeCN 
(1.0 mL) was added, BiCl3 (6.5 mg, 20 mol%), 
followed by distilled H2O (36 μL, 20 equiv). 
The reaction was stirred at rt for 4 h, then filtered and concentrated in vacuo. After 
dilution with EtOAc (10 mL), the reaction mixture was washed with saturated 
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aqueous NaHCO3 (2 × 8 mL) and the aqueous layer was extracted with EtOAc 
(3 × 8 mL). The organic layers were combined, dried (Na2SO4), and concentrated 
in vacuo. The product was purified by column chromatography (EtOAc/heptane, 
1:1→1:0) to afford 5 (1.22 g, 75% yield) as a white solid. Rf 0.46 (MeOH/CH2Cl2, 
1:9). Mp 89.4 °C. [α]D
20+29.7 (c 1.00, MeOH). IR (ATR) 3330, 3280, 3088, 2937, 
2872, 1642, 1546, 1089, 1033, 691 cm−1. 
1H NMR (CD3OD, 400 MHz): δ 3.88 (s, 
1H), 3.54-3.37 (m, 4H), 3.17-3.13 (m, 2H), 2.41 (t, J = 6.7 Hz, 2H), 1.53-1.46 (m, 
2H), 1.40-1.27 (m, 4H), 0.94-0.90 (m, 9H). 13C NMR (CDCl3, 75 MHz): δ 174.1, 
171.6, 77.5, 70.9, 39.8, 39.4, 35.9, 35.4, 29.2, 22.4, 21.4, 20.6, 14.1 HRMS (ESI) 
m/z calcd for C14H28N2O4Na (M+Na)
+: 311.1947, found: 311.1933.
(R)-N-[3-(heptylamino)-3-oxopropyl]-2,4-dihydroxy-3,3-dimethylbutanamide (N7-
Pan, 6)
Prepared as described for 5, starting 
from 4 (2.90 g, 8.13 mmol). Column 
chromatography (MeOH/CH2Cl2, 
0:1→1:9) afforded 6 (2.21 g, 86% yield) as a white solid. Rf 0.47 (MeOH/CH2Cl2, 
1:9). Mp 78.2 °C. [α]D
20+26.9 (c 1.01, MeOH). IR (ATR) 3352, 2483, 2068, 1119, 
973 cm−1. 
1H NMR (CD3OD, 400 MHz): δ 3.89 (s, 1H), 3.54-3.37 (m, 4H), 3.15 (dt, 
J = 1.2, 6.9 Hz, 2H), 2.41 (t, J = 6.7 Hz, 2H), 1.53-1.46 (m, 2H), 1.32-1.31 (m, 8H), 
0.92-0.89 (m, 9H). 13C NMR (CD3OD, 75 MHz): δ 176.1, 173.6, 77.3, 70.4, 40.5, 
40.4, 36.4, 32.9, 30.4, 30.1, 28.0, 23.7, 21.3, 20.9, 14.4. HRMS (ESI) m/z calcd 
for C16H33N2O4 (M+H)
+: 317.2440, found: 317.2429.
IC50 (µM)
Name Structure Rec. VNN1
Human 
serum FBS
N5-Pan - - -
N7-Pan - - -
RR6 0.54 0.040 0.041
Table S8.1 Structure and anti-vanin properties of N5-Pan, N7-Pan and RR6
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Organism Gram staining Strain N5-Pan(µg/ml)
N7-Pan 
(µg/ml)
S. aureus positive Xen8.1 8 0.5
ATCC6538 8 0.5
MRSA 8 0.5
S. pneumoniae positive R6 0.25 2
D39 0.5 16
TIGR4 0.5 8
G54 1 32
PMEN-1 4 16
PMEN-3 2 32
PMEN-4 0.5 8
PMEN-9 2 16
PMEN-13 2 32
PMEN-14 1 16
PMEN-15 0.5 8
PMEN-18 1 16
PMEN-19 0.5 16
PMEN-20 1 32
PMEN-21 1 16
PMEN-23 0.5 16
PMEN-24 0.5 16
PMEN-25 1 8
S. epidermidis positive ATCC12228 32 1
S. agalactiae positive RIVM861352 >256 >256
RIVM801284 >256 >256
RIVM861167 >256 >256
RIVM821256 >256 >256
RIVM782651 >256 >256
S. pyogenes positive ATCC43202 >256 64
E. coli negative BL21 64 256
ATCC25922 64 128
K. pneumoniae negative ATCC43816 32 >256
M. catarrhalis negative RH4 >256 128
P. aeruginosa negative Xen41 >256 >256
Table S8.2 Complete list of MIC values of N5-Pan and N7-Pan against various bacterial strains
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Historically, psoriasis and atopic dermatitis are considered to be immunological 
skin disorders in which immune cells are expected to play a causal role. Over the 
past 10 years this perspective has been changed, since keratinocytes appear to 
be involved as well. Nowadays, it is generally accepted that a complex interplay 
between immune cells and keratinocytes is responsible in the pathogenesis of 
psoriasis and atopic dermatitis. 
 The department of Dermatology at the Radboud university of Nijmegen has 
a history in epidermal skin biology with a focus on keratinocytes and its gene 
expression. In this context a microarray study was performed in which gene 
expression in involved skin of psoriasis patients was compared with involved 
skin of atopic dermatitis patients. These results has formed the basis for this 
thesis. The challenge was, after confirmation of results from this microarray, 
to investigate the relevance of disease-specific gene expression in aetiologic, 
diagnostic and therapeutic perspectives of these diseases.
 The skin, its structure and its function are described in chapter 1. Also 
the current status on the two most common skin diseases, psoriasis and 
atopic dermatitis, is described. Furthermore different in vitro skin models and 
approaches for transgenic gene expression or specific gene knockdown in 
cultured keratinocytes are summarized. 
Molecules & Markers
The most differentially expressed gene (VNN3) found in the microarray study 
performed by our department was further analyzed. In chapter 2 we first confirmed 
that VNN3 was indeed overexpressed in psoriatic skin as compared with atopic 
dermatitis skin and uninvolved/healthy skin. Besides the expression of VNN3, 
also the expression of VNN1, but not of VNN2, appears to be higher in psoriatic 
skin. The vanin expression was found to be induced by T cell derived cytokines 
of the Th1 (interferon-γ and TNF-α) and Th17 (IL22 and IL17) types, which are 
present at high levels is psoriatic skin lesions. The functional significance of vanin 
expression in psoriatic skin remains unclear, although it has been proposed that 
cysteamine, the metabolite that is formed after hydrolysis of pantetheine, plays a 
role in the regulation of cutaneous inflammation and differentiation. 
 The discovery of the beta-defensin copy number variation and its correlation 
with psoriasis in combination with the knowledge that beta-defensin-2 is highly 
upregulated in psoriatic skin, led us investigate hBD-2 expression at the protein 
level. In chapter 3 we describe a weak correlation between the beta-defensin 
copy number in healthy volunteers and the amount of hBD2 in their circulation. 
Subsequently, we examined the concentration of hBD-2 protein in the circulation 
of psoriasis patients and showed a much stronger correlation with disease activity 
(PASI) than with genomic beta-defensin copy number. We also confirmed the 
correlation between disease severity and hBD-2 expression in atopic dermatitis, 
although this correlation was less strong. In another disease which is characterized 
by inflammation (rheumatoid arthritis) we found no correlation between disease 
severity and hBD-2 levels in the circulation. These findings implicate that hBD-2 
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levels in the circulation of psoriasis patients could act as a surrogate marker for 
disease severity in psoriasis patients, but might also be used within individual 
patients to monitor disease severity in time.
 The outcome of microarray studies on the epidermal transcriptome of psoriatic 
and atopic dermatitis skin gave insight in disease-specific gene expression. In 
chapter 4 we show that using these disease-specific expression profiles, we 
were able to distinguish samples from healthy, psoriatic and eczematous skin. 
We further investigated whether we could select a set of genes, which expression 
was able to distinguish healthy, psoriatic, atopic dermatitis skin, irritant and allergic 
contact dermatitis. We found that a set of only seven genes could discriminate 
these various skin diseases based on the epidermal expression profiles, indicating 
that molecular diagnostics may be used for those patients where a distinction 
between psoriasis or eczema cannot be made clinically.
Methods
Over the past years our department has developed several models using human 
skin equivalents (HSE). These in vitro skin models can be used to study normal 
skin biology, but also diseased skin can be mimicked after addition of disease-
specific cytokines to the culture medium. Primary human keratinocytes are a 
limited factor for these skin equivalents, as their normal life span is between 30 
and 60 days of culturing before they stop dividing and reach senescence. For 
this reason only a very limited number of experiments can be performed using 
keratinocytes derived from patients as the keratinocytes first have to divide several 
times before enough cells are available for experiments. Chapter 5 describes 
that addition of Rho kinase inhibitor Y-27632 to the culture media increases the 
life span to over 100 days, without showing any signs of senescence. This implies 
that from the same number of skin biopsies large quantities of keratinocytes can 
be cultured and more experiments can be performed. Addition of Y-27632 also 
improved the quality of HSEs when added to the cells during the submerged 
phase. 
 Since primary human keratinocytes are hard to transfect using the 
traditional methods, the development of third-generation self-inactivating 
lentiviral transfection systems seems promising for this purpose. Indeed, 
lentiviral particles appeared to be able to infect keratinocytes efficiently, resulting 
in prolonged transgenic expression. In chapter 5 we showed that addition of 
Y-27632 to keratinocytes during transfection, the transfection efficiency is even 
higher. Another positive effect of Y-27632 on lentiviral transduced keratinocytes 
was that the increased quality of the subsequently formed HSE. In chapter 6 we 
used the lentiviral transfection system as a tool for delivering short hairpin RNAs 
into keratinocytes and examined the effects of knockdown of the CST6-gene 
on the formation of HSEs. Lack of the development of a multilayered epidermis 
suggested that CST6 deficiency would be incompatible with normal human skin 
development in the fetus. So far, no cases of patients or stillborn fetuses harboring 
CST6 mutations have been reported.
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Medicines
In chapter 2 we examined the expression of the vanin gene family in skin and other 
tissues. Because vanins are enzymes, we reasoned that it should be possible 
to inhibit the activity by specific inhibitors. We hypothesized that analogues of 
its natural substrate (pantetheine) that lack the amide-bond that is hydrolyzed 
by the enzyme, would act as competitive vanin inhibitors. Chapter 7 described 
the design, synthesis and analysis of pantetheine analogues and we report that 
some of these compounds have anti-vanin activity. Among these, RR6 was the 
most potent one, with an IC50 of 40 nM in human serum. Unfortunately, we could 
not find any consistent and positive effects in our in vitro psoriatic skin models 
(data not shown). 
 We found that RR6 is able to achieve a prolonged complete inhibition  of 
plasma vanin activity in rats given RR6 orally in doses of 50 mg/kg or via their 
drinking water at a concentration of 3 mg/l. Because the exact biological role of 
vanins remain unclear and some studies suggested a possible role for vanins in 
lipid homeostasis we investigated the effect of RR6 on fasting in rats. In RR6-
treated rats we found increased levels of free fatty acids in their plasma, while 
cholesterol levels decrease. These results indeed show that vanins are involved 
in lipid metabolism.  
 In our search for possible applications for vanin inhibitors, we ran into 
literature from the forties of the last century describing pantothenic acid analogs 
as possible antibiotic or antimalarial agents1,2. In 1970, Clifton et al.3 was the 
first who described a specific subset of pantothenic acid analogs (referred to as 
pantothenamides) that have antimicrobial activity against E. coli and S. aureus. 
Based on the structural similarities to pantetheine, the natural substrate for 
vanins, we reasoned that pantothenamides could be hydrolyzed by vanins as 
well, thereby preventing pantothenamides to be active in an in vivo situation. 
In chapter 8 we first showed that the effect of pantothenamides on bacterial 
growth was diminished when serum is added to bacterial cultures. Subsequently, 
we proved that pantothenamides are indeed hydrolyzed in serum. Finally, the 
addition of vanin inhibitors to pantothenamides result in protection of them, 
thus preserving their antibiotic activity in the presence of serum. These data 
provide evidence that the combination of an antimicrobial pantothenamide with 
an inhibitor of host (mammalian) pantetheinase activity, could act as a novel 
antibiotic strategy.
Final Remarks and outlook on future directions
The research presented in this thesis has potential application (1) in molecular 
diagnostics of inflammatory skin diseases, (2) analysis of skin biology in 
3D tissue engineered models and (3) drug development of vanin inhibitors. 
The findings of chapter 4 require further translational research on diagnostic 
problems in dermatology. It would be a challenge for clinical dermatologists to 
validate these findings in real clinical practice, and to see e.g. in hand eczema, if 
molecular diagnostics on epidermal expression profiles would have therapeutic 
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consequences. The application of 3D skin models combined with lentiviral 
delivery of transgenes or shRNA, is currently used and further optimized in our 
lab. We think that this holds great promise for studying keratinocyte biology, 
disease mechanisms and drug development. An example of the application of 
these models is a recent paper from our group that used gene knockdown in 3D 
models for atopic dermatitis to elucidate the mechanism of action of coal tar4. The 
third application, drug development of vanin inhibitors, is actively pursued by our 
lab and will be discussed here in more detail.
 Vanin inhibitors may have application in various fields of medicine, including 
metabolism and cancer, but the most obvious application would be the one 
outlined in chapter 7, the combination with pantothenamides as a novel antibiotic 
strategy. A number of issues, not addressed in my thesis, are important in this 
respect. These include selectivity of the compounds, potential toxicity and side 
effects, bioavailability, pharmacodynamics and pharmacokinetics. As the putative 
mode of action of pantothenamides is at the level of CoA-dependent biochemical 
pathways, this raised the question of selectivity for microbial versus host targets. 
Using high concentrations of vanin inhibitors and pantothenamides, no toxicity 
or significant inhibition of cell growth in the human kidney cell line 293T nor in 
primary epidermal keratinocytes was observed up to 100 µM (not shown). 
 For an effective protection of pantothenamides in vivo in experimental 
animals, complete inhibition of endogenous pantetheinase activity is crucial. In 
vitro experiments in chapter 7 suggest that in the presence of 10% human serum 
(not heat-inactivated) a concentration of N7-Pan of at least 2 µg/ml is required 
with at least 4 µg/ml of RR6, to establish complete growth inhibition of S. aureus. 
A number of experiments were performed to address the question if these levels 
can be achieved in vivo in rodents. Administration of RR2 and RR6 at 100 mg/
kg to mice should theoretically result in concentrations of pantetheinase inhibitor 
near 2 mM in serum. This concentration should be high enough for complete 
pantetheinase inhibition. After administration of pantetheinase inhibitor RR2 
(intraperitoneally or orally), sequential serum samples were collected and tested 
for pantetheinase activity. The administered compounds were well tolerated by 
the mice, but unfortunately no complete pantetheinase inhibition was achieved 
as shown in figure 9.1A. No differences were observed between the ways of 
administration. Oral administration of RR6, which is 100-fold more potent than 
RR2, resulted in a significantly stronger decrease in pantetheinase activity (figure 
9.1B), but still no complete pantetheinase inhibition was obtained and the half-life 
time remained relatively short (~80 min). 
 Although mice are the preferred experimental animals because many well 
characterized mouse models are available, the poor pharmacodynamics led us to 
test our compounds in other species. As shown in figure 7.2A, RR6 was able to 
completely inhibit pantetheinase activity in rats up to 8 hours after a single dose 
of 50 mg/kg. 
 Information on the concentration of pantothenamides in vivo is obviously 
important, as it should be high enough to have a bacteriostatic effect. Using 
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LC-MS we conducted pharmacokinetics of RR6 and N7-Pan in rats following a 
single dose of orally administered N7-Pan (250 mg/kg) alone, or in combination 
with 250 mg/kg RR6. When pantothenamides are not protected, their in vivo 
concentration decreases rapidly. Addition of RR6 increases the availability of N7-
pan dramatically, as expected (figure 9.2). In vitro we found approximate MIC 
values of S. aureus for N7-Pan of 4 µg/ml in 10% human serum (chapter 8). 
Extrapolating this to the in vivo situation, this implies that at the dosage of 250 
mg/kg for both compounds, the N7-Pan concentration is above MIC for 3 hours. 
This is at a borderline value, considering that in vivo the plasma concentration 
is 100% (as opposed to 10% serum in vitro). This was investigated in a pilot 
experiment were we did not find a clear antimicrobial effect of N7-Pan at 250 mg/
ml combined with 50 mg/ml RR6, using the rat thigh-muscle model with S. aureus 
(not shown here). 
 We are currently trying to improve our lead compound RR6, in a project 
funded by the Netherlands Genomics Initiative. This is done via a classical 
medicinal chemistry approach. In addition, we are building a homology model of 
human vanins based on published structures of the nitrilase family. Once such 
a model is established, this may allow a more rational lead optimization. So far, 
Figure 9.1 Pharmacodynamics of vanin inhibitors in mice. In (a) the type of administration was 
tested. RR2 was intraperitoneally and orally given at 100 mg/kg and blood samples were collected 
in time. Pantetheinase activity was measured and compared with pantetheinase activity in samples 
collected before administration. n=3. (b) Oral administration of 50 mg/kg of the more potent vanin 
inhibitor RR6, resulted in a stronger decrease of pantetheinase activity, but still no complete inhibition 
was achieved. n=3.
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attempts to improve the potency of pantothenamides have failed. N5-Pan and N7-
Pan, already known for more than 40 years are still the most potent compounds 
in their class. Although the targets of pantothenamides have been studied and 
were shown to affect CoA and lipid biosynthetic pathways5-7, there may be other 
targets. Identification of pantothenamide targets will further aid the optimization of 
these compounds to achieve antimicrobial potencies in the submicromolar range. 
Ideally, non-hydrolysable, vanin-resistant pantothenamides or analogues thereof 
would be an even better option as this will make the presence of vanin inhibitors 
superfluous. 
 In conclusion, we have proven that the principle of our strategy, protection 
of pantothenamide antibiotics against vanin hydrolysis, works. Current efforts are 
aimed at taking a next step to the development of vanin inhibitors for clinical use.
Figure 9.2 Pharmacokinetics of N7-Pan in rats. Pharmacokinetics of N7-Pan in rats after a single 
oral dose of 250 mg/kg N7Pan with and without 250 mg/kg RR6. RR6 is able to prolong the presence 
of N7-Pan. The dotted box represents the MIC for S. aureus based on in vitro determinations in 10% 
serum. 
Concluding remarks
205
References
1. Mead JF, Koepfli JB. The synthesis of potential antimalarials; the preparation of 
methylated amides of taurine and their pantoyl derivatives. J Org Chem 12, 295-7 
(1947)
2. Mead JF, Rapport MM, et al. The synthesis of potential antimalarials; derivatives of 
pantoyltaurine. J Biol Chem 163, 465-73 (1946)
3. Clifton G, Bryant SR, Skinner CG. N’-(substituted) pantothenamides, antimetabolites 
of pantothenic acid. Arch Biochem Biophys 137, 523-8 (1970)
4. van den Bogaard EH, Bergboer JG, Vonk-Bergers M, van Vlijmen-Willems IM, Hato 
SV, van der Valk PG et al. Coal tar induces AHR-dependent skin barrier repair in 
atopic dermatitis. J Clin Invest doi: 10.1172/JCI65642 (2013)
5. Zhang YM, Frank MW, Virga KG, Lee RE, Rock CO, Jackowski S. Acyl carrier pro-
tein is a cellular target for the antibacterial action of the pantothenamide class of 
pantothenate antimetabolites. J Biol Chem 279, 50969-75 (2004)
6. Thomas J, Cronan JE. Antibacterial activity of N-pentylpantothenamide is due to 
inhibition of coenzyme a synthesis. Antimicrob Agents Chemother 54, 1374-7 (2010)
7. Strauss E, Begley TP. The antibiotic activity of N-pentylpantothenamide results from 
its conversion to ethyldethia-coenzyme a, a coenzyme a antimetabolite. J Biol Chem 
277, 48205-9 (2002)

Appendix Nederlande samenvatting 
Dankwoord
List of publications
Curriculum vitae
208
Samenvatting
Nederlandse samenvatting
Historisch gezien worden psoriasis en atopisch eczeem beschouwd als 
immunologische huidaandoeningen, waarbij immuuncellen een belangrijke rol 
spelen. De afgelopen 10 jaar is dit beeld bijgesteld, omdat keratinocyten (de 
grootste groep huidcellen) ook een grote rol blijken te spelen. Tegenwoordig 
wordt algemeen aangenomen dat een complexe interactie tussen immuuncellen 
en keratinocyten verantwoordelijk is voor de pathogenese van psoriasis en 
atopische dermatitis.
 De afdeling Dermatologie aan de Radboud Universiteit van Nijmegen 
onderzoekt al geruime tijd de epidermale huid biologie, met een focus op 
keratinocyten en hun genexpressie. In dit verband is een microarray studie 
uitgevoerd waarin de genexpressie in die aangedane huid van psoriasispatiënten 
werd vergeleken met aangedane huid van atopisch eczeem patiënten. Deze 
resultaten vormen de basis voor dit proefschrift. De uitdaging was, nadat 
de resultaten uit de microarray studie bevestigd waren, om de relevantie van 
ziekte-specifieke genexpressie in etiologische, diagnostische en therapeutische 
perspectieven van deze ziekten te achterhalen.
 De huid, de structuur en de functie worden beschreven in hoofdstuk 1. 
Tevens wordt de huidige status van de twee meest voorkomende huidziekten, 
psoriasis en atopisch eczeem, beschreven. Verder worden in dit hoofdstuk 
verschillende in vitro huid modellen en methodes voor transgene genexpressie 
of specifieke gen knockdown in gekweekte keratinocyten samengevat.
 
Moleculen & Markers
Het meest differentieel tot expressie komend gen uit de microarray studie (VNN3) 
is door ons verder onderzocht. In hoofdstuk 2 hebben we eerst bevestigd 
dat VNN3 inderdaad tot overexpressie gebracht wordt in psoriatische huid in 
vergelijking met atopische eczeem huid en huid van gezonde vrijwilligers. Naast 
de expressie van VNN3 blijkt ook de expressie van VNN1, maar niet van VNN2, te 
zijn verhoogd in psoriatische huid. De Vanine expressie wordt geïnduceerd door 
T-cel afgeleide cytokinen van de Th1 (interferon-γ en TNF-α) en Th17 (IL22 en 
IL17) types, die in hoge mate aanwezig zijn in aangedane psoriatische plaques. 
Het klinische effect van een verhoogde vanine expressie blijft onduidelijk, maar 
cysteamine, de metaboliet die wordt gevormd na hydrolyse van pantetheine, zou 
een rol kunnen spelen in de regulatie van huidontsteking en differentiatie.
 Het bestaan van beta-defensine kopienummer variatie en de correlatie 
daarvan met psoriasis, in combinatie met de wetenschap dat beta-defensine-2 
(hBD-2) sterk opgereguleerd wordt in psoriatische huid, leidde ons ertoe de 
hBD-2 expressie op eiwitniveau te onderzoeken. In hoofdstuk 3 beschrijven 
we een zwakke correlatie tussen het beta-defensine kopienummer bij gezonde 
vrijwilligers en de hoeveelheid hBD2 in hun circulatie. Vervolgens onderzochten 
we de concentratie van hBD-2-eiwit in de bloedsomloop van psoriasis patiënten. 
Hier vonden we een veel sterkere correlatie met ziekteactiviteit (PASI) dan met 
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genomisch beta-defensine kopienummer. We tonen ook aan dat er bij atopisch 
eczeem patienten een correlatie is tussen de ernst van de ziekte en hBD-2 
expressie, maar dat deze correlatie een stuk minder sterk is dan in psoriasis. 
In een andere ziekte die wordt gekenmerkt door ontsteking (reumatoïde artritis) 
werd geen correlatie tussen ernst van de ziekte en hBD-2 waardes in de circulatie 
gevonden. Deze bevindingen impliceren dat hBD-2 niveaus in de circulatie van 
patiënten met psoriasis zouden kunnen fungeren als een surrogaat marker voor 
de ernst van hun ziekte. Ook kan het gebruikt worden om in individuele patiënten 
de ernst van de ziekte in de tijd te volgen.
 De resultaten van de microarray studies naar het epidermale transcriptoom 
van psoriasis en atopische eczeem huid verschafte inzicht in ziekte-specifieke 
genexpressie. In hoofdstuk 4 laten we zien dat door gebruik te maken van deze 
ziekte-specifieke expressie profielen, we in staat waren om onderscheid te maken 
tussen samples van gezonde, psoriatische en eczemateuze huid. Verder hebben 
we onderzocht of we een set van genen konen selecteren die in staat is om 
gezonde, psoriatische, atopische eczeem huid, irriterende en allergische contact 
eczeem te onderscheiden. We vonden dat met een set van slechts zeven genen 
deze verschillende huidziekten op basis van de epidermale expressieprofielen 
onderscheiden kunnen worden. Dit toont aan dat moleculaire diagnostiek gebruikt 
kan worden bij patiënten bij wie een onderscheid tussen psoriasis of eczeem niet 
klinisch vastgesteld kan worden.
 
Methodes
In de afgelopen jaren heeft onze afdeling diverse modellen ontwikkeld op basis 
van menselijke huidequivalenten. Deze in vitro huid modellen kunnen worden 
gebruikt om de biologie van normale huid te bestuderen, maar ook zieke huid 
kan worden nagebootst na toevoeging van ziekte-specifieke cytokines aan het 
kweekmedium. De hoeveelheid primaire humane keratinocyten is de beperkte 
factor bij de produktie van deze huidequivalenten. De normale levensduur 
van deze cellen in kweek ligt tussen de 30 en 60 dagen, waarna ze stoppen 
met delen en in een rusttoestand raken. Daarom kan slechts een zeer beperkt 
aantal experimenten uitgevoerd worden met keratinocyten afkomstig van 
patiënten als keratinocyten eerst meerdere keren moeten delen voordat 
genoeg cellen beschikbaar zijn om experimenten mee uit te kunnen voeren. 
Hoofdstuk 5 beschrijft dat toevoeging van Rho kinase remmer Y-27632 aan het 
kweekmedium de levensduur verhoogt tot meer dan 100 dagen, zonder enige 
tekenen van veroudering. Dit betekent dat van hetzelfde aantal huidbiopten 
grotere hoeveelheden keratinocyten kunnen worden gekweekt,  waarmee meer 
experimenten uitgevoerd kunnen worden. Toevoeging van Y-27632 verbetert ook 
de kwaliteit van huidequivalenten wanneer deze toegevoegd wordt aan de cellen 
tijdens de eerste fase van de kweek.
 Aangezien primaire humane keratinocyten moeilijk te transfecteren zijn met 
de traditionele methoden is de ontwikkeling van de zogenoemde derde generatie 
zelf-inactiverende lentivirale transfectiesystemen veelbelovend voor dit doel. 
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Lentivirussen blijken keratinocyten efficiënt te kunnen infecteren wat resulteert in 
langdurige transgen-expressie. In hoofdstuk 5 laten we zien dat door toevoeging 
van Y-27632 aan het medium tijdens de transfectie de transfectie-efficiëntie nog 
hoger wordt. Een ander positief effect van Y-27632 op lentiviraal getransduceerde 
keratinocyten was dat de kwaliteit van het later gevormde huidequivalent beter 
was. 
 In hoofdstuk 6 gebruiken we het lentivirale transfectie systeem om short 
hairpin RNA’s (shRNA) in keratinocyten tot expressie te laten komen. Hierdoor 
kunnen de effecten van het missen van het CST6-gen op de vorming van 
huidequivalanten onderzocht worden. De ontwikkeling van een meerlagige 
epidermis bleek zonder CST6 niet mogelijk, wat suggereert dat CST6 deficiëntie 
onverenigbaar is met de vorming van menselijke huid tijdens de ontwikkeling van 
de foetus. Tot nu toe zijn geen gevallen van patiënten of doodgeboren foetussen 
gemeld, waarbij mutaties in CST6 gevonden zijn.
 
Geneesmiddelen
In hoofdstuk 2 hebben we gekeken naar de expressie van de vanine genfamilie 
in de huid en andere weefsels. Omdat vanines enzymen zijn, beredeneerden 
we dat het mogelijk zou moeten zijn om de activiteit hiervan te remmen door 
specifieke remmers te ontwikkelen. Competitieve remmers zouden verkregen 
kunnen worden door analogen van het natuurlijke substraat (pentetheine) zonder 
de amide-binding, welke gehydroliseerd wordt door vanines, te maken. Hoofdstuk 
7 beschrijft het ontwerp, de synthese en de analyse van pantetheine analogen. 
Een aantal van deze verbindingen blijkt anti-vanine activiteit te hebben. Hiervan 
is RR6 de meest potente, met een IC50 van 40 nM in humaan serum. Helaas 
vonden we geen consistente en positieve effecten in onze in vitro psoriatische 
huid modellen (gegevens niet getoond).
 Door de toediening van RR6 in ratten (oraal in doses van 50 mg/kg of via 
het drinkwater in een concentratie van 3 mg/l) bleek een langdurige volledige 
remming van plasma vanine activiteit haalbaar. Omdat de exacte biologische rol 
van vanines niet bekend is en sommige studies een mogelijke rol voor vanines 
in lipide homeostase suggereren, zijn we het effect van RR6 op vasten bij ratten 
gaan onderzoeken. In RR6-behandelde ratten vonden we verhoogde niveaus 
van vrije vetzuren in het plasma, terwijl de cholesterol waardes daalden. Deze 
resultaten tonen aan dat vanines inderdaad betrokken zijn bij het vetmetabolisme.
 In onze zoektocht naar mogelijke toepassingen voor vanine remmers, vonden 
we in de literatuur uit de jaren veertig van de vorige eeuw de beschrijving van 
pantotheenzuur analogen die mogelijk als antibioticum of als anti-malariamiddel 
gebruikt konden worden1,2. In 1970 beschrijft Clifton et al.3 als eerste een specifieke 
subset van pantotheenzuur analogen (hierna pantothenamides genoemd) die 
antimicrobiële activiteit tegen E. coli en S. aureus vertoonden. Gebaseerd op 
de structurele overeenkomsten met pantetheine, het natuurlijke substraat voor 
vanines, beredeneerden we dat pantothenamides ook wel eens gehydrolyseerd 
konden worden door vanines. Hierdoor zullen pantothenamides in vivo niet actief 
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zijn. In hoofdstuk 8 laten we eerst zien dat het effect van pantothenamides 
op bacteriële groei vermindert, wanneer serum wordt toegevoegd aan 
bacteriekweken. Vervolgens tonen we aan dat pantothenamides inderdaad 
gehydrolyseerd worden in serum. Tenslotte laten we zien dat door toevoeging 
van vanine remmers, de pantothenamides niet afgebroken worden. Hierdoor 
blijft de antibiotische activiteit in de aanwezigheid van serum behouden. Deze 
gegevens tonen aan dat de combinatie van een antimicrobiële pantothenamide 
met een remmer van gastheer (zoogdieren) vanine activiteit, zou kunnen dienen 
als een nieuwe antibioticumstrategie.
 
Slotopmerkingen en toekomstplannen
Het onderzoek beschreven in dit proefschrift heeft potentiële toepassingen (1) 
in de moleculaire diagnostiek van inflammatoire huidziekten, (2) in de analyse 
van de huid biologie in 3D weefselkweek modellen en (3) in de ontwikkeling 
van geneesmiddelen met vanine remmers. De bevindingen van hoofdstuk 
4 vereisen meer translationeel onderzoek met betrekking tot diagnostische 
belemmeringen. Het zou een uitdaging voor de klinische dermatologen zijn om 
deze bevindingen te valideren in de echte klinische praktijk, en om bijvoorbeeld 
bij handeczeem te kijken of moleculaire diagnostiek op epidermale expressie-
profielen therapeutische consequenties kan hebben. De toepassing van 3D-huid, 
gecombineerd met lentivirale toediening van transgenen of shRNA, wordt op dit 
moment gebruikt en verder geoptimaliseerd in ons lab. Wij verwachten dat dit 
een grote invloed kan hebben bij het bestuderen van keratinocyt biologie, ziekte 
mechanismen en de ontwikkeling van geneesmiddelen. Een voorbeeld van de 
toepassing van deze modellen is een recent artikel van onze groep waarbij gen 
knockdown in een 3D model voor atopische eczeem het werkingsmechanisme 
van koolteer4 opgehelderd heeft. De derde applicatie, de ontwikkeling van 
geneesmiddelen met vanine remmers, wordt actief nagestreefd door ons lab en 
worden hieronder in meer detail besproken.
 Vanine remmers kunnen toepassingen hebben in verschillende 
vakgebieden, zoals metabolisme en kanker, maar de meest voor de hand liggende 
toepassing zou degene zijn die in hoofdstuk 7 besproken is: de combinatie 
met pantothenamides als een nieuwe antibioticumstrategie. Een aantal, niet 
in mijn proefschrift benoemde zaken, zijn in dit verband van belang, zoals 
selectiviteit van de verbindingen, potentiële toxiciteit en eventuele bijwerkingen, 
biobeschikbaarheid, farmacodynamische en farmacokinetische eigenschappen. 
De vermeende werking van pantothenamides is op het niveau van CoA-
afhankelijke biochemische processen, die de vraag rijzen over selectiviteit 
voor microbiële versus gastheer targets. Hoge concentraties vanine remmers 
en pantothenamides tonen geen toxiciteit of significante remming van celgroei 
in een menselijke nier cellijn (293T) noch in primaire epidermale keratinocyten 
waargenomen tot 100 µM (niet getoond).
 Voor een doeltreffende bescherming van pantothenamides in vivo is in 
proefdieren een volledige remming van endogene vanine activiteit cruciaal. In 
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vitro experimenten in hoofdstuk 7 suggereren dat de aanwezigheid van 10% 
humaan serum (niet hitte-geïnactiveerd) een concentratie van N7-Pan van ten 
minste 2 µg/ml nodig is met ten minste 4 µg/ml RR6 om volledig groeiremming 
van S. aureus te realiseren. We hebben een aantal experimenten uitgevoerd 
om te kijken of deze waardes in vivo kunnen worden bereikt in knaagdieren. 
Toediening van RR2 en RR6 van 100 mg/kg in muizen zouden in theorie moeten 
leiden tot concentraties van de remmers in de buurt van de 2 mM in serum. Deze 
concentratie moet hoog genoeg zijn om de volledige pantetheinase activiteit 
te remmen. Na toediening van vanine remmer RR2 (intraperitoneaal of oraal), 
werden in de tijd serummonsters verzameld en getest op pantetheinase activiteit. 
De toegediende verbindingen werden goed verdragen door de muizen, maar er 
werd geen volledige pantetheinase remming bereikt (zie figuur 1A). Er werden 
geen verschillen waargenomen tussen de toedieningsvormen. Orale toediening 
van RR6, die 100 maal krachtiger dan RR2, resulteerde in een significant 
sterkere daling van de pantetheinase activiteit (figuur 1B), maar nog steeds werd 
geen volledige remming van pantetheinase activiteit verkregen. Tevens was de 
halfwaardetijd relatief kort (~ 80 min ).
 Doordat veel goed gekarakteriseerde muismodellen beschikbaar zijn, is 
dit het proefdiermodel bij voorkeur. Door de slechte farmacodynamiek van onze 
Figuur 1 Farmakodynamiek van vanine remmers in muizen. In (a) is toedieningsmethode getest. 
RR2 (100 mg/kg) is intraperitoneaal en oraal toegediend, waarna bloedsamples in de tijd verzameld 
zijn. Pantetheinase activiteit in deze samples is gemeten en vergeleken met de pantetheinase ac-
tiviteit in het bloed van voor de toediening. n=3. (b) Orale toediening (50 mg/kg) van de potentere 
vanine remmer RR6 resulteert in een sterkere daling van de pantetheinase activiteit. Een complete 
remming wordt echter niet bereikt. n=3.
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stoffen in muizen zijn we onze verbindingen in andere diersoorten gaan testen. 
Zoals getoond in figuur 7.2A  (hoofdstuk 7) kan RR6 de pantetheinase activiteit in 
ratten volledig remmen tot wel 8 uur na een enkele dosis van 50 mg/kg.
 Informatie over de concentratie pantothenamides in vivo is uiteraard 
belangrijk, omdat deze hoog genoeg moet zijn om een  bacteriostatisch effect te 
hebben. Met LC-MS hebben we de farmacokinetiek van RR6 en N7-Pan bepaald 
in ratten na een enkele dosis oraal toegediend N7-Pan (250 mg/kg) alleen of 
in combinatie met 250 mg/kg RR6. Wanneer pantothenamides niet beschermd 
worden, neemt de concentratie in vivo snel af. Toevoeging van RR6 verhoogt, 
zoals verwacht, de beschikbaarheid van N7-pan enorm (figuur 9.2). In vitro 
vonden we MIC waarde voor N7-Pan tegen S. aureus van 4 µg/ml in 10% humaan 
serum (hoofdstuk 8). Geëxtrapoleerd naar de in vivo situatie betekent dit dat bij 
een dosering van 250 mg/kg van beide verbindingen de N7-Pan concentratie 
ongeveer 3 uur boven deze MIC is. Dit is een borderline waarde, aangezien de in 
vivo plasma concentratie 100% is (tegenover 10% serum in vitro). Dit hebben we 
onderzocht in een pilot experiment met behulp van een rat dijbeen-spier infectie 
model met S. aureus, waarbij we geen duidelijk antimicrobiële werking van N7-
Pan vonden bij 250 mg/ml N7-Pan in combinatie met 50 mg/ml RR6, (hier niet 
getoond).
 Wij zijn momenteel bezig om onze lead compound RR6 te verbeteren via 
een klassieke medicinale chemie benadering. Dit project wordt gefinancierd door 
het Nederlands Genomisch Initiatief. Daarnaast bouwen we een homologiemodel 
van menselijke vanines gebaseerd op gepubliceerde structuren van de nitrilase 
familie. Zodra een dergelijk model klaar is, kan dit mogelijk zorgen voor een meer 
Figuur 2 Farmacokinetiek van N7-Pan in ratten. Farmacokinetiek van N7-Pan in ratten na een 
enkele orale dosis N7-Pan (250 mg/kg) met en zonder RR6 (250 mg/kg). In aanwezigheid van RR6 
is N7-Pan langer aanwezig. Het gestippelde blok geeft de MIC van S. aureus aan, gebaseerd op in 
vitro bepalingen in 10% serum.
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rationele lead optimalisatie. Pogingen om de sterkte van de pantothenamides 
te verbeteren zijn tot dusver mislukt. N5-Pan en N7-Pan, die al meer dan 40 
jaar bekend zijn, zijn nog steeds de meest potente verbindingen in hun klasse. 
Hoewel de moleculaire targets van pantothenamides reeds onderzocht zijn en 
betrokken blijken te zijn in het CoA metabolisme en lipide biosynthese5-7, kunnen 
er nog andere targets zijn. De identificatie van targets van pantothenamides 
kan de optimalisatie van deze verbindingen om antimicrobiële potentie in 
submicromolaire range te bereiken verder verbeteren. De meest ideale 
compound zou een niet-hydrolyseerbare, vanine-resistente pantothenamide of 
analoog daarvan zijn, zodat dit de aanwezigheid van vanine remmers overbodig 
zou maken.
 Tot slot hebben we bewezen dat het basis idee van onze strategie, de 
bescherming van pantothenamides tegen vanine hydrolyse, werkt. De huidige 
inspanningen zijn gericht op het nemen van een volgende stap de ontwikkeling 
van vanine remmers voor klinisch gebruik.
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Dankwoord 
Ruim 7 jaar nadat ik begon aan mijn promotieavontuur ga ik dan eindelijk beginnen 
aan het laatste stuk, het dankwoord. Dit is niet alleen het meest gelezen stukje 
proefschrift, maar waarschijnlijk ook het meest gewaardeerde. Ik heb het geluk 
gehad met enorm veel mensen samen te mogen werken, wat er helaas voor kan 
zorgen dat ik onverhoopt iemand vergeet te bedanken hieronder. Vandaar dat ik 
begin met iedereen die, in de breedst mogelijke zin, een bijdrage heeft geleverd 
aan dit proefschrift te bedanken. Zonder jullie bijdrage is het resultaat er nooit in 
deze vorm gekomen: Bedankt!
Allereerst wil ik mijn beide promotoren bedanken. Joost, met Patrick sr. als 
rechterhand. Als ik nu terug kijk op de weg die we bewandeld hebben, kunnen 
we denk ik rustig concluderen dat het nooit de makkelijkste, kortste weg geweest 
is. Vergelijkbaar met een navigatie-systeem, waarbij naast de kortste en de 
energiezuinigste route ook de mooiste, zeg maar toeristische, route ingesteld 
kan worden. We hebben het aangedurfd om de grenzen van dermatologisch 
onderzoek te overschrijden. Dit heeft mij enorm geïnspireerd en gemotiveerd. 
Hopelijk gaan er nog leuke resultaten uit het vanine-werk komen. Mocht het 
onvehoopt toch tegenvallen uiteindelijk, dan hebben we in elk geval een leuke, 
leerzame weg bewandeld. Bedankt dat jullie mij deze mogelijkheden gegeven 
hebben. Hierbij wil ik ook Peter van de Kerkhof graag bedanken dat ik op zijn 
afdeling onderzoek heb mogen doen. 
Uiteraard wil ik ook graag een aantal directe collega’s bedanken. Judith, je 
kwam, zag, overwon en vloog naar Boston. Je enthousiasme heeft het een genot 
gemaakt om met je te mogen werken. En na een week hard werken in de stad 
even stoom uitblazen met een Bessen, of zelfs Goldstrike, was ook altijd een 
avontuur. Jeroen, we hadden eenzelfde gevoel voor zowel slechte muziek als 
slechte grappen. We hebben dus veel gelachen samen, maar ook praktisch 
hebben we prima samen kunnen werken. Je was voor mij dan ook een logische 
keuze om je te vragen me bij te staan als paranimf. Diana, Ivonne en Mieke, jullie 
waren als ‘analitische ondersteuning’ onmisbaar voor het lab in het algemeen, 
maar zeker ook voor mijn promotie onderzoek. Waar mogelijk hebben jullie me 
geholpen met kweken (Diana), histologie (Ivonne) en allerlei overige (rot)klusjes 
(Mieke). Het was altijd prettig met jullie samenwerken! Sandra en Ellen, dankzij 
jullie 3D kweekkwaliteiten heeft mijn boekje meer diepgang gekregen. Sandra, 
bedankt voor de samenwerking en gezelligheid op onze kamer. Ellen, we hebben 
elkaar goed kunnen helpen met onze gezamenlijk projectjes. Succes met het 
afronden van je boekje. Het wordt vast een meesterwerk. Marijke, de basis 
van ons onderzoek was hetzelfde. Jij meer gericht op eczeem en ik meer op 
psoriasis. We vulden elkaar denk ik goed aan. Bedankt voor je inzet en succes 
als dermatologe. Ook Piet wil ik graag even persoonlijk bedanken. Zijn FACS 
kwaliteiten en technische inzicht zijn ook voor dit proefschrift waardevol gebleken. 
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Als laatste wil ik Tsing graag even apart bedanken voor zijn gezelligheid. Je zit 
inmiddels alweer ruim 3 jaar in The Big Apple, maar de jaren dat we samen 
hebben gewerkt hebben we veel lol gehad in o.a. de Refter, de kroeg en op 
congressen.
Verder wil ik ‘mijn’ studenten graag bedanken. Mirjam, Paul, Corien en Linh. 
Ik heb jullie met veel plezier zowel wetenschappelijk als praktisch het een en 
ander bij proberen te spijkeren en ik hoop dat ik hier in geslaagd ben. Jullie 
inspanningen voor mij zijn door dit proefschrift heen terug te vinden. Ik wens jullie 
veel succes en plezier met jullie (wetenschappelijke) loopbaan. Linh, thanks for 
your contribution to my thesis. I hope that you’ve learned a lot during your time at 
our department. I wish you all the best with your career.
Verder wil ik de mensen van het CDL die geholpen hebben bij mijn onderzoek 
graag bedanken. Met name Daphne, Linda en Debby hebben mij veel werk 
(letterlijk) uit handen genomen. Maar ook Alex, Sophie, Annet en Helma zijn een 
vermelding waard voor hun inspanningen. En het was nog gezellig ook!
Ook de “vanine-groep” wil ik graag apart bedanken. Vanaf de synthese van de 
eerste remmers, vernoemd naar de chemici Rutjes en Ritsen, is het enthousiasme 
van de synthese-kant groot, wat uiteraard erg prettig samenwerkte. Dus Jodie, 
Bas, Floris, Pedro, Peter (Botman), Richard, Erik, Geeske en Christien: bij 
deze bedankt voor de prettige samenwerking. Uiteraard ben ik ook de overige 
betrokkenen bij het vanine onderzoek dank verschuldigd. Peter (van Galen), jouw 
hulp bij de HPLC heeft ons het directe bewijs gegeven dat de pantothenamides 
beschermd werden door de vanine-remmers. Peter (Burghout) en Marco wil ik 
graag bedanken voor het testen van de pantothenamides op pneumococcen 
en het leggen van de basis om de moleculaire targets te identificeren. Marga, 
Wouter en Geert-Jan wil ik graag bedanken voor hun hulp bij het testen van 
de pantothenamides en vanine-remmers in malaria. Hopelijk gaat dit nog leuke 
resultaten opleveren.
 
Op de laatste kamer van de gang heb ik tussen het labwerk door enorm 
veel tijd doorgebracht. In deze kamer-voor-4 heb ik in de loop der jaren veel 
kamergenoten mogen verwelkomen en uitzwaaien. De (weten)schappelijke en 
(on)zin besprekingen hebben zeker een goede invloed op me gehad. Het is bijna 
een wonder dat hier nooit conflicten zijn ontstaan. In chronologische volgorde, 
hopelijk zonder iemand te vergeten, wil ik de volgende (ex)roomies bedanken 
voor de gezelligheid: David, Marijke, Desiree, Sandra, Judith, Corien, Jeroen, 
Helmi, Ferry en Jorine. Hiervoor jullie dank!
Verder wil ik graag de overige (ex)-collega’s bedanken voor de gezelligheid op 
het lab, in de koffiekamer, met dagjes uit en de (kerst)borrels. Er heerst een 
prettige werksfeer, wat de resultaten alleen maar ten goede kan komen. Bedankt!
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Buiten het werk was er genoeg afleiding om het hoofd te legen. De atletiekbaan 
was een prima lokatie om frustraties van tegenvallende experimenten te 
relativeren en om nieuwe ideeën op te doen. Daarom wil ik graag Theo en alle 
me(d)e-lopers bedanken voor het afpeigeren tijdens de trainingen. Uiteraard wil 
ik ook mijn vrienden bedanken voor de nodige ontspanning onder het genot van 
een (speciaal) biertje.
Klaas, aan jou de eer om een hele alinea te krijgen! We hebben elkaar leren 
kennen op de atletiekbaan, maar ook daarbuiten konden we het altijd goed vinden. 
Ik mocht je zelfs bijstaan bij jouw promotie en nu heb je dezelfde taak bij de mijne. 
Het was prettig met iemand inhoudelijk over werk te kunnen praten, zonder dat 
je er direct bij betrokken was. Hierdoor keek je er net wat anders tegenaan, wat 
soms verhelderend werkte. Bedankt voor de gezelligheid en bedankt dat je mijn 
paranimf wilt zijn.
Verder wil ik graag mijn (schoon)familie bedanken voor hun interesse in en 
betrokkenheid bij mijn onderzoek. Een speciale dank gaat uit naar mijn ouders 
en zus(je) Suzanne. Jullie hebben me altijd gesteund in mijn (studie)keuzes en 
hier is dan eindelijk een fysiek resultaat. Ik ben blij dat na een aantal roerige jaren 
de rust is wedergekeerd. Ik ben blij dat iedereen weer gelukkig is.
Lieve Marjon, aan jou de eer om als laatste aan bod te komen in dit dankwoord. 
Jouw geduld en aanmoedigingen hebben indirect misschien wel het meest 
bijgedragen aan dit boekje. Vanaf de eerste dag heb je me gesteund en 
geprobeerd te begrijpen wat ik aan het doen was. Hoewel ik mijn werk erg leuk 
vind, is het nog steeds veel leuker om ’s avonds weer thuis te komen en om 
samen leuke dingen te doen. Ik hoop dan ook dat we de komende decenia nog 
ontelbaar veel leuke tripjes zullen gaan maken en dat we samen heel gelukkig 
oud mogen worden! 
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